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ABSTRACT
The E2F transcription factors are key components of the retinoblastoma tumour suppressor 
pathway which control the progression from G1 to S phase in the cell cycle and regulate the 
transcription of proteins required for S-phase entry and DNA synthesis. Deregulation of 
E2F-1 expression results in the loss of control of normal cell cycle progression. Aberrations 
of the retinoblastoma pathway have been reported in most human cancers. Alteration in cell 
cycle regulation may alter the activity of anti-cancer drugs. An increase in E2F-1 activity 
and transcription of E2F-regulated genes potentially influences the cellular sensitivity to 
chemotherapeutic agents. This study aimed to investigate the pattern, mechanism and 
potential inhibition of E2F-1 interactions with chemotherapeutic agents.
Initial experiments performed on an HT1080 cell line stably overexpressing E2F-1 
suggested a role in resistance to several DNA interactive agents, in particular the minor 
groove binding alkylating agent BGIII21. However, further characterisation identified the 
HT1080 transfectants to be CHO cell lines. Experiments using an inducible E2F-1 cell line 
showed increased expression of E2F-1 to have a minimal effect on chemosensitivity to 
BGIII21. A decrease in chemosensitivity was observed in response to BGHII21 in CHO 
cells. NER, homologous recombination or mismatch repair deficiency were not found to be 
the underlying causes for resistance in CHO cells.
Experiments using E2F-1 inhibitory peptides, despite exhibiting marked inter- 
experimental variations, suggested an inverse correlation between endogenous E2F-1 
expression level and peptide activity. Further, cell cycle analysis showed the E2F-1 
inhibitory peptides to cause G1 arrest or apoptosis in leukemic cell lines. In conclusion, 
inhibition of E2F-1 activity through peptides was found to be a valuable but unreliable tool 
to influence the effect of chemotherapeutic agents on cells expressing increased levels of 
E2F-1 due to persistent variations in factors affecting peptide activity.
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1. INTRODUCTION
Cancer is responsible for a high proportion of mortalities in developed countries and is 
second only to cardiovascular disease as a cause of mortality. Although understanding of 
the molecular basis of cancer has increased substantially further research is required for the 
rational development of potential anti-cancer therapies.
Cancer is defined through uncontrolled cell proliferation with the cell cycle 
machinery deregulated most frequently upon oncogenesis. Strict developmental controls are 
exerted upon every cell within the human organism. In normal tissues the number of 
actively proliferating cells and rate of cell division varies greatly. During a normal cell 
cycle cells enter an early gap phase (Gl) after exiting mitosis (M). Following the G1 
restriction point cells enter a phase of DNA synthesis (S) and subsequently a further gap 
phase (G2) before re-entering mitosis. Some normal as well as cancerous cells exit the cell 
cycle following mitosis and enter a quiescent phase (GO) or differentiation (Pardee, 1989; 
Sherr, 1996).
Deregulation of the cell cycle machinery occurs as a result of aberrations in the 
expression of cell cycle regulatory genes. These include, regulators of Gl to S phase 
progression and components of the Gl checkpoint mechanism namely the Gl restriction 
point (Bartek, 1999; Sherr, 1996). The Gl phase checkpoint mechanisms are critical in 
ensuring fidelity of DNA replication and orderly progression through the cell cycle phases 
therefore protecting genome integrity. Unlike transit through the S, G2 and M phases, Gl 
progression relies upon stimulation by extracellular growth regulating signals. Multiple 
mitogenic signalling pathways as well as growth inhibitory signals converge upon the Gl 
checkpoint in the form of mitogens, nutrients, cytokines and cell-cell or cell-surface 
interactions (Helin, 1998; Johnson et al., 1998; Lavia et al., 1999; Sherr, 1996). At the 
molecular level, several positive and negative regulatory proteins have been identified 
within the Gl restriction point. These cell regulatory proteins include proto-oncogenes such 
as cyclin D l, D2, D3, a number of cyclin-dependent kinases including cyclin-dependent 
kinase 4 and 6 (CDK4/6), tumour-suppressor proteins including CDK4 kinase inhibitor 
(INK4) and KIP/CIP kinase inhibitors as well as the retinoblastoma tumour suppressor 
proteins pRb, p i30 and p i07 commonly known as the pocket proteins due to the presence
17
of a highly conserved bipartite pocket domain within the protein structure (Helin, 1998; 
Sherr, 1996).
Another family of cell cycle regulatory proteins includes the E2F transcription 
factors involved in the regulation of growth inhibition, differentiation, apoptosis and 
oncogenic transformation. The E2F family of transcriptional activators have been found to 
be important constituents of the Gl restriction point in determining whether a cell 
undergoes Gl phase arrest or enters into S-phase by coupling the activities of the cell cycle 
machinery with the transcriptional regulation of proteins whose expression is required for 
S-phase entry and DNA synthesis (Johnson et al., 1998; Slansky et al., 1996). The E2F 
protein family executes these diverse activities through tight regulation of the spatial and 
temporal expression of distinct E2F factors and through associations with cell cycle- 
regulatory proteins resulting in various multiprotein complexes containing E2F factors 
(Johnson et a l, 1998). E2F DNA-binding sites are found in the promoters of genes 
encoding proteins involved in DNA synthesis, DNA replication, DNA repair and cell cycle 
regulatory activities (Helin, 1998; Johnson et a l, 1998; Nevins, 2001). In addition, 
regulation of some proto-oncogenes involved in cell proliferation, including c-myb, B-myb, 
c-myc and N-myc is also controlled by E2F activity (Johnson et al, 1998). Deregulation of 
E2F activity results in the loss of orderly cell cycle progression and division. In abandoning 
these Gl phase control mechanisms cells are being predisposed to malignant conversion. In 
conclusion, cancer cells tend to remain in cycle after passing the Gl restriction point and 
become refractory to extracellular growth regulatory signals (Lavia et a l, 1999; Sherr,
1996).
1.1 E2F transcription factor family
The E2F transcription factor was identified as part of the adenovirus E2 promoter 
transcription complex and a target for transactivation by the adenovirus E l A (Chellapan et 
a l, 1991; Kovesdi et al, 1986). It was first cloned through its association with the pRb 
pocket protein (Helin et a l, 1992; Kaelin et a l, 1992). Further, it was found that pRb and 
E2F interact in vitro and in vivo and it was suggested that E2F preferentially binds to the 
unphosphorylated form of pRb (Helin et al, 1992; Kaelin et a l, 1992). A number of DNA 
tumour viruses, including adenovirus E1A and simian virus 40 large T antigen, binding to 
pRb were found to provoke the release of the E2F transcription factor from its complex
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with pRb (Bandara et a l , 1991; Helin et a l, 1992; Kaelin et a l, 1992). The E2F 
transcription factor specifically recognises the E2F recognition sites of E2F-regulated gene 
promoters and is able to transactivate the adenovirus E2 promoter (Helin et a l, 1992; 
Kaelin et a l, 1992).
The E2F transcription factor family consists of at least seven distinct genes divided 
into two groups. E2F-1, E2F-2, E2F-3, E2F-4 and E2F-5 constitute one group while the 
E2F-associated DPI and DP2 genes constitute a separate group (Girling et a l, 1993; Ivey- 
Hoyle et a l, 1993; Lees et a l, 1993; Johnson et a l, 1998; Sardet et a l, 1995). The E2F 
protein subgroup consists of five members (E2F-1 to E2F-5) that can be further divided 
based on structure and affinity for members of the pocket protein family (pRb, p i30 and 
pl07) (Slansky et a l, 1996). E2F-1, E2F-2 and E2F-3 are structurally more closely related 
to each other than E2F-4 and E2F-5 (Fig. 1.1). The DNA-binding domain found in the 
amino terminus represents the area of greatest homology between the five E2F species 
(Sardet et a l, 1995). Adjacent to the DNA-binding domain is the DP heterodimerisation 
domain and the carboxy terminus of each of the five E2F polypeptides contains a defined 
transcriptional activation domain. Embedded within the transactivation domain of each E2F 
is a region of homology involved in binding to the pocket proteins (Helin et a l, 1992). An 
additional region of homology, termed the Marked box is highly conserved between the 
different E2Fs and is required for binding to the adenovirus E4(ORF6/7) protein (Cress et 
a l, 1996; Johnson et a l, 1998). E2F-1, E2F-2 and E2F-3 contain an additional region of 
homology not found in E2F-4 or E2F-5. This region was shown to have several functions, 
including cyclin A protein binding. Finally, the E2F-4 protein contains a stretch of 
consecutive serine residues between the Marked box and the pocket protein binding domain 
not found in other E2F family members (Johnson et a l, 1998). DPI and DP2 polypeptides 
contain DNA-binding and dimerisation domains related to the E2F proteins but do* not 
contain transcriptional activation domains or regions homologous to the pocket protein 
binding or Marked box domain (Johnson et al, 1998; Slansky et a l, 1996).
Recently an additional E2F transcription factor has been isolated called E2F-6 or 
EMA (E2F-binding site modulating activity). The dimerisation and DNA binding properties 
of E2F-6 are similar to those of the other E2F family members. E2F-6 shares
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Fig. 1.1: Schematic representation of the E2F protein family
(Johnson et al., 1998)
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homology with the other E2F proteins in the DNA-binding domain and the Marked box, 
but in contrast to all other E2F transcription factors lacks a C-terminal transactivation 
domain as well as the pocket protein binding domain (Cartwright et al., 1998). Instead it 
contains a short co-linear motif that mediates binding to the Rb family members (Kaelin, 
1999).
A functional E2F transcription factor consists of a heterodimer containing an E2F 
protein subunit and a DP protein subunit (Bandara et al., 1993; Huber et al., 1993). 
Heterodimerisation of the E2F and DP family members is required for high-affinity binding 
to E2F consensus sites and to pocket proteins (Bandara et al., 1994; Huber et al., 1993; 
Slansky et al., 1996). E2F/DP heterodimers binding to consensus E2F sites activate E2F 
site-dependent transcription in a synergistic fashion (Bandara et al., 1993). To elucidate 
DNA-binding of the E2F/DP heterodimer, an investigation into the structure of the E2F-4- 
DP2 heterodimer revealed both protein subunits to make similar contacts to the bases in the 
major groove of the DNA thereby recognising a CGCGCG binding sequence. In addition, 
an extension of the original CGCGCG-binding site through the addition of TTT to the 5’ 
end was found to aid in orientating the E2F-DP heterodimer on the promoter. The contact 
residues for the consensus bases and DNA phosphodiester backbone are highly conserved 
throughout the E2F protein family suggesting other combinations of E2F/DP heterodimers 
to bind DNA in a similar way (Zheng et al., 1999).
E2F-6 like all other E2F transcription factors forms heterodimers with DPI or DP2 
and binds E2F DNA-binding sites (Johnson et al., 1998). However, it appears that E2F-6 
performs as a repressor of E2F site-dependent transcription independent of pocket protein 
binding. The mechanism of repression has been proposed to be either through competitive 
inhibition with other E2F species or through an active transcriptional repression domain 
located in the amino terminus of E2F-6 (Johnson et al., 1998; Trimarchi et al, 1998).
1.2 Temporal and spatial expression of E2F transcription factors
Distinct differences in the pattern of expression, as a result of cell growth, have been 
reported for the five well-characterised E2F family member genes (Helin, 1998; Johnson et 
al., 1998; Nevins, 1998). However, the transcription control of E2F-6 has not been 
elucidated. The E2F-4 and E2F-5 genes are constitutively expressed throughout the cell 
cycle. A small temporary increase in E2F-4 protein expression level in response to growth
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stimulation in mid Gl occurs before returning to the base level of expression upon S phase 
entry (Moberg et al., 1996; Nevins, 1998; Sardet et a l, 1995 Slansky et al., 1996). E2F-4 
mRNA is the most abundant and consistent with this finding the E2F-4 protein makes up 
the majority of E2F complexes as well as DNA-binding activity in cells (Johnson et al., 
1998; Verona et al., 1997).
Similarly to E2F-4, E2F-5 expression levels increase in early-to-mid Gl and plateau 
thereafter as cells enter S-phase (Johnson et al., 1998). Thus, E2F-4 and E2F-5 appear to 
regulate the transcription of E2F-dependent genes in quiescent cells and early Gl phase 
prior to synthesis of E2F-1, E2F-2 and E2F-3 (Helin, 1998). The majority of E2F-4 and 
E2F-5 proteins are located in the cytoplasmic part of the cell but a fraction is found in the 
nucleus of asynchronously growing cells dependent on tissue specificity (Lindeman et al., 
1997; Mueller et al., 1997; Verona et al., 1997). Experiments showed that ectopically 
expressed E2F-4 and E2F-5 localises predominantly in the cytoplasm and is unable to enter 
the nucleus (Allen et al., 1997; Lindeman et al., 1997; Verona et al., 1997). Nuclear 
accumulation of E2F-4 and E2F-5 requires a nuclear localisation signal (NLS) provided by 
either the DP2 heterodimeric protein subunit or through the association with the pocket 
proteins, pl30 or pl07 (Allen et al., 1997; Lindeman et al., 1997; Mueller et a l, 1997; 
Verona et a l, 1997).
The mechanisms of nuclear accumulation contribute to the effect E2F-4 and E2F-5 
expression has on cell cycle progression. Throughout GO the pocket protein-mediated 
nuclear uptake of E2F-4 and E2F -5 prevents cell cycle progression through pocket protein- 
mediated transcriptional repression of E2F-responsive genes. In contrast, DP-regulated 
nuclear uptake promotes cell cycle progression through an enhanced transactivation of 
E2F-regulated genes (Allen et al., 1997). These findings suggest that E2F-4 activity is 
controlled at the level of sub-cellular localisation in addition to pocket protein binding.
A similar pattern of expression to E2F-4 and E2F-5 is observed with regard to DPI 
and DP2 (Johnson et al., 1998; Nevins, 1998). DPI is expressed constitutively with a peak 
in mid Gl (Johnson et a l, 1998; Sardet et al., 1995). The DPI protein is predominantly 
found in the cytoplasm while DP2, containing a NLS, is mainly localised in the nucleus 
(Allen e ta l, 1997; Lindeman et al., 1997; Verona e ta l, 1997). Nevertheless, experiments 
have shown DPI to be the prevalent partner in the majority of E2F heterodimeric DNA- 
binding complexes (Johnson et al, 1998; Sardet et al., 1995).
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Expression of E2F-1, E2F-2 and E2F-3 genes is dependent on stimulation of cell growth 
and all three proteins are found exclusively in the nucleus as a direct consequence of an 
innate NLS (Allen et a l, 1997; Lindeman et a l, 1997; Mueller et a l, 1997; Verona et a l,
1997). In quiescent cells no E2F-1, -2 or -3 gene expression is seen, however transcription 
is rapidly induced in response to mitogenic stimulation (Nevins, 1998). For example, upon 
stimulation of serum-starved fibroblasts or resting T cells to enter the cell cycle, the level of 
E2F-1 mRNA dramatically increases at the Gl/S-phase boundary (Johnson et a l, 1998). 
E2F-2 is expressed with similar kinetics although at an overall lower level in fibroblasts 
(Johnson et a l, 1998). Repression of E2F-1, -2 and -3 transcription in quiescent cells 
appears to be E2F-dependent as a result of the presence of E2F binding sites within the 
promoter regions of the E2F-1, -2 and -3 genes. E2F-4 and E2F-5, in conjunction with 
pl30 are suggested to control the expression of E2F-1, E2F-2 and E2F-3 (Nevins, 1998).
1.3 E2F-regulated genes
E2F regulated genes are involved in DNA synthesis, DNA replication, regulatory control of 
cell cycle progression and various DNA repair activities (Nevins, 2001). Proteins 
participating in DNA synthesis include dihydrofolate reductase (DHFR), thymidine kinase 
(TK) and the DNA polymerase a  subunit I and II, proliferating cell nuclear antigen 
(PCNA) as well as the DNA polymerase 8 catalytic subunit (DeGregori et a l, 1995; Fry et 
a l, 1997a; Kalma et a l, 2001; Sala et a l, 1994). Induction of these genes occurs in mid to 
late Gl phase as a direct result of E2F accumulation.
Experiments using an adenoviral vector containing E2F-1 cDNA confirmed the 
E2F-1 dependent activation of S phase genes required for DNA synthesis such as 
thymidylate synthase (TS), PCNA, ribonucleotide reductase (RR) and DNA polymerase a  
(DeGregori et a l, 1995). Furthermore, regulatory genes active during Gl to S phase 
progression such as cyclin E, cyclin A, B-myb and cdc2 were activated in the presence of 
E2F-1 (DeGregori et a l, 1995; Furukawa et a l, 1994; Ohtani et a l, 1995). Several proto­
oncogenes were shown to be induced by E2F including c-myc, N-myc, cyclin-Dl, c-myb 
and B-myb (DeGregori et a l, 1995; Ohtani et a l, 1995; Sala et a l, 1994). In addition, 
Kalma et a l provided evidence for the E2F-1 induced upregulation of novel genes 
encoding proteins that participate in DNA replication. These include the 32Kd subunit of
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the replication protein A (RPA2), topoisomerase Ila  and subunit IV of DNA polymerase cx 
(Kalma et al., 2001).
1.4 Pocket protein family (pRb, pl30 and pl07)
The retinoblastoma gene (.Rb) was the first tumour suppressor gene to be identified and was 
isolated by positional cloning from retinoblastoma tumours. The tumour suppressor protein 
function of pRb was confirmed by its ability to inhibit the malignant phenotype when 
expressed in retinoblastoma-tumour cells. Tumour suppression by pRb requires the central 
“pocket” domain, which is disrupted by tumour-promoting mutations and is targeted by 
viral oncoproteins. The E1A adenovirus protein disrupts pRb-E2F complexes by binding to 
the pocket region of pRb thereby releasing ‘free’ E2F which in turn binds DNA (Bagchi et 
al., 1991). Whereas the Rb gene is frequently found mutated in tumours such as 
retinoblastoma, osteosarcoma, small-cell lung cancer, bladder and mammary cancers, pRb 
function is found disrupted in the majority of tumours through either deregulation of 
upstream signalling pathways or mutation or deletion of the Rb gene (Harbour et a l, 2000; 
Hatakeyama et al., 1995). Loss of pRb function also creates a selective pressure for the 
tumour to inactivate the pro-apoptotic tumour suppressor p53, which serves to eliminate 
cells with mutations in the pRb pathway. As a result many tumours have mutations 
inactivating both pRb and p53 (Harbour et al., 2000).
The human pocket protein family includes three known members, pRb, pl07 and pl30, 
which are highly related in amino acid sequence as well as function (Nevins, 1998). The 
human pRb protein is a nuclear phosphoprotein spanning 928 amino acids (Herwig et a l , 
1997; Kaelin, 1999). The defining characteristic of the pocket protein family is a highly 
conserved bipartite pocket structure. These A and B pocket domains are necessary for 
interaction with viral oncoproteins such as the adenovirus E1A protein and for association 
with members of the E2F transcription factor family both containing the binding sequence 
LXCXE (Bagchi et al., 1991; Classon et al., 2001; Dahiya et al., 2000; Kaelin, 1999). 
These proto-oncogene-pRb interactions are critical for the transforming activity of the 
DNA viruses (Hatakeyama et al., 1995).
In addition the pocket proteins contain multiple sites for phosphorylation by CDKs, 
including a large cluster of sites in the extreme C-terminus of the pocket proteins. However,
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p i30 and p i07 are structurally more closely related to each other than they are to pRb. 
p i07 and p i30 each contain insertions within the B domain of the pocket domain that are 
missing from pRb. In addition the spacer sequences found in pl07 and pl30 which separate 
the A and B subdomains of the pocket domain are longer than the analogous region in pRb. 
The p i07 and p i30 spacer regions contain homologous sequences and include a high- 
affinity binding site for cyclin A/CDK2 and cyclin E/CDK2. This motif, not present in pRb, 
allows p i07 and p i30 to form stable complexes with these CDKs suggesting that p i07 and 
pl30 function as CDK inhibitors (Classon et al., 2001; Herwig et al, 1997).
1.5 Temporal and spatial expression of pRb, pl30 and pl07
A distinguishing feature of the members of the pocket protein family is the pattern of 
accumulation of the individual proteins during cell growth. Accumulation of p i30 drives 
cells to enter the quiescent phase of the cell cycle (GO). Within quiescent cells p i30 is 
found complexed to E2F-4, the most abundant member of the E2F family in GO phase 
(Mayol et al., 1998; Moberg et al., 1996). The pl30-E2F-4 complex has been suggested to 
actively repress the transcription of E2F-regulated genes such as E2F-1, -2  and p i 07 
(Johnson et al., 1994; Mayol et al., 1998; Sears et al., 1997; Zhu et a l, 1995). Upon re­
entry of quiescent cells into the cell cycle p i30 is phosphorylated by cyclin D-CDK4/6 and 
subsequently degraded by proteasomes (Mayol et a l, 1998; Nevins, 1998).
The p i07 protein is not found in quiescent cells and starts to accumulate as cells re­
enter the cell cycle (Nevins, 1998). The increase in pl07 protein level is a result of de­
repression of the E2F-responsive pl07  promoter following phosphorylation of the pi 30- 
E2F-4 repressor complex. Levels of pl07 increase as cells pass through G1 and remain 
relatively constant in proliferating cells (Nevins, 1998). The synthesis of pl07 promotes 
complex formation with ‘free’ E2F-4 following the degradation of pl30 (Moberg et al., 
1996). In contrast to pl30, pRb and pl07 although phosphorylated by cyclin D-CDK4/6, 
are not being targeted for degradation. The characteristic that singles p i30 out for 
degradation has been identified as a unique type of phosphorylation, as opposed to the more 
common types of phosphorylation found in quiescent cells (Mayol et al., 1998). To 
conclude, whereas p i30 is readily detected in quiescent cells, the p i07 protein is primarily 
found in proliferating cells (Nevins, 1998).
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In contrast to the cell cycle dependent expression of p i30 and p i07, pRb expression 
appears to be independent of the cell growth state. In G1 phase a small increase in pRb 
accumulation occurs, considered a consequence of E2F accumulation combined with the 
fact that the Rb promoter is responsive to E2F. Generally the level of pRb expression does 
not vary greatly between quiescent and proliferating cells. A major control of pRb function 
is the phosphorylation state of the protein. pRb is detected only as a hypophosphorylated 
form in cells in the GO and early to mid-Gl phases before phosphorylation occurs in mid- 
to-late G1 phase disrupting pRb interaction with the E2F proteins. The 
hyperphosphorylated form of pRb continues to persist until the end of M phase. When cells 
enter into the next G1 phase attached phosphates are stripped off pRb by phosphatases and 
the pRb protein is found once again in its hypophosphorylated form. Phosphorylation is 
shown to be predominantly dependent on the action of D-type cyclins in association with 
CDK4 and CDK6 (Hatakeyama et al., 1995; Nevins, 1998).
1.6 Control of E2F transcriptional activity
Various levels of control influencing E2F transactivation have been discussed already 
including spatial and temporal differences in intra-cellular E2F expression, heterodimer 
formation and associations with pocket proteins. In addition E2F activity is regulated at the 
level of phosphorylation through cyclin A-CDK2, acetylation, methylation and protein 
stabilisation. Finally, E2F transactivation activity has also been found dependent on the 
positioning of the E2F element in relation to the transcriptional start site.
1.6.1 Position of E2F element to transcriptional start site
Transcription of the E2F-1, -2 and -3 is upregulated during the Gl-S phase transition hence 
the respective DNA-binding activities encoded by these proteins are transient throughout 
the Gl-S phase (Nevins, 1998). All E2F transcription factors except E2F-5 and -6 are able 
to induce S phase and activate E2F regulated genes. Gene activation is regulated by a 
differential response to individual E2Fs. Some genes such as DNA pol a  are activated by all 
E2F transcription factors except E2F-5 and -6 while others such as TK and DHFR are 
preferentially regulated by E2F-2 (DeGregori et al., 1997). Normal progression from G1 to 
S phase is therefore dependent on the co-ordinated activation of E2F target genes by 
individual E2F transcription factors.
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Transcriptional regulation experiments using the DHFR promoter have shown that S phase 
specific transcriptional activation is dependent on the proximal positioning of the E2F 
element to the transcriptional start site to ensure high-level activity from the DHFR 
promoter. Thus, E2F-mediated growth regulation is position-dependent specified by the 
DHFR promoter and not by the characteristics of individual E2F elements. In contrast, 
transcriptional repression is independent of the position of the E2F element (Fry et al., 
1997a). Further, investigations into the protein-protein interactions required for DHFR 
promoter activation revealed that only recruitment of cAMP-response element-binding 
protein (CBP), appeared to play an effective role in promoter activation. Deletion analysis 
revealed a 38 amino acid long region (399-437) of E2F-1 to be adequate for maximal 
activation of the DHFR promoter and within the core E2F transactivation domain two 
phenylalanine residues are essential for transcriptional activation of DHFR and binding of 
CBP, TFIIH and the TATA-box-binding-protein (TBP). These have been identified to be 
up-regulators of E2F activity in contrast to the negative regulatory proteins p53 and pRb 
(Fry et al., 1997b; Martinez-Balbas et al., 2000).
1.6.2 E2F and acetylation
Binding of the p300/CBP co-activator complex has been shown to increase E2F activity. 
p300/CBP and the p300/CBP associated factor (P/CAF) both display histone acetylase 
activity suggesting E2F activity to be regulated through acetylation. P/CAF and p300/CBP 
have been shown to acetylate E2F-1, -2 and -3 in vitro and in vivo through an N-terminal 
acetylation site adjacent to the E2F-1 DNA binding domain (Martinez-Balbas et a l, 2000; 
Marzio et al., 2000). In contrast, acetylation was not detected with respect to E2F-4, -5 and 
-6 (Marzio et al., 2000). The site-specific acetylation by P/CAF and p300/CBP was found 
to increase DNA binding ability, transcriptional activation capacity and the protein half-life 
of E2F-1 (Martinez-Balbas et al., 2000). Finally, E2F acetylation was reversed in vitro by 
incubation with histone deacetylase-1 (HDAC-1) suggesting reversible acetylation as a 
general mechanism for the regulation of E2F activity (Marzio et al, 2000).
The proposed concept of reversible acetylation as a regulatory mechanism for E2F 
activity was further validated by an earlier study by Ferreira et al. that showed pocket 
proteins pRb, pl30 and pl07 were able to bind HDAC-1 through the LXCXE motif located 
within the A/B pocket in the C-terminus. Through the simultaneous association with
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HDAC-1 and E2F-4, p i30 and p i07 target histone-deacetylase activity to the E2F binding 
domain of E2F-4 responsive promoters, enforcing an E2F-4-mediated repression of the 
target promoter. An identical mode of action has been suggested for complexes including 
pRb, E2F-1 and HDAC-1 (Ferreira et al., 1998).
1.6.3 Methylation of E2F binding sites
Besides acetylation, methylation has been suggested as an additional mechanism involved 
in the regulation of E2F activity due to the fact that E2F binding sites in many E2F 
regulated promoters contain one or more CpG motif and, therefore, are candidates for 
regulation by methylation. A study using the E2F-binding elements of a selection of E2F 
regulated promoter sequences including DHFR, E2F-1, cdc2, c-myb and c-myc found 
hypermethylation of DHFR, E2F-1 and cdc2 blocked E2F-1 to -5 transcription factor 
binding. However, hypermethylation of c-myb and c-myc resulted in a selective binding of 
E2F whereby E2F-2 to -5 were able to bind both E2F elements while E2F-1 failed to bind 
either, in vitro and in vivo. All five E2F transcription factors were able to bind to the 
unmethylated E2F-binding sequences of DHFR, E2F-1, cdc2, c-myb and c-myc 
(Campanero et al., 2000).
1.6.4 Regulation of E2F activity through cyclin A/CDK2
Phosphorylation of the DPI protein associated with E2F-1 by a cyclin A-dependent kinase 
downregulates E2F activity in S-phase through the loss of DNA-binding and transactivation 
capacity of the E2F-1/DP1 heterodimer (Dynlacht et a l, 1997; Helin, 1998; Krek et al., 
1994; Nevins, 1998). This downregulation of E2F-1 activity stands in contrast to the 
inhibition of E2F-1/DP-1 activity during early-mid G1 phase as a result of binding to pRb 
and subsequent promoter repression. Hence, the observed transient accumulation of E2F in 
late G1 phase is the result of both early inhibition by pRb and other pocket proteins and late 
downregulation of E2F-1 activity by phosphorylation of the E2F protein complex by cyclin 
A-CDK2. A short region of eight amino acids within the cyclin A binding domain of E2F-1 
is required for the binding of E2F-1 to cyclin A and has been shown to be sufficient for the 
interaction between E2F-1 and cyclin A (Helin, 1998). Furthermore, the E2F-1 sequences 
recognised by cyclin A-CDK2 are also found in the E2F-2 and E2F-3 associated with p i07, 
p i30 and members of the p21-CDKI family suggesting a common basis for control of the
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inducible E2F proteins by cyclin A-CDK2 (Dynlacht et al., 1997; Helin, 1998; Nevins, 
1998). Neither E2F-4 nor E2F-5 contain the binding motif or binds cyclin A-CDK2. 
Downregulation of E2F-1 activity in the S-phase of the cell cycle is essential in order to 
allow cells to enter G2 (Helin, 1998). Disruption of this regulatory mechanism resulting 
from mutation of the cyclin A binding domain leads to cell cycle arrest, apoptosis and cell 
death (Nevins, 2001; Nevins, 1998). It appears that certain E2F regulated genes must be 
downregulated in order for cells to enter G2 and constitutive activity of such genes would 
be deleterious for the cell (Helin, 1998). Alternatively it has been proposed that prolonged 
binding of E2F to E2F recognition sites upstream of an origin of replication in certain 
promoters, like DHFR perturbs DNA replication (Krek et al., 1995).
1.6.5 Ubiquitination of E2F
Recent data have suggested that the activity of the E2Fs is also subject to ubiquitin- 
mediated degradation via the ubiquitin-26S-proteasome pathway in vivo (Campanero et al., 
1997; Hateboer et al., 1996; Helin, 1998; Hofmann et al., 1996; Nevins, 1998). By 
transfecting various cell lines with E2F expression plasmids in combination with Rb family 
members, it was demonstrated that E2F-1 and E2F-4 are stabilised by interaction with pRb 
or pl07/pl30, respectively. The half-lives of uncomplexed E2F-1 and E2F-4 are 2-3 hours, 
and the binding of an Rb family member increases the half-lives to 10-12 hours. Co- 
transfection of E2F-1 and E2F-4 with tagged ubiquitin, and subsequent treatment with 
proteasome inhibitors, further demonstrated that the E2Fs are able to be ubiquitinated in 
vivo (Campanero et al., 1997; Hateboer et al., 1996; Helin, 1998; Hofmann et al., 1996). 
The amino acid sequence within the carboxy-terminus of E2F-1 is required for degradation, 
and binding of pRb protects the E2F-1 protein from degradation. Therefore control of 
DNA-binding and protein stability regulate the accumulation of E2F-1 and possibly that of 
the related E2F-2 and E2F-3 proteins as cells progress through the cell cycle (Nevins,
1998).
1.7 Transcriptional repression by pocket protein/E2F complexes
Although there are distinctions in functional properties, each of the pocket proteins binds to 
E2F and is substrate for phosphorylation by G1 CDKs (Classon et al., 2001; Herwig et al., 
1997; Nevins, 1998). pRb, pl30 and pl07 have been found to block transcriptional
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activation by free active E2F and are capable of repressing E2F-regulated promoters 
(Classon et al., 2001).
The model of pRb binding and masking the E2F transactivation domain led to the 
assumption that pRb sequesters and inactivates E2F transactivation activity in GO and G1 
and phosphorylation of pRb in late G1 leads to the release of free, transcriptionally active 
E2F. However, elimination of the E2F sites from many E2F-responsive promoters led to an 
increase in transcriptional activity in G0/G1 rather than a decrease in S phase. This 
indicated that the role of E2F sites, at least in certain contexts, was to repress transcription 
in G0/G1. Furthermore, these findings suggested that pRb rather than simply neutralising 
E2F transactivation function are able to actively repress transcription when tethered to 
DNA by means of E2F (Kaelin, 1999) (Figure 1.2).
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Figure 1.2: Transcription control of E2F-regulated genes by E2F
pRb binds to an E2F-DP complex in cells in the G0/G1 stage of the cell cycle.
This leads to repression of E2F-responsive genes, firstly by inhibiting E2F from activating 
transcription by binding its transactivation domain, and secondly by active repression 
whereby it recruits factors such as HDAC, which modifies histone tails and therefore 
facilitates nucleosome packaging. Cyclin D-CDK4/6 and Cyclin E-CDK2 phosphorylate pRb 
resulting in the release of E2F, activating E2F responsive genes. Modified from Bell et al. 
2003.
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E2F bound pRb represses transcription of E2F-responsive genes through several 
mechanisms. For example, pRb prevents direct interaction of E2F with factors such as 
TATA-binding protein (TBP) thereby inhibiting activation through competitive binding 
(Connor et al., 2001). Also, pRb tethered to the promoter through E2F binds and inactivates 
adjacent susceptible transcription factors, blocking their interaction with the basal 
transcription complex (Connor et al., 2001). The E2F-mediated repressor activity of the 
pocket proteins results in the inhibition of promoters that include enhancers in addition to 
E2F sites. The repression of promoters is suggested to require the recruitment of several 
corepressors such as histonedeacetylases (HDAC) (Di Ciommo et al., 2000).
1.8 E2F and pocket proteins as part of cell cycle regulation
The family of pocket proteins controls gene expression mediated by the E2F family of 
heterodimeric transcriptional regulators. The pocket proteins interact with any of the 5 
well-characterised E2F isomers thereby regulating E2F activity so as to drive the exit from 
the cell cycle (Nevins, 2001; Nevins, 1998). The various E2F family members differ in 
their associations with the pocket proteins and E2F activity is either directly inhibited 
through pocket protein binding or transcription of E2F-responsive promoters repressed 
through E2F-mediated binding of pocket proteins (Classon et al., 2001; Helin, 1998; 
Johnson et al., 1998; Kaelin et al., 1998). E2F-1, E2F-2 and E2F-3 bind exclusively pRb 
and with low affinity pl07 or pl30 (Helin, 1998). E2F-4 and E2F-5 associate with all three 
of the pocket proteins in a cell cycle-regulated manner (Johnson et al., 1998; Moberg et al., 
1996). The DP heterodimerisation partner appears not to be involved in determining the 
binding specificity of E2F factors for the pocket proteins. However, DP factors do function 
in stabilising the interaction between E2F factors and the pocket proteins (Johnson et al., 
1998).
The predominant form of E2F in quiescent or differentiated cells is a complex 
involving either E2F-4 or E2F-5 protein in association with p i30 where E2F-mediated gene 
expression is repressed (Classon et al., 2001; Helin, 1998; Nevins, 1998). This 
characteristic E2F-4-pl30 complex appears following cell cycle exit or differentiation 
(Nevins, 1998). These complexes play an active role in maintaining the quiescent state by 
preventing the expression of growth-regulatory genes.
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Following growth stimulation, the E2F-pl30 complex disintegrates following 
phosphorylation of the p i30 protein by G1 CDKs and subsequent degradation of the p i30 
protein. The result is the de-repression of a number of genes encoding DNA replication and 
growth-regulatory activities. These include E2F-1, E2F-2 and E2F-3 (Johnson et al., 1998; 
Nevins, 1998). In addition elimination of the E2F-4/E2F-5-pl30 repressor complex leads to 
an activation of pl07  expression resulting in the accumulation of pl07 protein in late G1 
and S phase (Helin, 1998; Nevins, 1998; Sherr, 2000). pl07 is found to interact 
predominantly with E2F-4 and E2F-5 proteins and complexes containing p i07 in 
association with E2F-4 are detected at the Gl/S-phase transition, (Johnson et al., 1998; 
Nevins, 1998). The pl07 protein has the capacity to recruit cyclin A-CDK2 kinase into a 
multimeric complex involving either E2F-4 or E2F-5 and the cyclin A-containing pl07 
complex represents the predominant state of pl07 bound E2F in proliferating cells. It has 
been suggested that E2F-4 and E2F-5 although lacking the cyclin A binding domain found 
within E2F-1, E2F-2 and E2F-3 might be regulated by cyclin A-CDK2 with p i07 serving 
as an adaptor to bring the kinase to these proteins (Dynlacht et al., 1997). The fact that 
E2F-pl07 persists and is specifically expressed in proliferating cells suggests a 
proliferation-related rather than a growth-suppressing role (Nevins, 1998). However, recent 
studies have demonstrated that E2F-4-pl07-cyclin A-CDK2 complexes are found primarily 
in the cytoplasm where they would be unable to directly regulate transcription (Johnson et 
a l ,1998)
Cyclin-dependent protein kinases (CDKs) control the passage through the G1 restriction 
point and entry into S phase. CDK activity requires cyclin binding, regulated by cyclins D, 
E and A, depends on both positive (cyclin activating kinase- CAK) and negative regulatory 
phosphorylations and can be constrained by two families of CDK inhibitory proteins (INK 
and CIP/KIP). The expression of D-type cyclins is dependent on extracellular growth 
factors and both cyclin synthesis and assembly into catalytic units with CDK4 and CDK6 is 
reliant on mitogenic stimulation. Catalytic activity of the cyclin-CDK enzymes first occurs 
in mid-Gl and reaches its peak at Gl-S transition. The INK and CIP/KIP families of cyclin 
dependent kinase inhibitor proteins block CDK4 and CDK6 activity and lead to G1 arrest 
(Sherr, 1996; Sherr 2000) (Fig. 1.3).
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D-type cyclins modulate the function of pRb by activating the associated cyclin-dependent 
kinases (CDK4 and CDK6) that in turn phosphorylate pRb (Johnson et al., 1998). pRb 
phosphorylation occurs during the G1 phase of the cell cycle and is required for G1 exit. 
Therefore D-type cyclins not only function as regulatory subunits for their associated CDKs 
but also act to target pRb for phosphorylation through protein-protein binding (Johnson et 
al., 1998).
As previously discussed in section 1.7. hypophosphorylated pRb binds to a subset 
of E2F complexes, either resulting in repressor complexes through the recruitment of 
histone deacetylases and chromosomal remodeling SWI/SNF complexes to E2F-binding 
sites on E2F regulated gene promoters or inhibits the transactivation activity of E2F 
through containment of free E2F in pRb complexes (Classon et al., 2001; Sherr, 2000). 
Mitogen-dependent accumulation of cyclin D-dependent kinases results in the 
phosphorylation of pRb followed by a rapid increase in free E2F protein causing the de­
repression or activation of E2F-responsive genes required for DNA synthesis and 
replication (Fig. 1.3). Sequential phosphorylation of pRb initiated by cyclin D-dependent 
kinases is completed by the cyclin E-CDK2 complex (Johnson et al., 1998; Sherr, 1996; 
Sherr, 2000). Cyclin E forms active catalytic complexes with CDK2 and expression is 
maximal at Gl-S transition. A positive feedback mechanism facilitates progressive rounds 
of pRb phosphorylation and E2F release as cyclin E expression is regulated by E2F 
(Dynlacht et al., 1994; Sherr, 1996) (Fig. 1.3). E2F-1 in turn controls its own transcription 
by positive feedback. Therefore positive cross-regulation of E2F and cyclin E produces a 
rapid increase in both activities as cells approach Gl-S transition.
As a result pRb inactivation shifts from being mitogen-dependent (cyclin D-driven) 
to mitogen-independent (cyclin E-driven). This point is referred to as the restriction point 
defined by the irreversible commitment of the cell to progression through the cell cycle up 
to the completion of mitosis (Pardee, 1989; Pardee, 1974).
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Fig. 1.3: Restriction point control. The proteins most frequently targeted in 
human cancers are highlighted. Cyclins are shown in pink, CDKs in green.
Arrows depicting inhibitory phosphorylation (P) or inactivating steps are shown in red, and 
those depicting activating steps are shown in black (Sherr et al., 1996). For details refer to 
text.
Cyclin A- and cyclin B-dependent kinases maintain pRb in its hyperphosphorylated state 
and dephosphorylation of pRb does not occur until cells complete mitosis and re-enter the 
G1 phase (Sherr et al., 1999). Entry into S phase also results in the inactivation of cyclin E 
and E2F. Phosphorylation of cyclin E by CDK2 initiates ubiquitin-dependent proteolysis 
and the degradation of cyclin E. Cyclin A-CDK2 complexes accumulate throughout S 
phase, bind to E2F and phosphorylate the DP-1 protein subunit of the active E2F 
transcription factor thereby abrogating DNA binding of E2F and inhibiting transactivation 
of E2F regulated genes (Dynlacht et al., 1994; Dynlacht et al., 1997; Sherr, 2000).
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Cyclin D-, E- and A-dependent kinases are negatively regulated by a distinct family of 
CDK inhibitors (p21c,pl, p27Kipl, p57Kip2) (Fig. 1.4). Levels of p27Kipl in quiescent cells are 
high and decrease upon cell cycle entry. Accumulation of cyclin D-dependent kinases 
results in the sequestration of p21c,pl and p27Kipl kinase inhibitors into complexes with 
cyclin D-CDK4/6, alleviating repression of cyclin E-CDK2 and cyclin A-CDK2 activity in 
cycling cells. The p27101)1 kinase inhibitor is required for the assembly of the active cyclin 
D/CDK4/6 holoenzymes and the cyclin D-dependent kinases remain active thereafter 
(Sherr, 1996; Sherr, 2000) (Fig. 1.4). In addition, activation of cyclin E-dependent kinases 
leads to the phosphorylation of p27Kipl converting it to a form recognized by ubiquitin 
ligases targeting it for destruction by proteasomes (Sherr et a l, 1999; Sherr, 2000). Cyclin 
D-dependent kinase bound Cip/Kip kinase inhibitors persist throughout subsequent cell 
cycles until the withdrawal of mitogens releases them resulting in the inhibition of cyclin E- 
CDK2 and G1 arrest (Sherr et al, 1999).
1.9 E2F and apoptosis
Experiments in which the E2F-1 locus in mice is inactivated by homologous recombination 
have shown that E2F-1 has functions otherwise than cell proliferation. In addition to 
promoting cell proliferation E2F-1 suppresses cell proliferation depending on tissue 
specificity. Results showed that E2F-1 -/- mice were viable and fertile. However, with 
increasing age abnormalities occur including testicular atrophy, exocrine gland dysplasia 
and the development of tumours such as reproductive tract sarcomas, lung tumours and 
lymphomas (Tsai et a l, 1998; Yamasaki et a l, 1996). Defects in thymocyte (T) cell 
development due to E2F-1 deficiency resulted in aberrant hyperproliferation of T cells and 
provided support to the theory that E2F-1 not only functions to positively regulate cell 
proliferation but is also required for apoptosis and actively suppresses cell proliferation. 
Therefore E2F-1 alone is not critical for S phase entry but other E2F transcription factors 
seem to be as important for control of S phase entry (Field et a l, 1996).
Studies of adenovirus mutants revealed a role for the viral El A protein in the induction of 
p53-dependent cell death, dependent on E1A domains known to be involved in binding to 
pRb (Debbas et a l, 1993; Lowe et a l, 1993). Studies by Wu et a l, demonstrated that the 
enforced expression of E2F-1 in quiescent cells led to inappropriate S phase entry and to
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Fig. 1.4: Inhibition of Gl/S transition by cyclin-dependent kinase inhibitors.
Progression through G1 phase of the cell cycle is controlled by the functional 
state of the Rb family of proteins, pRb, pl07, pl30. Non-phosphorylated pRb 
proteins bind to E2F and prevent E2F-dependent transcription. Activation of cyclin-D 
dependent kinases 4 and 6 by their mitogen-controlled regulatory subunit results in 
phosphorylation of pRb proteins.
Activity of CDK4/6 is negatively regulated by the INK4 family of cell cycle 
inhibitors by preventing cyclin D binding to CDK4/6. CDK4/6-cyclin D complexes 
also activates CDK2 by binding Cip/Kip proteins thus preventing them from 
blocking CDK2-cyclin E activity. Hyperphosphorylation of Rb proteins by 
CDK2-cyclin E complexes is required for entry into S phase.
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induction of p53-dependent apoptosis. Experiments using overexpressed mutant E2F-1 
showed that the DNA binding ability of E2F-1 is essential for the initiation of cell death 
and co-expression of DP-1 augments cell death (Hiebert et al., 1995; Nevins, 2001; Wu et 
al., 1994). This suggests that E2F-1 regulates genes important for apoptosis.
A role for E2F-1 in apoptosis is supported by analysis of /fa-null mice, in which 
apoptosis associated with loss of pRb function was shown to be efficiently rescued by 
deletion of E2F-1 strongly supporting a role of E2F-1 in a protective response to abnormal 
proliferative signals (Pan et al., 1998; Tsai et al., 1998). Further analysis of E2F-1 deficient 
mice exhibited aberrations in T cell development causing the hyperproliferation of T cells 
by preventing apoptosis (Field et al., 1996). Therefore E2F-1 functions as part of a 
tumour-suppressing mechanism whereby uncontrolled or inappropriate E2F-1 activation 
results in apoptosis thus protecting the organism against oncogenic transformation (Phillips 
et al., 1999).
1.9.1 p53-dependent apoptosis
p53 is mutated in more than 50% of human cancers. In response to cellular stress from 
DNA damage, hypoxia and oncogene activation, the p53 protein stabilises and accumulates. 
The activated p53 initiates a transcriptional programme thereby triggering either cell cycle 
arrest or death (Sherr, 2001).
E2F-1 induced apoptosis following induction of S phase is largely dependent on p53. 
Neither, E2F-2 or E2F-3 induce apoptosis despite the fact that these E2F family members 
also induce S phase (Kowalik et al., 1998). E2F-4 or E2F-5 both do not have the ability to 
induce apoptosis either (DeGregori et al., 1997). In addition E2F-1 together with the 
heterodimeric partner DPI, but not E2F-2 induces the accumulation of p53 (Hiebert et al., 
1995; Nevins, 1998). This is consistent with earlier work showing that adenovirus E1A 
induces p53 accumulation (Kowalik et a l, 1998).
Pan et al. showed using Rb-/- mice that inactivation of E2F-1 resulted in an 80% 
decrease in apoptosis in the presence of active p53 as a result of a decrease in E2F-1- 
induced p53 accumulation. Therefore it appears that p53 serves as a checkpoint monitoring 
E2F-1 expression during cell proliferation. Further it was proven that E2F-1 lies upstream 
of p53 in the signalling pathway as expression of p53-dependent p21WAF, murine double 
minute 2 (MDM2) and Bax were reduced following E2F-1 inactivation (Fig. 1.5). Although
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p53-dependent apoptosis was diminished in the absence of E2F-1 no accelerated tumour 
growth as seen upon p53 inactivation was observed due to its requirement for efficient cell 
cycle activity meaning that p53-dependent apoptosis is defective in the absence of E2F-1 
but any impact on tumour growth is also counterbalanced by an accompanying reduction in 
tumour cell proliferation (Pan et al., 1998).
Results by Kowalik et al. and Wu et al. support findings that p53 and E2F-1 co­
operate in the induction of apoptosis, as p53-dependent induction of apoptosis through 
E2F-1 is regulated by MDM2 and p53 accumulation is inhibited by MDM2 (Kowalik et al. 
1998). Binding of MDM2 to p53 was found to antagonise the transcriptional activity of p53 
as well as induce p53 ubiquitination and enforce the export of p53 from the nucleus to the 
cytoplasm where p53 is degraded (Sherr, 2001).
The recently discovered pl4ARF protein was found to link the deregulated expression 
of E2F-1 with the subsequent occurrence of p53-dependent apoptosis. The p l4ARF protein 
stems from an alternative reading frame (ARF) within exon 2 of the INK4a gene locus that 
also codes for the p l6 INK4a kinase inhibitor protein. It is suggested that the p53-dependent 
apoptosis pathway relies on the induction of the tumour suppressor protein p l4 ARF, in 
response to abnormal proliferation signals, followed by the inhibition of MDM2 resulting 
in the accumulation and stabilisation of p53 (Bates et al., 1998) (Fig. 1.5).
Experiments have shown p l9 ^ F deficient mouse embryo fibroblasts (MEFs) from knockout 
animals grow continuously in culture without undergoing senescence and the MEFs were 
susceptible to transformation by oncogenic ras without any co-requirement for 
immortalising oncogenes, such as Myc or adenovirus E1A (Sherr, 2001). Finally, the MEFs 
were found to proliferate more rapidly in culture than their wild-type counterparts and had 
properties of permanently established cell lines. INK4a-nu\\ MEFs have normal cell cycle 
profiles, arrest upon serum withdrawal and have no colony forming advantage when plated 
at low density (Sherr, 2001). To conclude, loss of ARF or p53 leads to uncontrolled cell 
growth and rapid tumour formation.
1.9.2 p53-independent apoptosis
The p53-independent apoptosis pathway was shown to involve the p53 homologue p73. 
E2F-1 induces the transcription of p73 and disruption of p73 function inhibited E2F-1 
induced apoptosis in p53-defective tumour cells and p53'A mouse embryo fibroblasts.
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Hence p73 provides an alternative means for E2F-1 to induce apoptosis in the absence of 
p53 (Irwin et al., 2000) (Fig. 1.5).
Observations by Lissy et al. indicate that p73 serves to integrate receptor-mediated 
apoptotic stimuli. Stimulation of the T-cell receptor (TCR) in cycling peripheral T cells 
causes apoptosis by TCR-activation-induced cell death (TCR-AICD) independent of p53. 
Inactivation of p73 results in the inhibition of TCR-mediated apoptosis. Therefore, 
disruption of the E2F-1 gene significantly increases T cell number and splenomegaly but 
disruption of E2F-2, E2F-4 or p53 does not (Lissy et al., 2000).
In addition, E2F-1 is able to induce apoptosis via a death receptor-dependent 
mechanism and sensitises cells to apoptosis in response to tumour necrosis factor a  (TNFa) 
by downregulating expression of TNF-receptor associated factor 2 (TRAF2), therefore 
inhibiting normal activation of anti-apoptotic signals such as NF-kB. In addition, loss of Rb 
is sufficient to confer significant sensitivity to TNFa-induced apoptosis in primary cells 
(Phillips etal., 1999).
1.10 Deregulation of E2F-1
In the majority of tumours deregulation of the retinoblastoma pathway occurs through 
mechanisms including mutation or deletion of upstream regulators of E2F such as Rb and 
cyclin-dependent kinase inhibitor p l6 INK4a or cyclin D overexpression as a result of gene 
amplification, translocation, post-transcriptional or post-translational modifications 
(Buckley et al., 1993; Kaelin et al., 1999; Schauer et al., 1994; Sharpless et al., 1999). 
Alterations in the expression of Rb, cyclin D1 and p l6 INK4a lead to upregulation of the E2F 
transcription factors and a subsequent increase in the expression of genes required for DNA 
synthesis and progression from G1 to S phase of the cell cycle (Sherr, 1996).
Transfection or microinjection experiments documented the ability of overexpressed E2F-1 
protein to activate transcription, to stimulate cell cycle progression and to induce oncogenic 
transformation (Nevins, 1998). Overexpression of E2F-1 or E2F-1/DP1 co-operates with 
activated ras in fibroblast transformation assays and transformed cells result in tumour 
growth in nude mice demonstrating that E2F-1 has oncogenic capacity. The neoplastic 
transformation potential of E2F-1 is dependent on functional DNA binding and
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Figure 1.5: E2F involvement in apoptotic pathways
Mitogenic signalling activates E2Fs to advance cells into S phase. Stress signals 
that activate the INK4a-ARF locus inhibit the activity of cyclin D-dependent 
kinases (pl6INK4a) and induce p53 through either ARF-dependent or -independent 
pathways, reprogramming the cells to undergo growth arrest or apoptosis. 
Modified from Sherr et al. 2002.
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transactivation domains but does not rely on direct interaction with pRb (Singh et al., 1994; 
Yamasaki et al., 1996).
Microinjection of a cytomegalo-virus (CMV) promoter controlled E2F-1 cDNA 
into quiescent cells induced S phase entry and stimulated expression of DHFR and TK. 
Apart from promoting S phase entry ectopic E2F-1 expression also induced apoptosis in the 
presence of wild-type p53 in monkey kidney cells, rat fibroblasts and human osteosarcoma 
cells (DeGregori et al, 1995; Johnson et al., 1993; Qin et al., 1994; Shan et a l, 1994). In 
contrast, ectopic expression of the E2F heterodimeric partner protein DPI alone failed to 
promote S phase entry suggesting that the active E2F subunit is required for cell cycle 
entry. Finally, coexpression of DPI and E2F-1 resulted in a greater loss of G1 regulation 
and significantly more apoptosis than E2F-1 alone proposing a synergistic effect as a result 
of the interaction of E2F-1 and DPI (Shan et a l, 1996).
Experiments using a tetracycline-controlled E2F expression system as well as 
microinjection experiments showed that the pRb-associated E2F transcription factors (E2F- 
1, E2F-2 and E2F-3) all induced S phase in quiescent rat fibroblasts when expressed alone. 
In contrast, the pl30/pl07-associated E2F transcription factors (E2F-4 and E2F-5) both 
require co-expression of the heterodimeric partner protein DPI to promote S phase entry 
and accelerate G1 progression. Furthermore, the pRb-associated E2Fs were able to 
overcome a G1 arrest mediated by the pl6INK4 tumour suppressor protein and E2F-1 was 
shown to override a G1 block mediated by a neutralising antibody to cyclin Dl. In contrast, 
only simultaneous expression of E2F-4 and DPI could overcome these cell cycle blocks. It 
was concluded that E2F activity is rate limiting for G1 progression, is sufficient to induce S 
phase entry and overcomes a pl6-mediated and a cyclin Dl antibody mediated G1 phase 
block (Lukas et al., 1996).
Previous studies have shown the introduction of an adenovirus vector containing 
E2F-1 cDNA into y-irradiated, S phase inhibited cells to relieve the irradiation block by 
activating the transcription of cyclin A, cdc2, DHFR and E2F-1 genes (DeGregori et al., 
1995). Increased levels of E2F-1 expression as well as E2F-1 DNA binding activity have 
also been found in response to UV- or y-irradiation in human cancer cells implying 
increased expression of E2F-1 to serve as a mechanism to overcome the y-irradiation block. 
This result presents E2F-1 with a role in the DNA damage response pathway involving 
ATM (Hoefferer et al., 1999).
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In vivo knock-out experiments have shown that Rb(-/-) mice die during mid-gestation 
(E13.5-E15.5) with increased apoptosis in a variety of tissues and incomplete 
haematopoiesis in the foetal liver. An increase in apoptosis in the Rb(-/-) central nervous 
system correlates with an increase in cellular S phase entry, ‘free’ E2F DNA binding 
activity and cyclin E expression (Yamasaki et al, 1998). In contrast double mutant mice 
Rb(-/-); E2F-1(-/-) show a prolonged survival extending beyond E16.5 suggesting E2F-1 to 
determine the timing of lethality of /^-deficient embryos. Therefore, Rb deficiency in 
combination with loss of E2F-1 results in decreased levels of apoptosis and a reduction in 
inappropriate S phase entry compared to Rb deficiency alone. However, E2F-1 deficiency 
could not extend embryonic survival to term (Tsai et a l, 1998). Further experiments with 
Rb( +/-);E2F-1( +/-) and Rb( +/-);E2F-1(-/-) mice indicated that the majority of control mice 
Rb( +/-) and all of the double heterozygotes developed pituitary tumours while 62% of 
Rb(+/-);E2F-1(-/-) animals developed pituitary tumours. This shows that inactivation of 
both wild-type E2F-1 alleles reduces the penetrance of pituitary tumourigenesis compared 
to control mice (Yamasaki et a l, 1998). Regarding thyroid tumourigenesis it was found 
that none of the Rb(+/-);E2F-1(-/-) and 6% of the double heterozygotes developed C-cell 
adenomas or hyperplasias. However, 53% of control mice (Rb(+/-)) exhibited thyroid 
lesions. Hence, loss of E2F-1 reduces the occurrence of thyroid tumours significantly and is 
thought to interfere with thyroid tumourigenesis by reducing proliferation of the C-cell 
precursor population. Finally, testicular atrophy and exocrine gland dysplasia still 
developed with 100% penetrance in E2F-1 deficient animals and lung adeno-carcinoma or 
lymphoma were detected in E2F-1 deficient animals which developed pituitary tumours. To 
conclude, loss of E2F-1 reduced the lethality of the Rb( +/-) phenotype regardless of the 
genetic background (Yamasaki et al, 1998).
Mice deficient in p i 30 or p i 07 develop normally and exhibit no overt adult phenotypes. 
This suggests that p i 07 and p i 30 are either dispensable for development or exhibit 
redundancy. Mice lacking both p i07 and p i30 are bom with shortened limb and rib bones 
and die after birth. Interbreeding of Rb-, p i 07- and p 130-deficient mouse strains and 
generation of chimaeric animals lacking one or more Rb family members revealed an 
extensive functional redundancy between the members of this gene family during 
development (Classon et a l, 2001).
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1.11 Chemotherapeutic approach in the treatment of cancer
Chemotherapy is the use of cytotoxic drugs to kill cancer cells. Most cytotoxic agents 
destroy cancer cells by interfering with DNA synthesis, mitosis or other essential function 
in the cell thereby forcing the cell to arrest or undergo apoptosis. Chemotherapy is most 
effective against rapidly dividing cells and most cytotoxic agents are only effective against 
a fraction of cells, traversing a specific cell cycle phase, at any one time. Therefore it is 
essential to study the specific cell cycle behaviour of cancer cells in order to target the 
correct cytotoxic agent to the appropriate fraction of cells at the correct time.
At present anti-neoplastic drugs are discovered through empirical testing. Many of 
these drugs target no more than one cell cycle phase making the combination of drugs 
acting at different stages of the cell cycle a potentially improved strategy that could yield a 
synergistic effect therefore making tumour cells more vulnerable compared to individual 
drug treatment. However, with the discovery of genes that regulate the cell cycle and 
checkpoint function, new approaches to identify and design anti-neoplastic drugs that will 
specifically target the biochemical activities of oncoproteins and altered tumour suppressor 
gene products are being developed.
In the context of uncontrolled cell proliferation as a result of deregulation of E2F, 
CDK inhibitors (CKI) such as flavopiridols are one example of chemotherapeutic agents 
implied to counteract the effects of deregulated E2F activity. Flavopiridols were shown to 
have anti-proliferative effects on the growth of several human tumour cell lines (Meijer et 
al., 1999; Sausville et al., 1999). Furthermore, the in vivo effects of these compounds 
paralleled the in vitro efficiency as confirmed with the use of dominant negatives, the 
overexpression of natural CKI’s and the microinjection of inactivating antibodies and 
antisense technology (Camero, 2002; Schwartz et al., 2001; Senderowicz et al., 1998; 
Stadler et al., 2000; van den Heuvel et al., 1993). Flavopiridol, the first CDK modulator 
tested in clinical trials, demonstrated clinical features including cell cycle block at G1 and 
G2, induction of apoptosis, promotion of differentiation, inhibition of angiogenic processes 
and modulation of transcriptional events. In addition, flavopiridol was found to deplete 
cyclin D l and D3 by transcriptional repression (Carlson et al., 1999; Senderowicz, 2001).
A second CDK modulator tested in clinical trials is the staurosporine derivative 
UCN-01. UCN-01 has also been found to block cell cycle progression and promote
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apoptosis. Clinical activity has been shown in the treatment of melanoma, lung cancer and 
non-Hodgkin’s lymphoma (Camero, 2002).
The knowledge about oncogene function in the cell cycle may serve
■ to elucidate the mechanisms of anti-neoplastic drug action
■ to improve usefulness of existing drugs by identifying drugs that act synergistically
■ to select more specific drugs that target tumour cells more effectively
■ to decrease drug dosage
The delineation of pathways that regulate the balance among cellular proliferation, 
differentiation and apoptosis is currently an area of intense research interest as mutations 
that upset the balance in favour of proliferation are fundamental to the development of most 
cancers.
1.12 Combination chemotherapy
Combination chemotherapy describes the combined application of common and novel anti­
cancer agents to increase cytotoxic efficacy by attacking different biochemical targets, 
overcoming established drug resistance to single anti-cancer agents and taking advantage of 
tumour growth kinetics when considering the administration of the anti-cancer agents (Shah 
et al., 2001). It is of importance to obtain knowledge of the effects of chemotherapeutic 
agents on the cell cycle, as well as determine the appropriate administration sequences, 
time schedules and doses for the combined anti-cancer agents in order to prevent cell cycle- 
mediated resistance (Shah et al., 2001). The rationale for combination chemotherapy lies in 
selecting chemotherapeutic agents with different mechanisms of action thereby ensuring 
maximum effect through the disruption of a variety of cellular pathways essential for the 
maintenance and replication of genetic information and progression through the cell cycle. 
An example of the successful combination of two anti-cancer agents with differing 
mechanisms of action is the administration of paclitaxel followed by flavopiridol. This 
combination results in an accelerated exit from mitosis associated with an increase in 
apoptosis (Shah et a l, 2001).
A second example of combination treatment improving efficacy of chemotherapy 
has been reported with respect to the administration of gemcitabine followed by 
flavopiridol (Jung et al., 2001). Gemcitabine was found to inhibit ribonuclease reductase
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(RR), an enzyme involved in DNA synthesis during S phase. The RR-M2 subunit in 
particular was shown to be involved in RR enzyme activity and protein and activity level 
were correlated with DNA synthesis.
Flavopiridol was shown to inhibit the activity of CDKs 1,2,4 and 6 and was found 
to inhibit tumour cell growth in vitro through G1 and G2 phase arrest. Cell cycle arrest 
resulted due transcriptional inhibition of cell cycle specific genes. Hence, administration of 
gemcitabine and flavopiridol was observed to cause a potentiation of gemcitabine-induced 
apoptosis in a sequence-dependent manner. Potentiation was correlated with the down­
regulation of the RR-M2 subunit that had been found earlier to be regulated by E2F-1. In 
conclusion, downregulation of RR-M2 transcription as a result of increased proteasome- 
mediated degradation of E2F-1 and hypophosphorylation of pRb caused an increase in 
gemcitabine-induced apoptosis (Jung et al., 2001).
1.13 Drug resistance
Drug resistance to chemotherapeutic agents is often considered a major problem in 
chemotherapy and two types of drug resistance in tumours are recognised in the clinic:
■ intrinsic resistance is defines as the innate drug resistance of tumour cells prior to 
treatment
■ acquired resistance occurs due to newly acquired properties of tumour cells as a 
result of drug treatment
1.13.1 Mechanisms of drug resistance
Several mechanisms of drug resistance have been described at the cellular level.
■ decreased drug uptake - methotrexate and nitrogen mustards enter cells via a carrier 
system. Alterations in carrier resulting from mutations or decreased protein 
synthesis may limit entry of drug.
■ increased drug efflux through the cell membrane - P-glycoprotein dependent 
increase in drug efflux leads to multidrug resistance
Colon tumours serve as an example of intrinsic cellular resistance as they are 
inherently resistant to chemotherapy as a result of P-glycoprotein (P-gp). P- 
glycoprotein is a trans-membrane protein involved in the ATP-dependent efflux of a 
number of structurally unrelated anticancer drugs (Fardel et al., 1996). P-gp
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overexpression in cancer cells decreases intracellular drug concentrations and confers a 
multidrug resistant phenotype. Overexpression of P-gp has been shown in a wide 
variety of cancers including solid tumours and haematological malignancies. A high 
constitutive expression level of P-gp was found in tumours arising from tissues known 
to physiologically express P-gp including carcinoma of the colon, kidney, adrenal 
gland, pancreas and liver. By contrast tumours of the lung, esophagus, stomach, ovary 
and breast, melanomas, and some leukemias usually display low P-gp expression. P- 
glycoprotein overexpression maybe detected at the time of diagnosis prior to 
chemotherapy, or following relapse and has been correlated with treatment failure and 
poor prognosis in several types of cancer (Fardel et al., 1996). P-gp-mediated multidrug 
resistance may be reversed by various unrelated compounds called chemosensitisers or 
reversing agents. These drugs act through inhibition of P-gp function and have entered 
clinical trials (Fardel et al., 1996).
■ increased drug inactivation - occurs via glutathione adduct formation as conjugation 
of glutathione with free radicals inactivates drugs
■ decreased drug activation - e.g. an activating enzyme is required for the activation 
of 5-fluorouracil
■ enhanced repair of drug-induced DNA damage
■ decreased formation of drug-target complexes
- if the mechanism of drug action involves inhibition of enzyme or receptor 
molecule, resistance can be mediated by an increase in the level of target protein
- if formation of drug-target complex causes toxicity, resistance can be mediated by 
a decrease in target protein
Examples of drug resistance involving the above mechanism are found in response to 
treatment with antimetabolites such as methotrexate and 5-fluorouracil. Antimetabolites are 
compounds that replace natural substances as building blocks of DNA and other vital 
components of the cell thereby altering the function of enzymes required for cell 
metabolism and protein synthesis. This results in the prevention of DNA synthesis and 
replication subsequently leading to cell death. Antimetabolites are cell cycle specific and 
are considered to be most effective during the S phase of the cell cycle. Antimetabolites 
have been used in the treatment of non-Hodgkin’s lymphoma and colorectal cancer. The
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category of antimetabolites includes folate antagonists (methotrexate) and pyrimidine 
antagonists (5-fluorouracil) (Souhami and Tobias, 1998).
1.14 Pharmacology of major groove- and minor groove DNA- binding drugs
DNA-binding drugs may be categorised into minor groove-binding or major groove- 
binding drugs. Representatives of major groove-binding DNA-binding drugs are the 
nitrogen mustards including Melphalan and the platinum compounds including Cisplatin. 
The above drugs are classified as major groove alkylating agents and are highly reactive 
compounds that form covalent bonds with a number of nucleophilic groups on the DNA. In 
general, DNA-binding alkylating agents form a covalent bond between the reactive group 
of the drug and the 7-nitrogen group of guanine. Following formation of the initial covalent 
bond, bifunctional alkylating agents such as Cisplatin proceed to form a second covalent 
bond with a second nucleophilic group resulting in DNA inter-strand or intra-strand 
crosslinks .
The class of minor groove -binding anticancer drugs includes cyclopropylpyrrolo- 
indole (CC-1065) (Hurley et al., 1984; Swenson et al., 1982), the anti-tumour antibiotic 
distamycin A (Arcamone et al., 1964; Van Dyke et al., 1982) including its derivatives 
Tallimustine (Herzig et al., 1999), BGIII21 (Wyatt et al., 1995) and SCIII147, the latter 
two being novel minor groove binding alkylating agents, as well as the fluorochrome 
Hoechst 33258 (Albert et al., 1999). Molecular pharmacological studies indicate that non- 
covalent minor groove binding agents such as distamycin A, CC-1065 and Hoechst 33258 
interact preferentially with A-T rich sequences that are at least 3-4 base pairs in length. The 
preference of these drugs for AT sites has been attributed to the minor groove that 
characterises these sequences and to the complementary crescent shape of the minor 
groove-binding agent. Strong van der Waals contacts between the sides of the groove and 
the aromatic rings of the bound drug provide a significant contribution to the stability of the 
drug-DNA complex. The stability of the bound drugs is further enhanced by interactions 
between the negative electrostatic potential of the AT sequences and by hydrogen bonding 
between the drug and DNA. The relative importance of these factors for the stability of the 
drug-DNA complex remains a matter of discussion (Albert et al., 1999).
In addition, a number of minor groove-binding agents has been found to possess 
DNA sequence specificity of alkylation. For example, the novel minor groove-binding
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alkylating agent BGIII21 has been reported to preferentially alkylate at only two sequences, 
5’-TTTTGG and 5’-TTTTGA (confirmed as guanine-N3 and adenine-N3 lesions at the 
underlined bases, respectively) in preference to other sites (Brooks et al., 2000).
The effects of minor groove-binding agents on the regulation of gene transcription, 
the perturbation of the cell cycle, and the mechanism involved in the repair of the DNA 
lesions induced by these drugs strongly support the view that minor groove binding agents 
act by a mechanism different from those previously described for other anticancer drugs 
(D’lncalci et al., 1997).
1.15 Summary and PhD project aims
As previously discussed within this introduction, involvement of the cell cycle mechanism 
in tumourigenesis is not based on deregulation of individual components but tumourigenic 
properties of many oncogenes also rely on their ability to deregulate the cell cycle 
machinery (Hanahan et al., 2000). A number of cell cycle permutations involved in human 
neoplasia are shown in table 1.1
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PROTEIN ALTERATION TUMOUR
CDK4 Mutation Melanoma
Cyclin D1 Overexpression Breast and prostate cancer, 
parathyroid adenoma, gastric 
and esophagic carcinoma, 
multiple myeloma
Cyclin D2 Overexpression Colorectal carcinoma
Cyclin E Overexpression Breast, ovary and gastric 
carcinoma
Cyclin A Overexpression Hepatocellular carcinoma
p27ICIP1 Inactivation/ degradation Colon breast and prostate 
cancer
p l^K ^ Deletion/ inactivation 
mutation
Melanoma, lymphomas, 
non-small cell lung cancer, 
pancreatic carcinoma
pRb Inactivation Retinoblastoma, small cell 
lung cancer, sarcoma and 
bladder cancer
Table 1.1: Cell cycle regulatory elements involved in human neoplasia (adapted from 
Camero, 2002).
The result of an alteration of one or more cell cycle elements shown in table 1.1 leads to an 
increased expression and activity of the E2F transcription factors. A number of approaches 
using chemotherapy to counteract the occurrence of deregulated E2F activity have been 
attempted and specific examples of these are given within the relevant sections. However, 
in general, the studies performed to investigate and exploit mechanisms and downstream 
effects of E2F-1 deregulation have included:
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1) Overexpression of E2F-regulated proteins
Proteins required for DNA synthesis and G1 to S phase transition such as DHFR or TS 
potentially bind or are a drug target. E2F-1 dependent overexpression of these proteins 
potentially reduces cellular drug sensitivity due to a decreased formation of drug-target 
complexes (section 3.1.1).
2) Increase of the proportion of cells in S phase and chemosensitivity 
Overexpression of E2F-1 and the resultant increase in E2F-regulated gene expression has 
been shown to drive cells into S phase (Shan et al., 1994; Shan et al., 1996). An E2F- 
induced increase in the proportion of cells in S phase might lead to an increased cell kill 
using S phase specific drugs (section 3.1.2).
3) E2F-1 mediated apoptosis and chemosensitivity
As discussed within section 1.9, deregulated E2F-1 activity enhances apoptosis through 
induction of pl4ARF followed by inhibition of MDM2 resulting in the accumulation and 
stabilisation of p53 (Bates et al., 1998). Alternatively, E2F-1 is able to induce p53- 
independent apoptosis via p73, a p53 homologue (Irwin et al., 2000). Combination 
chemotherapy may be considered a useful tool to potentiate drug-specific apoptosis through 
the sequential administration of a second chemotherapeutic agent (section 3.1.3)
The identified causes and effects of E2F-1 deregulation are useful in targeting the 
appropriate anti-cancer agent to a characterised tumour. These patterns include the deletion 
or mutation of cell cycle regulatory genes upstream of the E2F-1 transcription factor 
leading to an abnormally increased expression of E2F-1.
In addition, the combined loss of the Rb and subsequent loss of p53 thereby 
preventing activation of the apoptotic pathway in response to deregulated expression of 
E2F-1. Other genes potentially affected by deletion or mutation include pl4ARF or MDM2 
and alterations in these genes interfere with the cell’s ability to conduct the proapoptotic 
signal allowing E2F-1 overexpression to stimulate cell proliferation (Dyson, 1998; Muller 
et al., 2000).
As an example, mutations in p53, p i  6 and p l4ARF occur frequently in colon cancer, 
and coupled with high levels of E2F-1 activity point to a more aggressive phenotype of the
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tumour. Along with loss in the apoptotic signalling pathway, overexpression of E2F-1 may 
also activate transcription of genes implicated in a more invasive phenotype.
To provide a model system portraying the situation of E2F-1 deregulation in cancer cells, 
an E2F-1 stably transfected HT1080 human fibrosarcoma cell line was used, with an Rb 
deficient and p53 proficient genetic background. Inspite of the HT1080 transfectants being 
p53 proficient, no increased level of apoptosis in response to E2F-1 overexpression has 
been reported. Hence it may be assumed that deletions or mutations of other components, 
such as the p M ^  or MDM2 gene, of the apoptotic pathway are present.
The aims of this project are:
• to determine the pattern of chemosensitivity secondary to E2F-1 
overexpression.
• to determine the mechanisms of E2F-1 interactions with chemotherapeutic 
agents.
• to examine the effects of a novel E2F-1 inhibitory peptide on cell cycle 
progression within the HT1080 transfectants as well as other established 
cancer cell lines. The inhibitory peptide has been shown to inactivate the 
transactivation potential of E2F-1 by preventing the heterodimerisation of 
the E2F-1 subunit and DP-1 subunit to form an active transcription factor 
complex. However, the E2F-1 inhibitory peptide does not prevent E2F-1 
from binding to DNA.
• to combine the information from the above investigations in order to set up 
experiments to investigate possible additive or synergistic effects a 
combination of anti-cancer agent and E2F-1 inhibitory peptide has.
51
2. MATERIALS AND METHODS
2.1. Materials
2.1.1 Chemical reagents and cytotoxic drug source
All reagents and plastics were obtained from Sigma Chemical Co. Ltd., Poole, UK or VWR 
International Ltd., Poole UK respectively unless otherwise stated.
Cytotoxic drugs (table 2.1) were prepared in advance or fresh before every 
experiment depending on the individual compounds stability and activity in solution as well 
as experimental requirements. The concentration ranges used for experiments were adapted 
from previous personal communications on the cytotoxicity of individual agents if required.
2.1.2 Experimental cell lines
Cell lines were obtained from the departmental cell bank unless otherwise stated. Tissue 
culture media and supplements including trypsin was supplied by Autogen Bioclear, Caine, 
UK. Foetal calf serum (FCS) was heat-inactivated for 30 minutes (min.) at 57°C prior to 
use. The growth medium described for the routine propagation of exponential growing cell 
lines is referred to as complete growth medium throughout.
2.1.3 Tissue culture procedures
2.1.3.1 Maintenance of cell lines
Cell lines were maintained at 37°C and 5% C 02 in dry incubators (Forma Scientific, UK) 
and all procedures were carried out in Class II MDH biological safety cabinet (Intermed 
MDH, UK) using aseptic techniques. All cell lines were grown in 75cm2 (T75) flasks 
unless otherwise indicated in specific experiments. Exponentially growing cells were 
maintained at a cell concentration according to the European Collection of Cell Cultures 
(ECACC), Salisbury, UK.
Cells were routinely passaged when they became confluent (every 2-3 days). The 
cell monolayer was washed with 10ml of 0.01M phosphate buffered saline (PBS) to remove 
serum. Then 3ml of IX Trypsin/EDTA was added to each flask and incubated for 2-5 
minutes at 37°C. When cells had detached from the flask, trypsin was inactivated by adding
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Drug Chemical structure Stock solution 
(mM)
Solvent Supplier
Anthramycin
?H „o c h 3
N\ f ^ ^ ' c o m 2
0
10 100% DMF departmental drug supply
BGIII21
• ' " ' ° r :n v=
10 orlOO 10% conc. HC1 
+ DMSO
Dr. Moses Lee, 
Furman University, 
South Carolina, USA
CC1065 10 100% DMA Upjohn Lab, Kalamazoo, 
Michigan, USA
Cisplatin M M  3  
1
M 3 I S I ------- R t --------O l
I
C l
3.3 Solution for injection DBL, Warwick, UK
Distamycin A 100 ddH20 Sigma, UK
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Etoposide 100 100% DMSO Sigma, UK
^ o ,I
Hoechst 33258 100 Sigma, UK
Melphalan 100 200 pi ethanol (100%) per 1ml 
DMSO (100%)
Sigma, UK
(XHM
not available 100% DMA10 orlOO Dr. Moses Lee, Furman 
University, SC, USA
Tallimustine 10% conc. HC1 
+ DMSO
Pharmacia, Milan, Italy
Table 2.1: Cytotoxic drugs used (for chemical name see ‘Abbreviations’)
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10ml of complete growth medium, and the cell suspension was pelleted by centrifugation at 
400g for 5 minutes at room temperature. The cells were then resuspended in complete 
growth medium and re-plated at an appropriate passage ratio for the cell line. The passage 
number was increased by one. Cells were discarded after approximately 20 passages and 
fresh cells were taken from the initial passage number used.
2.1.3.2 Quantification of attached or suspended cell yield
Cells were trypsinised, resuspended in a known volume of complete growth medium and 
counted using a haemocytometer. Cell number was determined for each of five separate 
1mm2 fields, and the average was multiplied by lxlO4 to give the number of cells per ml of 
suspension.
2.1.3.3 Determination of cell doubling time using growth curves
Cells were seeded out at an initial total cell number of lxlO4 cells in a total volume of 10ml 
of complete growth medium for suspension cells, or lxlO5 cells per 25cm2 (T25) flask 
containing 10ml of complete growth medium for adherent cell lines. Adherent cell lines 
required an individual flask for every time-point. For suspension cells, 10/d samples were 
taken every 24hrs from the flask and the number of cells counted using a haemocytometer. 
Adherent cells were trypsinised, centrifuged and resuspended in a known volume of 
complete growth medium. Again a 10/d sample was used to count the cell number using 
the haemocytometer. The cell concentrations (number of (no.) cells xl04/ml) obtained were 
used in both cases to calculate the total number of cells per flask. Further samples were 
taken every 24 hours until confluency or plateauing of cell growth was achieved. The 
doubling time of each cell line was calculated by reading off the exponential portion of the 
growth curve derived by plotting number of hours against total number of cells counted.
2.1.3.4 Mycoplasma testing
Cell cultures were routinely tested for Mycoplasma contamination every 6 months. The 
NIH 3T3 (3T3) mouse fibroblast indicator cell line was grown in DMEM medium 
supplemented with 10% New bom calf serum and 2mM glutamine. The 3T3 cells were 
maintained at 10% C 02 at 37°C. A total number of 2xl04 3T3 cells were seeded onto a 
sterile coverslip which had been placed into a flat bottom Falcon tube. Cells were allowed
55
to adhere to the coverslips for 24 hours at 37°C and 10% C 02. Previously, the cell lines to 
be Mycoplasma tested had been set up such that the cells reached confluency concurrently 
with the set-up of the Mycoplasma test. Thus, from a flask containing a confluent cell 
population to be tested, 500/xl of the supernatant growth medium were removed and 
transferred to the Mycoplasma testing tube. The cell-free supernatant must not contain 
additives such as hydrocortisone, cholera toxin or antibiotics that might interfere with 
Mycoplasma growth. The 3T3 cells were incubated for 4 days or until confluent. The 
medium was removed and the cells washed once with 0.01M PBS. Cells were fixed in 
absolute methanol for 5 minutes. Afterwards the cells were washed twice with 0.01M PBS 
and stained with 5pg/ml of Hoechst 33258 dissolved in 0.01M PBS for 10 minutes. Two 
more washes with 0.01M PBS were carried out, the cover slips were carefully removed 
from the Mycoplasma testing tube, placed cell surface upwards on a glass microscope slide 
and covered with a coverslip. Analysis was performed under a fluorescent microscope 
using a x40 objective and ultra-violet (UV) illumination. Control cells showed intense blue- 
white staining of the nuclei only. Mycoplasma infected cells would have been covered in a 
fine “lawn” of speckles all over.
2.1.3.5 Storage and retrieval of cells in liquid nitrogen
Frozen cell stocks in liquid nitrogen were routinely prepared. Cells were grown in a 175cm2 
(T175) flask to semi-confluency. They were trypsinised and resuspended in 10ml complete 
growth medium containing 10% dimethylsulphoxide (DMSO). Aliquots of 1.5ml were 
frozen slowly in cryotubes in a styrofoam box at -80°C overnight before the cryotubes 
were transferred into liquid nitrogen tank the next day. Each cryotube contained cells at a 
10X higher concentration compared to the concentration at which they were grown.
Cells were recovered from liquid nitrogen by thawing rapidly in a 37°C water bath 
before being transferred into a T25 flask containing 10ml of complete growth medium. 
Each cryotube was wiped off with paper towel sprayed with 70% industrial methylated 
spirit (IMS) to prevent accidental contamination of cell lines through bacteria and other 
cells stuck to the outer wall of the cryotube. Cells were split after 24 hours to remove any 
DMSO present in the media.
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2.2. Methods
2.2.1 Western Blot Analysis
2.2.1.1 Method 1
This technique was initially employed to analyse the relative E2F-1 content in the HT1080 
Neo cell line and the related E2F-1 over-expressing clones (see chapter 3).
Preparation of protein samples
Cells were harvested during exponential growth by aspirating off medium, adding ice-cold 
0.01M PBS before continuing with trypsinisation. Cells were lysed in a buffer consisting of 
50mM TrisHCl (pH7.5), 150mM NaCl, 1% IGEPAL, 0.2% SDS and IX Boehringer’ 
complete, EDTA-free protease inhibitor mixture (Roche Diagnostics, UK). Protein 
concentration was measured and standardised using Bio-Rad protein assay reagent based on 
the Bradford method at optical density (OD) 595nm. Whole cell protein extracts were made 
up with ddH20  to achieve equal protein concentrations per sample and diluted in 2X SDS- 
sample buffer (4%SDS, 10% (3-inercaptoethanol, 20% glycerol, 0.02% bromophenol-blue 
and lOOmM TrisHCl (pH 6.8)) before heating at 95°C for 5 minutes.
Gel preparation and electrophoresis
Two gels were prepared each consisting of a running gel [(30% AA, 42.6% ddH20 , 25% 
4X running buffer (0.4% SDS, 1.5M TrisBase pH8.8), 2.5% APS (10%), 0.08% TEMED)] 
and a stacking gel [(9.9% AA, 61.6% ddHzO, 26.1% 4X stacking buffer (0.4% SDS, 0.5M 
TrisBase pH 6.8), 2.4% APS (10%), 0.04% TEMED)]. Prior to loading of the samples the 
10X electrophoresis buffer (1% SDS, 250mM TrisBase pH 8.3 ,1.92M glycine) was diluted 
1:10 with ddH20  and the samples and marker (Kaleidoscope pre-stained standards, BioRad, 
Hemel-Hempstead, UK) were boiled at 90°C for 5 minutes. The samples were separated on 
the 10% SDS polyacrylamide gels at 70-100V for 2 hours using the Xcell II™ Mini-Cell 
electrophoresis tank (Novex® Western Transfer Apparatus, Invitrogen, UK).
Protein transfer and immunoblot
Proteins were electrically transferred to polyvinylidenedifluoride membranes (PVDF) 
(Millipore, UK) at 25V for 1 hour using the XCell II™ Blot Module (Novex® Western 
Transfer Apparatus) as described in the Novex® provided protocol. Prior to the transfer the 
10X protein transfer buffer (3% TrisBase, 14.4% glycine and 20% methanol) was diluted 
1:10 with ddH20. Membranes were blocked in 1% casein blocking buffer (lOmM TrisBase
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pH 7.6, 154mM NaCl, 0.5% casein (BDH, UK), 0.02% thimerosal, ddH20) and incubated 
consecutively for one hour each with a E2F-1 specific mouse monoclonal primary antibody 
(Santa Cruz, UK) (1:1000) in Tris buffered saline (20mM TrisHCl pH7.5, 150mM NaCl) 
(TBS) followed by 3x 20 minute washing steps with TBS complemented with Tween 20 
(TBS-T). A second incubation with an anti-mouse horseradish peroxidase conjugated 
secondary antibody (Santa Cruz, UK) (1:5000) in TBS was performed followed by 3 
separate washing steps with TBS-T lasting 20 minutes each. All incubation and washing 
steps were carried out at room temperature (RT). Immunocomplexes were visualised using 
the enhanced chemiluminescence (ECL) system (Amersham Pharmacia, Little Chalfont, 
UK) by incubating the Western blots in the ECL system solution for 1 minute before 
wrapping the moist blots in cling film and exposing the blots to Kodak X-OMAT™LS film 
(Sambrook, et al., 1989).
Modifications to the above method were included in order to perform an increased number 
of experiments within the same time-span and hence screen clones derived for the E2F-1 
inducible system produced during later stages of the project.
2.2.1.2 Method 2
Preparation of protein samples
Cells to be examined were seeded in 6 well plates at a cell density of 4xl05 cells/well and 
incubated overnight to allow them to adhere. The medium was removed and 200pl of 3X 
sample buffer (60mM TrisHCl pH6.8, 4% SDS, 5% glycerol, 50mM P-mercaptoethanol, 
0.01% bromophenol-blue) were added per well. The lysis mixture was transferred to 1.5ml 
Eppendorf tubes. A further 400pl ddH20  was added to each well to wash out any remaining 
lysis mixture and then transferred to the Eppendorf tube. Lysed samples were vortexed, 
heated at 90°C for 5 minutes and finally frozen down at -20°C.
Gel preparation . electrophoresis, protein transfer and immunoblot
As previously described (section 2.2.1.1) the samples were run on 10% SDS 
polyacrylamide gels and electrically transferred to PVDF (Millipore) membranes. 
Membranes were blocked for 1 hour in a dried milk powder based blocking buffer (IX 
TBS, 5% non-fat dry milk, ddH20) at room temperature (RT). Incubation with a specific 
primary antibody was at 4°C overnight followed by 3 times 20 minute long washing steps
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with TBS-T. Subsequent incubation with a horseradish peroxidase conjugated secondary 
antibody carried out for 1 hour at RT followed by 3 separate washing steps with TBS-T 
lasting 20 minutes each. For dilution ratios used for individual antibodies refer to previous 
section (2.2.1.1). As described in method 1 before, immunocomplexes were visualised 
using enhanced chemiluminescence (ECL). To ensure equal protein loading per well, blots 
were stained with Coomassie blue (45% methanol, 10% acetic acid, 0.1% Coomassie 
brilliant blue, ddH20 ) for 10 min., washed 4-5 times with destaining solution (45% 
methanol, 10% acetic acid, ddH20) and air-dried.
2.2.2 Electrophoretic mobility shift assays (EMSA)
Electrophoretic mobility shift assays were performed following the protocol provided by 
van der Sman, et al., 1999. This technique was used to examine the binding specificity of 
E2F-1 and supershift assays were performed to identify proteins present in the E2F-1 
protein-DNA complex.
To obtain nuclear proteins, exponentially growing cells were lysed in 450mM NaCl, 
25% glycerol, ImM K-EDTA, lx Boehringer’ complete EDTA-free protease inhibitor 
mixture, 0.5M DTT (dithiothrietol) and 20mM K-Hepes (pH 7.9) using alternating heat- 
freeze steps. Pellets were heated at 30°C for 30 seconds followed by transfer to dry ice until 
pellets were completely frozen. Heat-freeze steps were repeated 3-4 times before 
centrifugation at 20,000g for 10 minutes. The supernatant (lysate) was transferred to fresh 
Eppendorf tubes and the protein concentration was measured using a Bio-Rad DC protein 
assay reagents package based on the Lowry assay at OD 750nm. Samples were stored at - 
80°C until further use. A double stranded E2F oligonucleotide containing the distal E2F 
binding site from the adenovirus type 5 E2A promoter (Bandara et al., 1991) was prepared 
by mixing 2pl Forward primer (200pmol), 2pl Reverse primer (200pmol), lOpl KC1 
(lOOmM), 12.5pl Hepes pH7.9 (200mM) and 8.5pl ddH20. The primers were annealed by 
PCR (1. 95°C for 5 min.; 2. 70°C for 36 sec. -0.5°C/cycle; 3. 99x go to step 2; 4. 20°C for 
60 min.; 5. 20°C for 1 min. 42 sec. -0.5°C/cycle; 6. 32x go to step 5; 7. 4°C). The 
radioactive probe was prepared by incubating 1.5fxl pre-prepared double stranded oligomer, 
lpl NaCl2 (5M), Klenow buffer (Promega, Southampton, UK); 7pi a -32P-dGTP (lOpCi/pl) 
(Amersham Bioscience, UK), 13pl ddH20  and 1.5pl Klenow enzyme (5u/pl) (NEB, 
Hitchin, UK) for 25 minutes at RT. Twenty pg of nuclear extract was incubated in the
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presence of binding buffer consisting of 25mM Hepes (pH7.9), 2mM MgCl2, ImM DTT, 
lx Boehringer’ complete EDTA-free protease inhibitor mixture, lOOng/ml salmon sperm 
DNA, lOpg/ml Bovine serum albumin (BSA), 33% glycerol and ddH20  at 30°C for 3 
minutes. Excess unlabelled mutant E2F-1 (contains a mutated E2F-1 site) or excess 
unlabelled E2F-1 oligonucleotide were added to the binding reaction according to 
individual experimental requirements. Then l-2ng of a-32P-labeled consensus oligomer was 
added to the mixture and incubated at 30°C for 10 minutes. The DNA bound complex was 
separated on 4% polyacrylamide gel run in 0.5X Tris borate EDTA (89mM TrisBase, 
89mM boric acid, 2mM EDTA) (TBE) at 170 Volts for 1.5-2 hours at 4°C. The gel was 
mounted on Whatman 3MM paper (Maidstone, UK) and Whatman DE81 paper 
(Maidstone, UK) and dried on gel dryer (BioRad, Hemel-Hempstead, UK) for 2 hours at 
80°C. The dried gel was exposed to Kodak X-OMAT™LS film.
In case of supershift, lpl of concentrated specific antibodies for pRb, p i30 and p i07 
(kindly provided by E. Lam, Ludwig Institute for Cancer Research, Imperial College 
School of Medicine at St. Mary’s, London, UK) were pre-incubated with the nuclear 
extracts in the presence of binding buffer at 30°C for 5 minutes. Subsequently the 
radioactive probe was added and the antibody complexes separated as described above.
2.2.3 In vitro cytotoxicity assays
2.2.3.1 Sulphorhodamine B growth inhibition assay
The assay is based on the binding of the purple Sulphorhodamine B (SRB) dye to cellular 
protein.
Cytotoxicity of drugs was determined by the SRB assay in 96-well microtitre plates 
as described previously (Skehan et al., 1990). The optimal cell concentrations were 
determined from the previously calculated doubling times in order to achieve a final cell 
concentration ideal for accurate optical density (OD) measurement. Cells were plated in 96- 
well flat-bottomed microtitre plates, each well containing 100/xl cell solution (2.5xl03 
cells/well or 5xl03 cells/well depending on cell doubling time). Prior to drug treatment, 
cells were allowed to adhere at 37°C and 5% C02 overnight. Drug incubations performed 
were either acute (1 hour) or continuous (72 hours). All drugs were diluted in complete 
growth medium and 100/d of the relevant concentration added to the appropriate wells.
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One solvent control lane was included in each experiment. The concentration range for 
each drug was optimised if necessary following analysis of results from the first 
experiments. For acute drug exposure cells were incubated for 1 hour with the relevant drug 
prepared in FCS-free medium. Following this, the drug solution was removed and replaced 
with 200jxl drug free complete growth medium. Plates were incubated at 37°C, 5% C 02 for 
72 hours. Media was carefully removed and the cells subsequently fixed with 100/zl 10% 
trichloroacetic acid solution for 20-30 minutes at 4°C. The fixed cells were washed three 
times with tap water and any remaining water flicked out of the wells. 100/xl SRB stain 
(0.4% in 1% acetic acid) was then added to each well to allow visualisation of cellular 
proteins and incubated for 20-30 minutes at 4°C. Any excess SRB was removed by 
washing 4-5 times with 1% acetic acid. Plates were air-dried overnight. Finally the dye was 
dissolved in 100/d lOmM Tris/lmM EDTA for 10 minutes on a plate shaker. Plates were 
read at absorbance of 540nm on a Tecan microplate reader and analysed using computer 
spreadsheets (Microsoft Excel).
Growth inhibition was calculated using the following equation and the mean of growth 
inhibition for each drug dose with standard deviations were calculated. At least three 
independent experiments were carried out for each drug.
OP (treated) xioo = % growth inhibition
OD (control)
Dose-response curves for all cell lines were obtained for each drug tested. The IC50 values 
were calculated from the curves. The IC50 is defined as the drug concentration needed to 
produce a 50% growth inhibition. The relative resistance factor (RF) for the HT1080 E2F 
1-1 cell line was determined with the following equation:
IC™ HT1080 E2F 1-1 = r f
IC50 HT1080 Neo
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2.2.3.2 MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide] 
cell proliferation assay
MTT assays were essentially performed as previously described by Carmichael et al., 1987 
and Twentyman et al, 1987. Acute (lhr) and continuous (72hrs) drug incubations were 
performed in 2ml of cell suspension (serum-free medium) at a cell concentration 5xl04 
cells/ml. After 1 hour drug incubation the cells were centrifuged at 400# for 5 minutes, the 
supernatant removed and resuspended in drug free complete growth media. Cells were 
plated out at 200/d/wellin microtitre plates to give a final cell density of lxlO4 cells/well 
and incubated at 37°C, 5% C 02 for 72 hours. Cell suspensions for continuous drug 
exposure were plated out immediately and incubated as described above for 72 hours. 20jnl 
MTT dye (5mg/ml) was added to each well and plates incubated for 5 hours at 37°C. Plates 
were centrifuged (5min., 400g), supernatant was removed, and formazone crystals were 
dissolved in 200pl DMSO. After dye pellet was completely dissolved the absorbance was 
read at OD 540nm on a Tecan microtitre plate reader. Cell survival was calculated from the 
following equation and the mean of the cell survival figures for each drug were calculated:
n n  xlOO = % cell survivalOD (control)
At least three independent experiments were performed for each drug.
Modifications of the above method were made to account for the frequent 
insolubility of the E2F antagonising peptide in the presence of FCS. Experiments involving 
the peptide alone or a pre-incubation with peptide followed by drug exposure included 
using growth medium supplemented with 2mM glutamine only, for any peptide preparation 
steps. Invariably, suspension cells were spun down at 400g for 5 min., the medium was 
removed and the cell pellet was resuspended in FCS free medium. Cells were aliquoted out 
into Eppendorf tubes at a concentration of 5xl04cells/ml before the appropriate amount of 
peptide was added. After 10 minutes of incubation at RT, medium supplemented with 10% 
FCS was added and 200/d of cell/peptide solution were plated out in 96-well round bottom 
plates.
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In the case of experiments requiring a peptide pre-incubation step, cells were dosed with 
the appropriate peptide concentration in T25 flasks for 24 hours, before being aliquoted out 
and drug dosed as described above. Again the peptide solution was initially made up in 
FCS free medium before 10% FCS was added and the cells exposed with the peptide 
solution.
2.2.3.3 Statistical analysis
Multiple regression models were fit using SAS Version 9.0 general linear models. The 
terms included in the model were linear, quadratic and cubic terms for dose and a linear 
term for cell line. Where appropriate, each drug was evaluated separately. Bonferroni 
adjustment to the overall alpha = 0.05 was made as there were about 800 contrasts. Thus, a 
p-value of 0.0001 was required for evidence of significant difference (Draper and Smith, 
1981).
2.2.4 Soft agar clonogenic assay
The clonogenic assay was initially developed as an in vitro test for the growth of potential 
tumour cells in a semi-solid medium without exogenously added cytokines (Hamburger et 
al., 1978). Inhibition of colony formation is a measure of the effectiveness of a particular 
drug in inhibiting the expansion of the cell population of the malignant tumour. The assay 
was essentially carried out as described in the protocol by Plumb et al., 1999.
Clonogenic assays were performed using 5xl05 exponentially growing cells plated 
out into a T25 flask. After 50-60% confluency has been reached drug was added at the 
appropriate concentration and left for the required duration. The cells were harvested using 
1.5ml cell dissociation solution, followed by neutralization with 4ml complete growth 
medium and centrifuged at 400g for 5 minutes at RT. Cells were washed with 0.01M PBS 
and resuspended in 2ml fresh complete growth medium. Cells were syringed to achieve a 
single cell suspension before cells were counted as described before (section 2.1.3.2) and a 
series of dilutions performed to achieve a cell concentration of 200 to 2000 cells/ml in 
order to plate out the required number of cells per petri dish. The cells were plated out for 
colony formation in complete growth medium containing 20% FCS and 0.2% low melting 
point agarose. The sloppy agar medium was prepared earlier and kept at 42°C in the water- 
bath until required. Cells were plated out in petri dishes at a concentration of 100 cells/
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plate. Plates were left for 7-14 days at 37°C and 5% C 02 for colonies to form depending on 
the growth rate of the cells. Colonies of approximately 50 cells were visualised by 
incubating each plate in 5ml 1% methylene blue for 1-2 hours at RT. A Gallenkamp colony 
counter was used to determine number of colonies formed and percentage colony forming 
potential was calculated using the formula below (Brown, et al., 1999).
number of colonies counted = plating efficiency 
number colonies plated out
followed by:
plating efficiency (treated) x 100 = % colony formation 
plating efficiency (control)
2.2.5 Flowcytometric (FACS) analysis
A commonly used method for cell cycle analysis is to measure the DNA content of a cell 
by staining the DNA with a dye that binds to the nucleic acid stoichiometrically and whose 
fluorescence is enhanced upon binding. The most commonly used dye is Propidium iodide 
(PI) which is excluded by an intact cell plasma membrane hence cells need to be fixed or 
permeabilised for analysis (Shenton et al., 1996. The obtained cell cycle histogram is 
considered an important tool in the study of action of cytotoxic drugs (Fig. 2.1). However, 
the information gained is essentially static and for example does not provide information 
about whether a cell with S phase DNA content is actually synthesising DNA.
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Fig. 2.1: DNA histogram illustrating relative DNA content of cells 
in G1 phase (Gl), S phase (S) and G2 phase (G2) as analysed by 
FACS analysis
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Cells were plated out in T25 flasks or 6-well plates as to achieve a total number of lxlO6 
cells for each FACS sample in order to ensure that at least 10,000 cells could be analysed 
by the fluorescence-activated cell sorter (FACS). Therefore, depending on the duration of 
the drug incubation, cells were plated out at densities of 5x10s or lxlO6 cells per flask, 
accounting for loss of cells during subsequent experimental steps.
Exponentially growing cells were incubated with the relevant drug in individual 
T25 flasks. After drug incubation, cells were washed with 0.01M PBS and lifted from the 
flask using cell dissociation solution and centrifuged at 400g for 5 min.. Following 
centrifugation the cells were washed with ice-cold 0.01M PBS and centrifuged for a second 
time. Cells were resuspended in 200/d ice-cold 0.01M PBS and fixed in 2ml 70% ice-cold 
ethanol while vortexing. The fixed cells were stored at 4°C for a minimum of lhr. For the 
staining procedure cells were centrifuged at 400g for 5 min. and the ethanol fix poured off. 
The cell pellets were washed in 1ml 0.01 M PBS and centrifuged once more. After removal 
of the PBS, cells were resuspended in 925/d ice-cold 0.01M PBS, treated with 25/d RNAse 
(lOmg/ml) and stained with 50/d PI (1000/tg/ml). The FACS samples were stored at 4°C in 
the dark for a minimum of 30 min. before analysing. Analysis occurred within 1-3 hrs of 
cell preparation. A minimum of 10,000 cells were analysed on a fluorescence-activated cell 
sorter (Coulter FACscan) (Ormerod, 1994). PI staining was detected using an Argon-ion 
laser at 488nm. Acquisition of cell cycle data was performed with WinMDI or CellQuest 
and further analysis of the acquired data was carried out with FCS Press 3.1 or CellQuest 
FACS analysis program.
2.2.6 Apoptosis assay (TACS™ Annexin V-FITC Apoptosis Detection kit-R&D 
Systems)
Apoptosis is an important mode of cell death, both in natural development and in response 
to cytotoxic insults. Apoptotic cells undergo membrane alterations exposing new entities 
such as phosphatidyl serine (PS) groups on the membrane surface. The above assay was 
employed to detect such in situ cell surface changes characteristic for early apoptotic 
processes using Annexin V-fluorescein isothiocyanate (FITC) conjugates that bind PS 
hence allowing rapid fluorimetric detection of apoptotic cells (Shenton et al., 1996).
Cells were plated out in T25 flasks to achieve a total number of lxlO6 cells per 
sample. Therefore, depending on the duration of the drug incubation cells were plated out at
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densities of 5x10s or lxlO6 cells per flask, accounting for loss of cells during subsequent 
experimental steps. Exponentially growing cells were incubated with the relevant drug in 
individual T25 flasks. After the drug incubation, cells were washed with PBS, lifted from 
the flask using cell dissociation solution and centrifuged at 400g at 5 min. at RT. Following 
centrifugation the cells were washed with 500/d ice-cold 0.01M PBS and centrifuged for a 
second time. Cells were gently resuspended in 100/d of the Annexin V-FITC incubation 
reagent prepared as described in the provided protocol included with the kit and incubated 
in the dark for 15 minutes at RT. Simultaneously, cells were counter-stained with PI as 
required by the protocol provided with the kit. Within 1 hour, the cells were analysed by 
flow cytometry as described for cell cycle analysis (section 2.2.5), including an additional 
acquisition parameter taking into account the green fluorescent colour emitted by the 
Annexin V-FITC conjugate. The combination of Annexin V-FITC and propidium iodide 
allows for the differentiation between early apoptotic cell (Annexin V-FITC positive), late 
apoptotic and/or necrotic cells (Annexin V-FITC and propidium iodide positive) and viable 
cells (unstained). Analysis of the data acquired was performed using FCS Press 3.1 as 
described before.
2.2.7 Genomic DNA isolation
After harvesting by trypsinisation, cells were lysed by resuspending in 5ml lysis buffer 
(50mM TrisHCl, pH 7.5; 5mM CaCl2) in a 15ml Falcon tube to which 100/d proteinase K 
(20mg/ml) and 250/d SDS (10%) were added. The solution was mixed and incubated at 
65°C for 1 hour or until the initially turbid solution had turned clear. To continue, 2.5ml 
phenol (lOmM Tris pH 8.0 saturated) and 2.5ml chloroform (24:1 chloroform:iso-amyl 
alcohol) were added to the lysed cells. The solution was mixed well by inversion and 
centrifuged for 15 minutes at 2100g at RT. The supernatant was transferred to a clean tube 
without disturbing the protein interphase. The phenol-chloroform treatment was repeated 
until the protein interphase had disappeared. An equal volume of chloroform was added to 
the supernatant collected from the previous step and the centrifugation step repeated. The 
supernatant was transferred into a clean tube and DNA was precipitated by adding 1/10 
volume 3M sodium acetate, pH 5.5 and 2X volume ice-cold 100% ethanol. The precipitated 
DNA was centrifuged for 15 minutes at 2100g. The DNA pellet was washed twice with
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70% ethanol (RT) and the pellet was dried briefly before finally dissolving in 500/xl ddH20. 
The DNA was stored at -20°C for future use.
2.2.8 Polymerase chain reaction (PCR)
For all PCR experiments a PCR mixture was set-up containing 2/xg DNA, 2/xl primer 1 
(lOOpmol) and 2/xl primer 2 (lOOpmol), 12.5mM dNTPs (Amersham Bioscience, UK), 
25mM MgCl2, IX Taq polymerase buffer (Promega, Southampton, UK), 3u Taq 
polymerase (Promega, Southampton, UK) in a total volume of 100/xl ddH20. All custom- 
made primers were purchased from MWG Biotech, UK (Table 2.2). The PCR mixture was 
put into PTC-100 Programmable Thermal Cooler (MJ Research Inc., UK) PCR machine 
and exposed to the following PCR cycle:
1. 94°C for 5 minutes
2. 94°C for 1 minute
3. 54°C for 1 minute
4. 72°C for 1 minute
5. 35 x go to step 2
6. 72°C for 10 minutes
7. 4°C
Finally 5pl 10X DNA formamide loading buffer [0.5g amberlite added to 10ml formamide 
(stirred for 30 min. and filtered through Whatman 3MM paper), 3mg bromophenol blue, 
3mg xylene cyanol, 200pl EDTA (500mM)] was added to PCR product and the PCR 
product was run on 0.8% - 2% agarose gels (IX TBE, ethidium bromide, agarose). A lkb 
DNA ladder (Gibco-BRL, Paisley, UK) was run aside the PCR product to aid in the 
identification of the correct PCR product. The gel was run at 90-100V for 30-45 minutes 
depending on how much separation of the PCR products was required.
Name Sequence
N-ras (3.8) 5' - CTT TGG ACA GAT TTA GGA CC- 3'
N-ras (5.8) 5' - AAC TTT ATA TCA CGG GAA TG -3'
Topoisomerase Ila  FWD 5'-CTC AGC TCT TTG GCT CGA TTG -3’
Topoisomerase Ila  REW 5'-TGG CAA AGG TTC TTC TCC ATC-3'
Table 2.2: Custom-made primers used for investigative PCR experiments.
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2.2.9 Southern blot analysis
The above method has been previously described by Sambrook et al., 1989 and was used to 
compare the Dral restriction patterns of the HT1080 Neo cell line and associated E2F-1 
overexpressing clones (HT1080 E2F 1-1, HT1080 E2F 1-4 and HT1080 E2F 1-6). The cell 
lines were grown in individual T175 flask until the cells had reached semi-confluence 
followed by the isolation of DNA from the four cell lines according to the previously 
described genomic DNA isolation method (see section 2.2.7).
Preparation of DNA samples
A restriction digest was set up containing 250|il isolated genomic DNA, 5pl Dral (lOu/pl) 
(Promega, Southampton, UK), 50p,l 10X reaction buffer and 5jxl BSA both supplied with 
Dral, 5pl Rnase ONE™ (5u//d) (Promega, Southampton, UK) and 185j l i 1 ddH20  at 37°C 
overnight. The DNA was precipitated using 3M sodium acetate and 100% ethanol and 
resuspended in lOOpl ddH20  as described previously (section 2.2.7) before the DNA 
concentration was measured fluorimetrically (Kowalski et al., 1979). The measured DNA 
was stored at -20°C for future use.
Preparation of blot
The DNA samples (20jmg) were loaded onto a 0.8 % agarose (0.8% agarose, IX TBE, 
ethidium bromide) gel and run in IX TBE buffer at 28mV for 16-20 hours. A lkb ladder 
(Gibco-BRL, Paisley, UK) was run alongside the samples. Under UV illumination a picture 
was taken with a ruler placed next to the size marker in case size analysis of the DNA 
bands on the blot was required later. Afterwards any excess gel was trimmed off including 
the lkb DNA ladder.
The DNA was denatured by soaking the gel in 1.5M TrisHCl (pH8.0) and 0.5M 
NaOH for > 30 minutes at room temperature with constant shaking. The gel was neutralised 
by soaking in 1M TrisCl (pH8.0) and 1.5M NaCl for > 30 minutes, again, at room 
temperature with constant shaking. Overnight the DNA was transferred onto Hybond N+ 
membrane as shown in Figure 2.2. After 24 hours the blot was exposed (membrane plus 
DNA) to UV light for 2min. 30sec. If necessary the blot was stored in 2X SSC pH7.0 that 
had been pre-prepared by diluting 20X SSC (175.3g NaCl, 88.2g sodium citrate, adjust to 
11 with ddH20) at a ratio ofl:10 at 4°C for future use.
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~*| 5x Whatman 3MM paper
Hybond N+ membrane 
placed on top of gel
Fig. 2.2: Illustration of set-up to blot DNA onto Hybond N+ membrane (Amersham 
Pharmacia Biotech, UK) overnight.
Whatman paper was placed on top of a perspex “table” such that the paper may be folded 
into the tank containing 6X SSC. The gel was placed onto the Whatman paper and the 
Hybond N+ membrane, as well as 5 sheets of Whatman paper were stacked on top of the 
gel. Two packs of tissue pressed down by weights complete the set-up that works by 
drawing up the 6X SSC through the gel onto the Hybond N+ membrane into the tissue 
hence transferring the DNA onto the membrane in the process. All sheets of Whatman 
paper as well as the Hybond N+ membrane were presoaked in 2X SSC solution.
Preparation and radio-labelling of probes
The N-ras PCR product (see section 2.2.8) and the topoisomerase Ila  cDNA insert within 
the pTRE200 topoisomerase Ila  vector (gift from B. Tolner) were used as probes. The 
pTRE200 topoisomerase Ila  vector was cut with the restriction enzymes Xhol and Notl to 
release the topoisomerase Ila  insert. Following gel separation of insert and cut vector the 
insert was isolated using the Gene-clean® II kit Bio 101 (Anachem, UK). In addition, the N- 
ras PCR product was extracted from the relevant PCR gel again using the Gene-clean kit. 
The DNA for both probes was measured fluorimetrically as described by Kowalski et al., 
1979.
r 6X SSC
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Approximately 20ng of recovered DNA were resuspended in 13.5pl ddH20  and denatured 
at 90°C for 10 minutes. On ice, 4pl 5X High Prime (Roche Diagnostics, UK) and 2.5pl 
a 32P-dCTP (lOpCi/pl) were added to the denatured probe and the mixture was incubated at 
37°C for 30 minutes. The reaction was stopped through the addition of 60pl IX TE (lOmM 
TrisBase, ImM EDTA pH8.0) before the entire mixture was purified on a Bio-Spin-6 spin 
column (Bio-Rad, Hemel-Hempstead, UK). The final product was denatured at 90°C for 10 
minutes and left on ice for 3 minutes before being added to the hybridising cylinder. 
Hybridisation of blot
The blot was pre-hybridised using pre-hybridising solution made up to 20ml total volume 
with ddH20  containing 6X SSC, 0.5% SDS, 5X Denhardt's solution [0.1% BSA, 0.1% 
Ficoll™, 0.1% polyvinylpyrrolidone (PVP)] and lOOug/ml denatured (at 90°C for 5 
minutes) salmon sperm DNA. The blot together with pre-hybridising solution was placed in 
the hybridiser (Techne Hybridiser HB-1D) for 1 hour at 67°C. The relevant labelled probe 
was added and the blot was left to hybridise at 67°C for >16 hours.
The hybridised blot was washed with the following solutions ensuring that the blot is 
covered in solution at all times:
1) 2X SSC, 0.1% SDS for 20 minutes at 65°C
2) IX SSC, 0.1% SDS for 20 minutes at 65°C
3) 0.1X SSC, 0.1% SDS for 20 minutes at 65°C
The damp blot was wrapped in cling film and placed on a piece of Whatman 3MM paper in 
a film cassette. An X-ray film was placed (Kodak X-OMAT™LS) on the blot and exposed 
overnight at -80°C.
2.2.10 Single-strand ligation PCR
The method used within this thesis had been described by McGurk et al., 2001. An outline 
of the procedure is shown in Figure 2.3. The modified method described below was 
adapted from already existing TD-PCR and Sslig-PCR procedures. Here, single-strand 
ligation PCR is used to identify DNA lesions produced as a result of BGIII21 binding.
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------------  Damaged genomic DNA, cut with
”  appropriate restriction enzyme(s)
------------- Linear PCR using biotinylated primer 1 .B
-  —  b o  Capture on Streptavidin Dynabeads
i
rGrGrG________ b O  Ribonucleotide tailing by Terminal
^  Deoxynucleotidyl Transferase
c c c
rGrGrG-------------- b Q  Ligation of double stranded linker by
^  T4 DNA ligase
C C C-----------  Exponential PCR with Upper oligo primer
rGrGrG---------------2* and radiolabelled Primer 2
i
Run DNA on sequencing gel
Fig. 2.3: Schematic illustration showing steps involved in the Sslig-PCR
(adapted from McGurk, et al., 2000).
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Primers
Table 2.3 shows primer sets for N-ras promoter and Hprt exon 9 region both used in 
single-strand ligation PCR experiments (section 3.3.10,4.3.2 and 4.3.3).
Name Nucleotide sequence
N-ras primer 1 5’-GGA CAG ATT TAG GAC CAC AG-3’ ; biotinylated at 5’ end
N-ras primer 2 5’-GAC CAC AGC CGG GAA AAA TGT TGG AGA-3’
Hprt primer 1 5’-GTT TAG AAC AGT GTG AAG CAC TCA-3’ ; 
biotinylated at 5’ end
Hprt primer 2 5’- GAA GCA CTC AGT TTT CAT GTC AG-3’
Table 2.3: Primer sets used in single-strand ligation PCR
Preparation of DNA samples
Adherent cells grown to near confluence were treated with relevant BGIII21 doses at 37°C 
for 5 hours. Cells were harvested by washing gently with 0.01M PBS before trypsinisation. 
DNA was isolated using the method as described previously (section 2.2.7). It is necessary 
to include an RNAse step as the DNA is to be measured spectrophotometrically and excess 
RNA contributes to the total measurement of the DNA in each sample hence leading to an 
overestimate of the DNA and inconsistency between samples.
To create a natural stop site the DNA was digested with a restriction enzyme chosen 
to cut between one hundred and a few hundred base pairs downstream of the binding site of 
the biotinylated primer that is used in the first PCR step. The DNA concentration was 
measured fluorimetrically as this provides an extremely accurate way of measuring small 
quantities of DNA (Kowalski et al., 1979).
First-round TD-PCR
For the initial TD-PCR step 3|xg of DNA per sample were taken and the volume brought up 
to 10pl with ddH20. A PCR mix was prepared containing IX of reaction buffer [10X: 
100mM Tris-HCl (pH9.0 at 25°C), 500mM KC1 and 1% Triton® X-100] supplied with the 
enzyme; 5mM MgCl2 (25mM); 0.25mM dNTP mixture (2.5mM of each dNTP), 
(Amersham Bioscience, UK); 0.6pmoles oligonucleotide primer T ; 2% DMSO (50%); 
25mM TMA (0.5M) and ddH20 . 25pl of the PCR mix was added to the DNA. The Taq
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DNA polymerase (5u/pl; Promega, Southampton, UK) was diluted to 0.2u/pl in a total 
volume of 5jxl per sample using ddH20. 5pi (lu) diluted Taq DNA polymerase were added 
to each sample tube, and tapped gently to mix.
The DNA was denatured at 95°C for 5 min., followed by 10 one-minute cycles at 
95°C, 56°C for 3 min. and 74°C for 2 min. For complete extension of all products samples 
were incubated at 74°C for 5 min,, subsequently denatured at 95°C for 2 minutes and then 
cooled down to 4°C.
Capture of PCR product
Streptavidin-coated magnetic beads (Dynabeads® M-280, Dynal®, UK) were used to 
capture the biotinylated PCR products. 5pi of beads (lOpg/pl) per sample plus an additional 
5pl was used. The Dynabeads were sedimented in a magnetic rack (Dynal MPC®-E) to 
remove the supernatant. The beads were washed twice by resuspending Dynabeads in IX 
Washing-binding buffer (WBB) (lOmM Tris-Cl, pH7.7; ImM EDTA; 2M NaCl), followed 
by sedimentation in magnetic rack to remove supernatant. Dynabeads were resuspended in 
40pl/sample IX WBB. Aliquots of 40pl of Dynabeads were transferred to clean 1.5ml- 
tubes, sedimented and the supernatant removed.
To each tube containing 40pl products from the first-round PCR lOpl 5X WBB 
(50mM Tris-HCl, pH7.7; 5mM EDTA; 10M NaCl) were added. The mixture was 
transferred to tubes containing prepared Dynabeads. Incubation at 37°C for 30 minutes with 
occasional agitation to resuspend Dynabeads followed. The protocol was continued by 
washing the Dynabeads three times with 200pl TE (lOmM Tris-HCl, pH 7.6, ImM EDTA) 
as described before. The Dynabeads were resuspended in 50pl ddH20  and centrifuged at 
20,000g for 10 seconds.
Ribo-tailing of PCR product
During the Terminal Deoxynucleotidyl Transferase (TdT) Ribo-Tailing step riboGs were 
added to the 3’ ends of the single-stranded products from linear PCR. The majority of the 
ends will possess 3’ riboGs (Komura and Riggs, 1998).
All the reagents for ribo-tailing and ligation were stored at -20°C (except 
polyethyleneglycol (PEG) which was stored at 4°C), defrosted when necessary and kept on 
ice until needed except for TdT and DNA ligase which were kept at -20°C until needed.
The tubes containing Dynabeads bound to biotinylated PCR products were placed 
into a magnetic rack and the supernatant was removed. The Dynabeads were resuspended
73
in 10|xl 0.1X TE (ImM Tris-HCl pH7.6, O.lmM EDTA). A ribo-tail mix was prepared in a 
1.5 ml tube containing 4pl of 5X TdT buffer (as provided with enzyme, 0.5M potassium 
cacodylate, pH7.2, lOmM CoC12 and ImM DTT), 4p,l of lOmM rGTP (Promega, 
Southampton, UK), 1.33 pi distilled water; 0.67 pi of TdT (15 u/pl) (GIBCO-BRL, Paisley, 
UK). All above volumes were multiplied by the number of samples + 1.
Ten microlitre of the ribo-tail mix were placed into the tubes with the Dynabeads 
and mixed. Incubation at 37°C for 15 min. with occasional agitation followed. Next 180pl 
TE (lOmM Tris-HCl pH7.6, ImM EDTA) were added, the tubes were placed in a magnetic 
rack and the supernatant was removed. The Dynabeads were washed again with 2x 200pl 
TE. The Dynabeads were resuspended in 15pl 0.1X TE (ImM Tris-HCl pH7.6, O.lmM 
EDTA).
Preparation of double stranded linker
The double stranded linker was the annealing product of a
‘Lower oligo’: 5 ’ - A ATTC AGATCTCCCGGGTC ACCGC-3 ’ and an
‘Upper oligo’: 5’-GCGGTGACCCGGGAGATCTGAATTCCC-3’.
The ‘Lower oligo’ was required to be phosphorylated at the 5’ end as well as possess a 3’- 
terminal amine group to block self-ligation. The ‘Upper oligo’ is complementary to the 
‘Lower oligo’ except for a three C overhang at the 3’ terminus. Phosphorylation of the 
‘Lower oligo’ was carried out using a kit containing T4 polynucleotide kinase and Forward 
reaction buffer (Gibco-BRL, Paisley, UK). Stock solutions of 200pmol/pl of both 
oligomers were prepared and a reaction mixture set up containing l l . lp l  ‘Lower oligo’ 
(200pmol/pl), 20pl Forward reaction buffer (5X as provided), 62.9pl ddH20 , lp l ATP 
(lOOmM) and 5|li1 T4 polynucleotide kinase (lOu/pl). The mixture was incubated at 37°C 
for 2 hours followed by heat inactivation of the kinase at 65°C for 20 min.. To anneal both 
primers, ll.ljxl of ‘Upper oligo’ (200pmol/pl) were added to the phosphorylated ‘Lower 
oligo’. The mixture was heated to 95°C for 3 min. and gradually cooled to 4°C by placing 
the sample in a 70°C removable hot block for 1 min. and transferring the hot block into a 
refrigerator. The linker was stored at -20°C until ready for use in the ligation reaction. 
Ligation of double-stranded linker
The families of single-stranded molecules that possess rGTP tails were ligated to the 
double-stranded linker. The double-stranded limker's 3 C single-stranded overhang is 
complementary to the 3 riboG tails. The ligation reaction contained PEG that effectively
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concentrated the reagents and kept the Dynabeads partially suspended important when 
incubating for long periods of time.
A ligation mix was prepared containing 2.7|xl of ligation buffer (622mM Tris-HCl 
pH7.6, 126mM MgCl2, 126mM DTT and 12.6mM ATP); 3.0jxl of 20pM prepared double­
stranded linker (see before); 9.1pl of 50% PEG; 0.2pl of T4 DNA ligase (20u/|xl, Promega, 
Southampton, UK). All the above volumes were multiplied by the number samples + 1.
A volume of 15pl of the ligation mix was placed into the tubes with the Dynabeads 
from the ribo-tailing reaction and mixed. Samples were incubated at 17°C overnight. To 
continue 170p,l TE (lOmM Tris-HCl pH7.6, ImM EDTA) were added, the tubes were 
placed in the magnetic rack and the supernatant removed. The Dynabeads were washed 
again twice with 200jLtl TE. The Dynabeads were resuspended in 40jxl distilled water for 
PCR and transferred to 0.5ml tubes.
Second-round PCR
Ten pmoles of oligonucleotides were required per sample for second-round PCR. Primer 
‘2’ was phosphorylated with T4 polynucleotide kinase using kits (GIBCO-BRL, Paisley, 
UK) with forward reaction buffer. Once labelled the primer was stored at 4°C until ready 
for use in second-round PCR.
The 5’ terminus of the second-round primer ‘2’ was labelled by incubating lpl of 
oligonucleotide primer ‘2’ (10 pmoles/pl) per sample + 1, 6pl of 5X forward reaction 
buffer (as provided with enzyme, 5X is 350mM Tris-HCl pH7.6, 50mM MgCl2, 500mM 
KC1, 5mM p-mercaptoethanol), 3pi y-32P-ATP (lOpCi/pl), (Amersham Pharmacia Biotech, 
Little Chalfont, UK), 3pl of T4 polynucleotide kinase (lOu/pl). The volume was brought to 
30pl with distilled water. Incubation at 37°C for 30 min. followed. Distilled water was 
added to bring total volume to lOpl per sample + 1. To purify the labelled primer from 
unincorporated nucleotide the mixture was centrifuged through a Bio-Spin-6 spin column 
(Bio-Rad, Hemel Hempstead, UK).
The second-round exponential PCR was carried out with template DNA bound to 
Dynabeads. Ten pmoles of second-round nested region-specific primer ‘2’ and ‘upper 
oligo’ primers were required per sample. For each new primer set the number of cycles 
necessary during the exponential step was determined empirically and fell between 16 and 
22 cycles. It is important for the number of cycles to fall in the exponential range especially 
when quantifying bands.
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A PCR cocktail mix was prepared containing lOpl of 10X reaction buffer [as provided with 
enzyme, 10X is 100M Tris-HCl (pH 9 at 25°C), 500mM KC1 and 1% Triton® X-100], 8p,l 
of 25mM MgCl2; 20pl distilled water; lOjul of a mixture containing 2.5mM of each dNTP 
(Asmersham Pharmacia Biotech, Little Chalfont, UK); l.Opl pmoles/pl oligonucleotide 
y32P-labelled primer ’2’; ljxl of lOpmoles/pl ‘upper oligo’ linker primer. A 50pl volume of 
the PCR mix was placed into 0.5ml tubes with the Dynabeads from the ligation reaction 
and mixed well. In a separate 1.5ml tube Taq DNA polymerase (5u/p,l; Promega, 
Southampton, UK) was diluted to 0.2u/p,l in a total volume of lOjul per sample using 
distilled water. Ten microlitre (2u) of diluted Taq DNA polymerase were added to each 
tube, which were tapped gently to mix.
Next the samples were denatured at 95°C for 5 min., then cycled 16-22 times at 
95°C for lmin., 68°C for 2 min. and 74°C fori min. plus 1 sec.-extension per cycle. For 
complete extension of all products samples were incubated at 74°C for 5 minutes.
The tubes were centrifuged for 10 sec. at 20,000# and 100(xl of supernatant were 
transferred without Dynabeads to fresh 1.5ml tubes. Distilled water (lOOpl) were added to 
the 0.5ml tubes to wash the Dynabeads, respun and 100pl of supernatant were transferred 
without Dynabeads to the 1.5ml tubes. To precipitate the DNA of each sample, 20jxl 3M 
sodium acetate (pH 5.2) were added as well as 3 volumes of 95% ethanol (-20°C). The 
samples were vortexed, then all samples were placed in a dry ice bath for 20 min. and 
centrifuged for 15 min. 20,000# at 4°C. The DNA pellet were washed with 200pl 70% 
ethanol (RT) by gently inverting the tube, centrifuged for 5 min. at 20,000# at RT and the 
supernatant was discarded. The wash was repeated and DNA pellet dried under vacuum.
The DNA was resuspended in 5|xl sequencing gel-loading buffer [96% (v/v) 
formamide (deionized), 20mM EDTA, 0.03% xylene cyanol, 0.03% bromophenol blue]. It 
was important that the samples were completely and uniformly resuspended. To achieve 
this, each sample was vortexed vigorously for at least 10 sec. and centrifuged at 20,000# for 
10 sec. to collect liquid. Samples were stored at -20°C overnight.
The next day radiolabelled amplified fragments were separated in a 50cm x 21cm x 
0.4mm, 6% denaturing polyacrylamide sequencing gel (National Diagnostics, Hull, UK; 
5.7% acrylamide, 0.3% bisacrylamide, 8.3M urea, 0.1M Tris-borate pH 8.3, 2mM EDTA). 
The gel was pre-electrophoresed for 30 min. prior to loading. The gels were run in IX TBE 
buffer (89mM Tris borate, 2mM EDTA pH 8.3) at 1700-2000 V for 2 hours or until the
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bromophenol blue dye reached the bottom of the gel. A y^P-labelled lObp marker (Gibco- 
BRL, Paisley, UK) (see section 2.2.12) was run next to the sample lanes to make it easier to 
identify potential bands representing BGIH21 drug lesions.
The samples were denatured at 95°C for 2 min. prior to loading, cooled on ice and 
each sample was loaded into an individual well. After running of the gel is completed, the 
gel was covered with Saran wrap and placed gel onto Whatman 3MM paper (Maidstone, 
UK) Supported by a layer of Whatman DE 81 paper (Maidstone, UK) which bound the 
shorter fragments that passed through the 3MM. The gel was dried on a gel dryer (Bio-Rad, 
Hemel Hempstead, UK) under vacuum at 80°C for at least 1 hour. The gel was exposed to 
X-ray film (Kodak X-OMAT™LS) or a phosphoimaging screen, for an appropriate time. If 
an intensifying screen was used, the film is exposed at -80°C. Exposure to X-ray film was 
usually around 18 hours without the aid of an intensifying screen and exposure to 
phosphoimager was usually 2 hours to visualise the bands using these conditions.
2.2.11 Labelling of lObp DNA ladder
TsAP treatment of lObp DNA ladder (Gibco-BRL, Paisley, UK):
Reaction mixture: lpl lObp DNA ladder
2\i\ 10X TsAP buffer 
ljul TsAP 
16jxl ddH20 
20\ii total
The mix was incubated at 65°C for 30 minutes, followed by the addition of 0.5pl TsAP and 
a further incubation at 65°C for 15 minutes. A volume of 2.2pl Stop mix (provided with 
kit) was added to the mixture and the TsAP was inactivated at 65°C for 20 minutes.
Kinase treatment of “TsAP-ed” lObp DNA ladder:
Reaction mixture: 5pl ‘TsAP-ed” lObp DNA ladder
l|Lil 10X kinase buffer 
lpl T4 kinase 
3\i\ y-32 P-ATP 
10pl total
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The mix was incubated at 37°C for 30 minutes. After incubation 90jli1 TE were added to the 
mixture and the mixture was applied to a equilibrated column (BioRad, Hemel-Hempstead, 
UK).
2.2.12 Preparation of competent E.Coli cells
The initial stab of E.coli cells was ToplOF purchased from Invitrogen, UK.
Competent cells were prepared based on the method described by Hanahan, 1983. 
Cells from a single colony were grown at 37°C in 5ml of broth (2% bacto tryptone, 0.5% 
yeast extract, 0.4% magnesium sulphate and lOmM potassium chloride) in 50ml Falcon 
tubes to an OD550 of around 0.3 overnight. Of this culture 2.5ml were used to inoculate 
100ml of pre-warmed Luria-Bertani (LB) broth pre-prepared in 2 litre sterile glass flasks. 
The culture was grown for another 2-3 hours until the OD550 was 0.48. This required 
vigorous aeration provided by the shaker set at 250-350 rpm. The culture was cooled on 
ice, and transferred to 2 x 50ml Falcon tubes. These were spun in a pre-chilled centrifuge at 
400g for 5 min. at 4°C. All subsequent work was carried out on ice. The cells were 
resuspended in ice-cold filter sterilized TfBI (lOOmM rubidium chloride, 50mM manganese 
chloride, 30mM potassium acetate, lOmM calcium chloride, 15% glycerol, pH to 5.8 with 
0.2N acetic acid), 30ml per 100ml per culture. Cells were spun down as before and again 
resuspended in ice-cold filed TfBI. The cultures were left on ice for 30 minutes. The cells 
were again spun down, and gently re suspended in ice-cold TfBII (lOmM MOPS, pH 7.0 
[adjust with NaOH], lOmM rubidium chloride, 75mM calcium chloride, 15% glycerol) at a 
concentration of 4ml per 100ml of starting culture. Aliquots of 0.2ml of the suspension 
were dispensed into 1.5ml tubes and immediately placed into a dry-ice bath at -80°C. 
Afterwards all aliquots were moved to the -80°C freezer to be stored for up to 6 months.
2.2.13 Transformation of E. coli
An aliquot of pre-prepared competent E. coli cells was thawed on ice for approximately 10 
minutes. Plasmid DNA was added to the E. coli aliquot at a ratio of 5pi plasmid DNA (1- 
5pg /pi) per 200pl cells. The mixture was incubated on ice for 30 minutes. The cells were 
heat shocked in a waterbath at 42°C for 90 sec. before being placed on ice for 3 minutes. 
Meanwhile 1ml of LB broth (20g/l) were pre-warmed at 37°C. The transformed cells were
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added to the 1ml pre-warmed LB broth (containing no antibiotics) and incubated at 37°C 
for 1 hour and 30 minutes.
1) For maxi preps
The complete transformation mixture was transferred into 200ml of media containing 100- 
150|xg/ml ampicillin and left shaking at 320rpm and 37°C overnight. The protocol was 
continued as described in the instructions provided by the Maxi prep kit (Qiagen, Crawley, 
UK). The concentration of plasmid retrieved after the maxiprep procedure was measured by 
adding 15/il of obtained plasmid DNA into 3ml of ddH20 at OD260. An OD260 value of 0.1 
indicated a concentration of lpg/pl.
2) For bacterial colonies
After the final incubation step of the transformation protocol the transformed E. coli culture 
was spun down at 1500rpm for 3 minutes and 1ml of supernatant was discarded. The 
remaining portion of E. coli culture was spread on 5 plates (LB agar, 100/ig/ml ampicillin) 
at a volume of 1 drop per plate. Plates were incubated at 37°C overnight. Colonies were 
later grown up by transferring single colonies each into 2ml LB broth containing ampicillin 
in a loosely capped 10ml tube. The colonies were shaken at 320rpm at 37°C overnight. The 
resulting 2ml of bacterial culture were decanted into a 2ml Eppendorf the next day and the 
plasmid DNA retrieved by following the protocol provided by the miniprep kit (Qiagen, 
Crawley, UK).
2.2.14 Transient transfection
This assay was used to determine the transfection efficiency of the HT1080 Tet-Off cell 
line using the pCHllO plasmid (Fig. 2.4) and pTRE-luc plasmid (Fig. 2.5). Transfection 
efficiency was later tested using the p-galactosidase assay kit (Promega, Southampton, UK) 
and luciferase assay kit (Promega, Southampton, UK) respectively.
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Fig. 2.4: Schematic representation of the pCHllO vector
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Fig. 2.5: Schematic representation of the pTRE-Luc vector
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Initially, lxlO5 cells per well were plated out in 6 well plates and left for 48hrs to reach 60- 
70% confluency. On the day of transfection mixtures containing the following ingredients 
were prepared in order to be able to achieve maximum transfection efficiency.
2.5\ig
5ng
7.5|ng
pTRE-luc + ljug pCHllO +
lOpl
20pl
Superfect + 150pl free DMEM 
(Qiagen, UK) (no glutamine or FCS)
The transfection mixtures were incubated at RT for 10 minutes. Meanwhile the cells on 6- 
well plate were washed with FCS-free DMEM medium. Following the incubation period, 
lml of complete DMEM (2mM glutamine, 10% FCS, no antibiotics) medium was added to 
each of the transfection mixtures and the mixture added to individual wells of the 6-well 
plate so as to have one well per transfection mixture. Cells were incubated with the 
transfection mixtures at 37°C for 2 hours. The medium was changed and 4ml of complete 
growth medium was added to the cells. The medium was changed again after a further 
18hours. Finally the cells were left to grow for 48 to 72 hours before being harvested for 
analysis using the P-galactosidase kit and luciferase kit.
2.2.15 Stable transfection
The protocol for stable transfection was the same as for transient transfection described 
previously. After transient transfections carried out to determine the amount of DNA and 
Superfect required for meaximum transfection efficiency, stable transfections were 
performed using 5pg plasmid DNA and 20pl Superfect. Therefore, the transfection mixture 
contained:
5pg plasmid DNA + lpg pTK-Hyg (Fig. 2.6) + 20pl Superfect + 150pl free DMEM
The pTK-Hyg vector is required for selection of transfected cells using hygromycin 
containing medium. The plasmid DNA was either pTRE-E2F-l, pTRE-E2F-l AS or 
pTRE300 (section 2.2.17) depending on whether E2F-1 inducible, E2F-1 inducible anti­
sense or control clones were produced. All clones were further propagated in DMEM
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medium containing 10% FCS, 4mM glutamine, 100 units/ml penicillin, lOOug/ml 
streptomycin, 100/xg/ml of G418, 25pg/ml hygromycin and 500ng/ml doxocycline as 
recommended by Clontech,UK and verified by repeat experiments. Induction of E2F-1 
expression in clones was initiated by the removal of doxocycline from the medium.
ECCjP I (5040)
A m p r
H S V  TK 
p o l y  A
p U C
o r i
HSV TK
Ecoft I (2718) f r o R  I (2330)
Fig. 2.6: Schematic representation of the pTK-Hyg vector
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3. DEREGULATION OF E2F-1 AND CHEMOSENSITIVITY
3.1 Introduction
Aberrations in the expression levels of genes associated with the regulation of cell 
proliferation and apoptosis are found in all cancers. Alterations in gene expression are 
observed in particular with respect to the retinoblastoma pathway, regulating the transition 
from G1 to S phase, and the p53 pathway, responsible for induction of cell cycle arrest and 
apoptosis in response to DNA damage and inappropriate proliferative signalling. 
Deregulation of the retinoblastoma pathway occurs through several mechanisms including 
mutation or deletion of Rb, cyclin D overexpression and mutation and/or deletion of the 
cyclin-dependent kinase inhibitor p l6 INK4a. Mutations or deletions of Rb have been reported 
in hereditary and sporadic retinoblastoma, small cell lung cancer, breast cancer and 
osteosarcoma (Kaelin, 1999; Schauer et al., 1994; Weinberg, 1995).
Overexpression of cyclin D1 has been observed as a consequence of gene 
amplification, translocation, post-transcriptional or post-translational modifications in a 
variety of cancers including breast cancer, head and neck cancer and non-small cell lung 
cancer (Bartkova et al., 1995; Buckley et al., 1993; Schauer et al., 1994; Scully et al., 
2000).
Mutation and/or deletion of p l6 INK4a, the cyclin-dependent kinase inhibitor 
regulating the activity of cyclin D-dependent kinases has been reported for many human 
cancers including pancreatic adenocarcinomas, and melanomas (Sharpless et al., 1999). 
Mutation and deletion of p l 6 lNK4a was found in non-small-cell lung cancer, but 
hypermethylation of the p l6 INK4a gene promoter was an additional mechanism found to be 
involved in gene silencing (Chen et al., 2002; Zochbauer-Muller et al., 2001).
Alterations in the expression of Rb, cyclin D1 and p l6 INK4a lead to upregulation of 
the E2F transcription factors and a subsequent increase in the expression of genes required 
for DNA synthesis and progression from G1 to S phase of the cell cycle. An increase in 
E2F activity and transcription of E2F-regulated genes such as DHFR and TS potentially 
influences the cellular sensitivity to chemotherapeutic agents leading to altered drug 
responses through one or more of the following mechanisms (Hochhauser, 1997; Kohn, 
1996).
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3.1.1 Overexpression of E2F-1 regulated proteins and chemosensitivity
Proteins required for DNA synthesis and G1 to S phase transition such as DHFR or TS 
potentially bind or are a drug target. Hence, E2F-1 dependent overexpression of these 
proteins potentially reduces cellular drug sensitivity. Hochhauser et al., investigating the 
effects of cyclin D1 overexpression on chemosensitivity, observed a decrease in sensitivity 
to methotrexate as a result of an increase in DHFR expression levels (Hochhauser et al., 
1996).
An investigation into the effects of human E2F-1 cDNA overexpression on growth, 
tumourigenicity and sensitivity to chemotherapeutic agents was conducted using an E2F-1 
overexpressing HT1080 human fibrosarcoma cell line (Banerjee et al., 1998). HT1080 cells 
were co-transfected with an E2F-1 expression vector and neomycin resistance vector to 
yield stable clones overexpressing E2F-1. Following selection, protein expression was 
determined by Western blot. Immunohistochemical analysis revealed a differential pattern 
of subcellular E2F-1 expression within chosen clones. E2F-1 expression pattern ranged 
from predominantly nuclear, to nuclear and cytoplasmic expression, to exclusively 
cytoplasmic expression of E2F-1. In addition, doubling times of E2F-1 overexpressing 
clones and tumour growth in nude mice were faster compared to the control. Cells from 
clones with predominantly nuclear E2F-1 expression were found to show the fastest rates of 
growth in vitro and in vivo (Banerjee et al., 1998).
Further, E2F-1 overexpressing cells were able to overcome a G1 cell cycle block 
induced by methotrexate in comparison to control cells that exhibited a persistent G1 block 
following methotrexate treatment. Growth inhibition studies showed HT1080 E2F-1 
overexpressing cells to be less sensitive to 5-day exposure to 5-fluorouracil (5-FU). This 
decrease in chemosensitivity observed after treatment with 5-FU appeared as a direct 
consequence of an E2F-1 dependent increase in TS expression, a 5-FU target gene 
(Banerjee et al., 1998). No increase in resistance to methotrexate, a DHFR specific drug, 
was observed. E2F-1 overexpressing HT1080 cells were more sensitive to etoposide and 
doxorubicin, both topoisomerase II inhibitors, and SN38, a topoisomerase I inhibitor. 
Western blot analysis showed topoisomerase II expression levels to be higher in the E2F-1 
transfectants compared to the control cells (Banerjee et al., 1998).
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3.1.2 Increase of the proportion of cells in S phase and chemosensitivity
Overexpression of E2F-1 and the resultant increase in E2F-regulated gene expression has 
been shown previously to drive cells into S phase (Shan et a l, 1994; Shan et al., 1996). 
Hence, an E2F-induced increase in the proportion of cells in S phase might lead to an 
increased cell kill using S phase specific drugs. A recent study by Hofland et al. reported an 
increase in chemosensitivity in response to etoposide. Etoposide, a topoisomerase II 
inhibitor forms stable drug-protein-DNA complexes resulting in a double-strand break 
(DSB) upon collision with the replication machinery. The increase in chemosensitivity to 
etoposide was correlated with an observed increase in the percentage of cells in S phase as 
a result of E2F-1 induction. Further, an S phase-mediated increase in topoisomerase Ila  
expression was observed as topoisomerase Ha promoter activity is regulated independently 
of direct E2F-1 protein interaction (Hofland et al, 2000). An investigation using an E2F-1 
overexpressing myeloid progenitor cell line also found that E2F-1 overexpression resulted 
in an increase in chemosensitivity to etoposide through increasing the fraction of cells in S 
phase thereby causing an increase in topoisomerase Ila  expression levels. Furthermore, the 
observed increase in the rate of apoptosis in response to etoposide treatment was found to 
be independent of p53 accumulation, hence was initiated via a p53-independent pathway 
(Nip et a l, 1997). Finally, a study using an E2F-1 overexpressing HT1080 human 
fibrosarcoma cell line observed an increase in chemosensitivity in response to etoposide 
and found the same observation to hold true for doxorubicin (Banerjee et a l, 1998)
3.1.3 E2F-1 mediated apoptosis and chemosensitivity
As discussed previously in the introduction (section 1.9) deregulated E2F-1 activity 
enhances apoptosis through induction of p l4ARF followed by inhibition of MDM2 resulting 
in the accumulation and stabilisation of p53 (Bates et a l, 1998). Alternatively, E2F-1 is 
able to induce p53-independent apoptosis via p73, a p53 homologue (Irwin et a l, 2000). In 
a study to evaluate the in vitro and in vivo effects of adenovirus-mediated E2F-1 gene 
transfer alone or combined with topoisomerase II inhibitors, both etoposide and adriamycin 
were found to inhibit cell growth alone through arresting cells in G2 phase. Neither drug 
was able to induce cell death effectively. However, etoposide and adriamycin in 
combination with an increased exogenous expression of adenovirus-mediated E2F-1 led to 
an synergistic loss of viability in human osteosarcoma cells compared to treatment with
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either E2F-1 or chemotherapeutic agents alone. The increased loss of cell viability was 
found to be independent of p53. Instead the activation of the caspase cascade appeared to 
be involved in triggering the apoptotic processes. In vivo experiments supported the above 
findings, as adenoviral-E2F-l gene transfer or a single topoisomerase II inhibitor alone had 
a minimal anti-tumour effect while the combination of adenovirus-mediated E2F-1 and 
topoisomerase II inhibitor treatment produced an enhanced response and a significant 
reduction in tumour size (Yang et al., 2001).
3.1.4 Chapter aims
Understanding the interactions between drug mechanisms of action and genetic alterations 
within cancer cells provides a basis for exploitation of the potential vulnerability of 
tumours harbouring genetic alterations. For example, attempts have been made to 
counteract cyclin D1 overexpression with flavopiridol, a flavonoid derivative of the plant 
alkaloid rohitukinea. Flavopiridol has been shown to be a potent inhibitor of CDKs 1,2,4 
and 7 by decreasing the expression of cyclins D1 and D3 through affecting the transcription 
of cyclin D mRNA (Owa et al., 2001).
The aims of this chapter are
• to evaluate the possibility of enforced expression of E2F-1 to selectively sensitise 
cancer cells to chemotherapeutic agents.
• to establish the underlying mechanism that causes the differential chemosensitivity 
to a variety of anti-cancer drugs.
• to translate the understanding of mechanisms of chemosensitivity into a potential 
therapeutic approach.
To achieve the above, a validated E2F-1 overexpressing cell system previously described 
by Banerjee et al. was taken for studies, using a wide range of common and novel 
chemotherapeutic agents (Banerjee et al., 1998).
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• [Cis-diamminedichloroplatinum (II)] (cisplatin), a cross-linking agent prevents cell 
division by binding to DNA and preventing the unwinding of the DNA double helix 
for replication thereby inhibiting mRNA synthesis. DNA damage is predominantly 
caused through the generation of intra-strand cross-links although inter-strand and 
DNA-protein cross-links have also been identified (Murray, 2000). Cisplatin is cell 
cycle non-specific and has been shown to be effective in the treatment of 
adenocarcinomas of ovary, breast and stomach, bone and soft tissue sarcomas, liver 
and bladder cancer (Souhami and Tobias, 1998).
• Melphalan, a nitrogen mustard compound is an alkylating agent that exerts its effect 
by forming monofunctional adducts at the N7-guanine and the N3-adenine as well 
as by producing inter- and intra-cross-links of DNA strands, abnormal base pairing, 
or DNA strand breaks thereby preventing uncoiling of the DNA and preventing 
DNA replication and cell division. Melphalan is considered to be cell cycle non­
specific (Murray, 2000; Souhami and Tobias, 1998).
• Etoposide, a topoisomerase Ila  inhibitor produces cleavable complexes involving 
etoposide, topoisomerase Ha and DNA, resulting in DNA strand breaks.
• BGIII21, a novel minor groove-binding agent was selected (Fig. 3.1). BGIII21 is a 
distamycin A derivative first described by Wyatt et al., 1995. It is a tri-pyrrole 
compound that specifically binds to the minor groove of DNA in a sequence 
specific manner. The preferred binding site of BGIII21 is TTTTGPu. BGIII21 is a 
monofunctional alkylating agent, alkylating the N3-guanine or N3-adenine of the 
binding sequence, represented by Pu (Wyatt et al., 1995).
3.2 Materials and Methods
3.2.1 Experimental cell lines
Unless otherwise stated adherent cell lines were maintained in Dulbecco’s Modification of
Eagles Medium (DMEM) containing 10% FCS and 2mM glutamine.
3.2.1.1 HT1080 and derivatives HT1080 Neo/ HT1080 E2F1-1, E2F1-4 and E2F1-6
HT1080 is a human fibrosarcoma cell line. Confluent cultures were passaged and seeded at
a concentration of l-4xl04 cells/cm2 as recommended by the European Collection of Cell
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Fig. 3.1: Chemical structure of the novel minor groove binding alkylating agent BGIII21
Cultures (ECACC, Porton Down, UK). A variety of E2F-1 stably transfected HT180 
human fibrosarcoma cell lines were provided by the Sloan-Kettering Institute, New York, 
USA (Banerjee et a l , 1998).
3.2.1.2 Chinese hamster ovary (CHO)
The Chinese hamster ovary cell line (CHO-AA8) purchased from Clontech, Basingstoke, 
UK was maintained in F-12 HAM medium supplemented with 10% FCS and 2mM 
glutamine. Confluent cultures were seeded at a concentration of l-3xl04 cells/cm2 unless 
otherwise stated (ECACC).
3.2.1.3 HT1080 Tet-Off E2F-1 inducible clones
The human fibrosarcoma Tet-Off cell line was purchased from Clontech, Basingstoke, UK 
and maintained in DMEM containing 10% Tet-Off FCS (Clontech, UK), 4mM glutamine, 
lOOunits/ml penicillin, 100pg/ml streptomycin and lOOjig/ml of neomycin (G418) as 
recommended by the supplier. The cells were split as described for HT1080 cell lines 
(section 3.2.1.1).
3.3 Results
3.3.1 Growth curves and cell morphology
Of initially eight E2F-1 overexpressing HT1080 clones obtained, four representative clones 
were selected at random for the experimental investigation. All four clones are listed in 
Table 3.1 and include the control and three E2F-1 overexpressing cell lines.
Name Characteristic Doubling time
HT1080 Neo control neo transfectant 21 hours
HT1080 E2F1-4 E2F-1 transfectants 21 hours
HT1080 E2F1-1 E2F-1 transfectants 10 hours
HT1080 E2F 1-6 E2F-1 transfectants 12 hours
Table 3.1: E2F-1 stably transfected HT1080 human fibrosarcoma cell lines selected for 
experimental investigation showing characteristics and cell doubling time of cell lines.
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The doubling time for each of the cell lines was established using the method previously 
described in section 2.1.3.3. Two of the E2F-1 transfected cell lines, HT1080 E2F 1-1 and 
HT1080 E2F 1-6, exhibited a doubling time of 10 and 12 hours respectively. In comparison 
the HT1080 Neo and HT1080 E2F 1-4 cell lines both had a doubling time of 21 hours.
A comparison of cell morphology revealed a marked difference in morphology between the 
HT1080 E2F 1-1 and HT1080 E2F 1-6 cells on one hand and the HT1080 Neo and HT1080 
E2F 1-4 cells on the other hand, as shown in Figure 3.2. The HT1080 Neo and HT1080 
E2F 1-4 cells are larger and irregular in shape and are of a more granular appearance. In 
comparison both HT1080 E2F 1-1 and HT1080 E2F 1-6 are much smaller and exhibit a 
regular and round to spindle-like shape as well as a smooth appearance.
3.3.2 Increased E2F-1 expression in E2F-1 transfectants
Initial Western blot analysis confirmed the increased E2F-1 expression levels in the E2F-1 
overexpressing transfectant cell lines (Fig. 3.3A). The E2F-1 protein appeared as the 
characteristic doublet of 60kd as determined by a Pre-stained Standard size marker 
(BioRad, Hemel-Hempstead, UK). The upper protein band depicts the phosphorylated E2F- 
1 protein while the lower protein band depicts the unphosphorylated E2F-1 protein. Figure 
3.3A shows E2F-1 expression in all HT1080 E2F-1 transfectants. However, HT1080 E2F 
1-1 and HT1080 E2F 1-6 exhibit a higher level of E2F-1 expression compared to HT1080 
Neo. HT1080 E2F 1-4 shows an increase in E2F-1 expression compared to HT1080 Neo. 
Further analysis of HT1080 E2F 1-1 indicated that expression of E2F-1 in total cellular 
protein extracts was increased to a lower extent compared to nuclear extracts (Fig. 3.3B).
Following the observed increase of E2F-1 expression in the HT1080 E2F 1-1 and 
E2F 1-6, the HT1080 E2F 1-1 cell line was selected as a representative E2F-1 
overexpressing cell line for further experiments. As Western blot analysis does not 
demonstrate functionality of the overexpressed E2F-1 protein, EMSA and supershift 
analyses were used to examine DNA binding as well as protein complex formation ability 
of the overexpressed E2F-1 protein.
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Fig. 3.2: Images of HT1080 Neo and HT1080 E2F 1-1 cells taken 
at x40 magnification to highlight differences in size and morphology.
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E2F-1
Fig. 3.3A: Increased expression of E2F-1 in E2F-1 transfected cells.
E2F-1 appears as the characteristic doublet of ~60kd as determined by 
Pre-stained Standard size marker. 10pg cellular extract was separated on 
10% SDS-PAGE gel as described by Western blot protocol.
Neo (HT1080 Neo); 1-1 (HT1080 E2F 1-1); 1-4 (HT1080 E2F 1-4);
1-6 (HT1080 E2F 1-6)
Coomassie staining of the blot to verify equal protein loading was not 
included as the blot did not photograph well.
Nuclear Whole cell 
extract extract
Neo 1-1 Neo 1-1 
E2F-1
Fig. 3.3B: Increased nuclear and cellular expression of E2F-1 
in E2F-1 transfected cells (1-1) compared to control cells (Neo) 
as determined by Western blot analysis. lOpg of nuclear or 
cellular protein extract were separated on 10% SDS-PAGE gel. 
Coomassie staining of the blot to verify equal protein loading was not 
included as the blot did not photograph well.
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3.3.3 Overexpressed E2F-1 exhibits DNA binding and complex formation
In a representative mobility shift experiment (Fig. 3.4) an increased level of E2F-1 
expression within HT1080 E2F 1-1 compared to HT1080 Neo was demonstrated. In 
addition, the mobility shift analysis identified one species of DNA binding complex 
containing E2F-1 (complex B, lane ‘C’) therefore verifying the DNA binding ability of the 
overexpressed E2F-1. In order to identify additional proteins present in the observed DNA 
binding complex containing E2F-1, supershift analysis using an E2F-1 antibody and 
antibodies against the pocket proteins pRb, p i30 and p i07 were performed. The resulting 
complex A confirmed the identity of the overexpressed protein to be E2F-1 (lane ‘E2F-1’) 
but did not indicate complex formation between E2F-1 and pRb (lane ‘pRb’), p i30 (lane 
‘pl30’) or pl07 (lane ‘pl07’). However, persistence of complex B in lane ‘pRb’ and ‘pl30’ 
suggested the presence of ‘free’ E2F-1. ‘Free’ E2F-1 is defined as the heterodimer 
consisting of E2F-1 and DPI not found in higher complexes with pocket proteins (Bandara 
et al., 1993; Huber et al., 1993). In conclusion, the identity of the overexpressed E2F-1 
protein was confirmed and the E2F-1 protein was shown to be functional as it binds DNA.
3.3.4 Deregulated expression of E2F-1 induces S phase entry
As stated in the introduction (section 1.10), a number of previous investigations revealed 
E2F-1 overexpression to result in an increase in the percentage of cells in S phase of the 
cell cycle as a consequence of inappropriate S phase entry (Johnson et al., 1993; Shan et 
al., 1994). To confirm that the E2F-1 overexpressing cell line (HT1080 E2F 1-1) contains 
functional E2F-1, FACS analysis was carried out as previously described (section 2.2.5). 
HT1080 Neo and HT1080 E2F 1-1 cells were fixed and stained with propidium iodide and 
subsequently sorted according to DNA content (Fig. 3.5). It was found that in a 
representative experiment 31% of HT1080 E2F 1-1 cells were present in S phase of the cell 
cycle compared to 13% HT1080 Neo cells. A concomitant decrease of HT1080 E2F 1-1 
cells in G1 and G2 phase was observed.
3.3.5 Resistance to BGIII21 in E2F-1 overexpressing cells
To examine the effect of E2F-1 overexpression on chemosensitivity, a range of 
chemotherapeutic agents was selected for growth inhibition studies (section 3.1.4).
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Neo 1-1
Fig. 3.4: DNA binding and complex formation of overexpressed E2F-1
as shown by EMSA and supershift analysis. E2F-1 protein of HT1080 Neo 
(Neo) and HT1080 E2F 1-1 (1-1) bound radio-labelled E1A probe (lanes 'C') 
(B). E2F-1 protein fraction was identified by E2F -1 antibody (+Ab)
(lane 'E2F-1') in supershift analysis (A). Additional protein components of 
E2F-1 DNA-binding complex were not verified by supershift analysis (A) 
(lane 'pl30'), (lane 'pRb') and (lane 'pl07').
20pg of nuclear extract was separated on 4% polyacrylamide gel.
Cold E2A probe was used as a negative control (lane 'N').
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Fig. 3.5: Increased percentage of cell accumulation in S phase of cell cycle 
in E2F-1 overexpressing cell line (HT1080 E2F 1-1). Exponentially 
growing cells were stained with propidium iodide and sorted according to 
DNA content (FL2-H) using FACS analysis. The resulting histogram was 
analysed by gating the individual cell cycle phase populations to obtain the 
% cells in each cell cycle phase.
Ml (G1 phase-2n); M2 (S phase-2n/4n); M3 (G2 phase-4n)
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Sulphorhodamine B (SRB) growth inhibition assays were used to investigate the growth 
inhibitory effect of selected chemotherapeutic agents on E2F-1 overexpressing cell lines as 
this method provides a rapid and sensitive way of screening by way of measuring the total 
cellular protein content (Skehan et al., 1990). Growth inhibition analysis based on 3 or 
more repeat experiments from which the mean IC50 (± s.d.) was derived, revealed the 
continual survival of HT1080 E2F 1-1 (>50jxM ± N/A) compared to HT1080 Neo (0.72pM 
± 0.26) in response to BGIII21, following continuous drug exposure (Fig. 3.6). Additional, 
statistical analysis found the difference in chemosensitivity of HT1080 Neo and HT1080 
E2F 1-lto BGIII21 to be significant (p-value < 0.0001) (section 2.2.3.3). After 72hours 
drug treatment with etoposide a decrease in chemosensitivity was observed in the HT1080 
E2F 1-1 cells (0.89pM ± 0.08) compared to HT1080 Neo (0.36pM ±0.1) cells. However, 
further analysis showed the difference in chemosensitivity between the two cell lines to be 
non-significant (p = 0.1642). Results for cisplatin indicated an increase in chemosensitivity 
in HT1080 E2F 1-1 (1.7pM ± 0.26) compared to HT1080 Neo (3.95p,M ± 0.84) but 
statistics revealed the difference in chemosensitivity to cisplatin to be non-significant (p = 
0.2824). The same result applied to melphalan as although HT1080 E2F 1-1 cells were 
found to be more sensitive (6.8pM ± 1.65) than HT1080 Neo cells (8.86p,M ± 1.53) using 
IC50s, the difference in chemosensitivity was not found to be statistically non-significant (p 
= 0.0333).
Additional SRB analysis including the HT1080 E2F 1-4 and E2F 1-6 cell line were 
performed and representative results for HT1080 E2F 1-6 showed an equally increased 
resistance to BGIII21 treatment as was shown for the HT1080 E2F 1-1 (Fig. 3.7). Results 
for the HT1080 E2F 1-4 cell line were similar to the HT1080 Neo cell line indicating the 
E2F-1 expression level to influence chemosensitivity to BGIII21. To conclude, the IC50 for 
HT1080 E2F 1-1 and HT1080 E2F 1-6 were both >50pM and the HT1080 Neo and 
HT1080 E2F 1-4 cell lines had IC50 of 0.72pM and 0.43pM respectively following 72 
hours of BGIII21 treatment. Further statistical analysis of the data using a global 
multivariate model showed significant differences in chemosensitivity between HT1080 
Neo and HT1080 E2F 1-4 on one side and HT1080 E2F 1-1 and HT1080 E2F 1-6 on the 
other side (p < 0.0001). Therefore, overexpression of E2F-1 appears to modulate the 
cellular sensitivity in response to minor groove binding alkylating agents such as BGIII21.
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Fig. 3.6: Growth inhibitory effect of common chemotherapeutic agents 
and a novel minor groove binding alkylating agent (BGIII21) as measured by 
Sulphorhodamine B assay. All drug exposures were continuous (72hrs) and 
graphs represent 3 or more individual experiments.
Neo (HT1080 Neo); 1-1 (HT1080 E2F 1-1)
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Fig. 3.7: Growth inhibitory effect of a novel minor groove binding alkylating 
agent (BGIII21) as measured by Sulphorhodamine B assay. All drug exposures 
were continuous (72hrs) and graphs for Neo (HT1080 Neo) and 1-1 
(HT1080 E2F1-1) represent 3 or more individual experiments while graphs 
for 1-4 (HT1080 E2F 1-4) and 1-6 (HT1080 E2F 1-6) depict representative 
experiments.
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3.3.6 E2F-1 overexpression results in resistance to minor groove binding agents
To expand the investigation with respect to the novel minor groove binding agent BGIII21, 
further SRB growth inhibition experiments were performed. These included a range of 
minor groove binding agents such as Distamycin A, Hoechst 33258 and anthramycin and 
minor groove binding alkylating agents such as Tallimustine, CC-1065 and SCIII147 
(Murray, 2000). The range of drugs selected was used to investigate the mechanism of 
action responsible for the resistance effect observed in E2F-1 overexpressing HT1080 cells. 
Results obtained are based on 3 or more repeats performed for each individual experimental 
set-up i.e. cell line, drug and exposure time. The mean IC50 for each set of results was 
calculated and the relative resistance (RF) was normalised according to the formula shown 
in section 2.2.3.1 (Table 3.2).
Calculated values for relative resistance were either above or below 1. Any value 
above 1 signified a decrease in sensitivity of the cell line of interest i.e. HT1080 E2F 1-1 
compared to the control cell line (HT1080 Neo) in response to a specific drug tested. 
Values below 1 represented an increase in sensitivity of the cell line of interest (HT1080 
E2F 1-1) compared to the control cell line (HT1080 Neo) for a specific drug tested. The 
exact value of 1 represented no observed difference in chemosensitivity to a particular 
agent in the HT1080 E2F 1-1 compared to the control cell line (HT1080 Neo) (Colella et 
al., 1999). Previously obtained results for cisplatin, melphalan and etoposide were included 
in Figure 3.8 for comparative purposes.
Figure 3.8 shows an increase in relative resistance with respect to all minor groove binding 
agents in the HT1080 E2F 1-1 cell line compared to HT1080 Neo following acute or 
continuous drug exposure. However three exceptions to the above statement were observed. 
Anthramycin and CC-1065 both resulted in an increase in sensitivity of HT1080 E2F 1-1 
after 1 hour (RF = 0.77) and 72 hours (RF= 0.53) drug incubation respectively. In addition 
only a negligible increase in relative resistance of HT1080 E2F 1-1 cells to Distamycin A 
(RF = 1.05) was observed after 1 hour drug incubation.
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Fig. 3.8: Relative resistance of HT1080 E2F 1-1 to a range of minor 
groove binding and alkylating agents. Drug exposures were either acute 
or continuous for SRB assays performed. The resistance factor (RF )was 
calculated, using the average IC50 of 3 or more repeats for each 
experimental set-up, as described in section 2.2.4.1. RF values below 1 
indicate an increased sensitivity, values above 1 indicate an increased 
resistance of HT1080 E2F 1-1 to a specific drug in comparison to 
HT1080 Neo.
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Drug RF (1 hr drug exposure) RF (72 hrs drug exposure)
BGIII21 >8.06 >69.4
Anthramycin 0.77 4.68
CC 1065 1.6 0.53
Distamycin A 1.05 3.49
Hoechst 33258 3.2 8.54
SCini47 2.41 2.54
Tallimustine 5.48 4.13
Cisplatin 0.29 0.43
Etoposide 1.71 2.47
Melphalan 0.34 0.77
Table 3.2: Resistance factor values for minor groove binding, alkylating agents and 
chemotherapeutic agents cisplatin, etoposide and melphalan. RF was calculated, using 
the mean IC50 of 3 or more repeats for each experimental set-up, as described in section 
2.2.3.1.
Relative resistance factors calculated for acute and continuous drug exposures to 
cisplatin, etoposide and melphalan confirmed results obtained in section 3.3.5. These 
showed an increase in chemosensitivity of HT1080 E2F 1-1 cells to cisplatin and 
melphalan while a decrease in chemosensitivity is observed with respect to etoposide.
Tallimustine, structurally most closely related to BGIII21 (Fig. 3.9) resulted in a 
5fold increase in resistance of HT1080 E2F 1-1 following acute or continuous drug 
exposure. This stood in contrast to the RF values obtained for BGIII21 which indicated a 8 
fold and 70 fold increase in resistance of E2F-1 overexpressing cells after acute and 
continuous drug exposure respectively.
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Fig. 3.9: Chemical structure of the minor groove binding agent alkylating tallimustine
3.3.7 No effect on colony forming potential of E2F-1 overexpressing cells in response 
to BGIII21 treatment
Previous studies were performed using the Sulphorhodamine B (SRB) method, which gives 
a measure of growth inhibition only. To answer the question whether cells treated with a 
particular drug underwent cell cycle arrest or cell death further studies, looking at colony 
formation were performed to investigate cell survival (Brown et al., 1999).
To determine the response of HT1080 E2F 1-1 cells to BGIII21 treatment, cell survival 
assays were carried out to measure the effects of drug exposure on cells resulting in either 
cell death or recovery. A survival assay thus required a measure of the ability of cells to 
proliferate and this is usually an estimate of the ability of the individual cells to form 
colonies. In a representative clonogenic assay HT1080 E2F 1-1 cells demonstrated 
continued proliferation throughout the range of BGIII21 concentrations applied, while 
HT1080 Neo cells were cell cycle arrested or dead after IOjhM and 50jnM BGIII21 
treatment (Fig. 3.10). Continued cell proliferation is represented as the percentage of 
colony formation. Percentage colony formation was calculated by determining the cloning 
efficiency i.e. the number of colonies formed divided by the initial fixed number of control 
cells plated out. The value representing the cloning efficiency was then multiplied by the 
fraction obtained when dividing the number colonies attained for the drug treated cells by 
the number treated cells initially plated out (see section 2.2.4). The above illustrated the 
proliferative potential of HT1080 E2F 1-1 after treatment with BGIII21 compared to 
HT1080 Neo.
3.3.8 BGIII21 treatment results in S phase block in HT1080 E2F 1-1 cells
Further investigation was required into the way in which BGIII21 influences the cell 
cycle of E2F-1 overexpressing cells. FACS cell cycle analysis was performed on cells 
treated with increasing concentrations of BGIII21 for 1 hour followed by the cells being 
fixed and stained with propidium iodide (see section 2.2.5) (Fig. 3.11). In a representative 
experiment the results for HT1080 Neo cells showed that an increased accumulation of 
cells in G2 phase occurred from 30% at OpM to 52% at lpM BGIII21, before complete cell 
death is observed at 5jxM BGIII21. The percentage of cells in S phase doubled from 12% at 
0|iM to 24% at 5pM BGIII21 while the percentage of cells in G1 phase decreased 
concomitantly. In contrast, HT1080 E2F 1-1 cells exhibited an initial gain in percentage of
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Fig. 3.10: Effect of BGIII21 treatment on colony forming potential of 
HT1080 Neo and HT1080 E2F 1-1 cells. 50-60% confluent cells were 
treated with BGIII21 for 1 hour beforebeing plated out on petri dishes 
and left to proliferate and form colonies for 7-14 days. The cloning 
efficiency for HT1080 Neo and HT1080 E2F 1-1 was deduced to be 
-50% and -100% respectively. % colony formation was calculated as 
described previously in section 2.2.5.
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Fig. 3.11: Effect of BGIII21 on the cell cycle distribution of fi 11U8U r\eo 
and HT1080 E2F 1-1 cells. Cells were exposed to increasing doses of BGIII21 
for 1 hour before being fixed, stained with PI and sorted according DNA content 
using FACS. The resulting histogram was analysed by gating the individual cell 
Cycle phase populations to obtain the percentage of cells in each cell cycle phase. 
Ml (G1 phase-2n); M2 (S phase-2n/4n); M3 (G2 phase-4n)
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cells in G1 phase at lpM BGIII21 (59%) that progressively declined with increasing drug 
concentrations of 5pM (51%) and 50pM BGIII21 (24%). The fraction of cells in S phase 
showed an increase at 50pM BGIII21 (62%) resulting in an S phase block. The number of 
cells in G2 phase exhibited variations with increasing concentrations of BGIII21 
concomitant with changes seen in the distribution of cells in G1 and S phases of the cell 
cycle. Further, the appearance of a sub-Gl peak at 50pM BGIII21 was noticed indicating 
that a fraction of E2F-1 overexpressing cells did undergo apoptosis and die. In conclusion, 
following treatment with 50pM BGIII21 E2F-1 overexpressing cells continued to 
proliferate albeit with an altered cell cycle distribution and the appearance of a sub-Gl peak 
implying apoptotic cell death.
3.3.9 E2F-1 overexpressing cells do not undergo apoptosis in response to lOpM 
BGIII21
To complement the studies into the effect of BGIII21 on cell proliferation and cell cycle 
distribution, apoptosis assays using the TACS™ Annexin V-FITC detection method were 
carried out as described in section 2.2.6. HT1080 Neo and HT1080 E2F 1-1 cells were 
treated with lOpM BGIII21 for 1 hour and samples taken immediately after drug treatment 
(0 hr) as well as at 24 hours, 48 hours and 72 hours time intervals post drug treatment (Fig. 
3.13A and 3.13B). The results are presented in the form of a quadrate containing four 
sectors each representing a distinct population of cells (Fig. 3.12).
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Fig. 3.12: Example of the quadrate used for analysis of apoptosis assay results.
Sector 1: viable cells (PI -ve / Annexin V-FITC -ve)
Sector 2: apoptotic cells (PI -ve / Annexin V-FITC +ve)
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Sector 3: necrotic cells (PI +ve / Annexin V-FITC +ve)
Sector 4: damaged and fractionated cells (PI +ve)
Within 24 hours post BGIII21 drug treatment a distinct shift of viable HT1080 Neo cells 
into apoptosis or necrosis was observed (Fig. 3.13A). At 48 hours post drug treatment the 
majority of cells (51.2%) was necrotic as illustrated by the Annexin V/PI double-staining of 
the cells. At 72 hours post drug treatment the majority of HT1080 Neo cells were evenly 
divided between apoptotic (39.6%) and necrotic (34.4%) cells. The observed reduction in 
the percentage of necrotic cells at 72 hours post drug treatment may occur as a result of the 
analysis having been performed on an ungated (total) population of cells. Analysis of an 
ungated (total) population includes cells that would be otherwise excluded if analysing a 
gated (selected) population of cells. In the control experiment, 80-90% untreated HT1080 
Neo cells remained viable throughout the timecourse as illustrated by cells not being 
stained by either propidium iodide or Annexin V-FITC. A fraction of cells damaged by 
experimental processes invariably occurred and was disregarded for analysis.
When the same experiment was performed on E2F-1 overexpressing cells the result 
was different in that BGIII21 treated cells even at 72 hours post drug treatment did not 
exhibit any apoptosis or necrosis (Fig. 3.13B). Instead the cells were as viable as the 
untreated control cells. This supported results obtained from the clonogenic assay that 
altered cell cycle distribution as established by cell cycle analysis.
3.3.10 BGIII21 specific DNA lesions produced in HT1080 Neo and E2F 1-4
The investigations into the effects of BGIII21 treatment on E2F-1 overexpressing cells 
required detailed analysis of DNA damage produced and potential repair pathways 
involved.
To answer the above questions Single strand-ligation (Sslig) PCR as described in section
2.2.10 was carried out. Sslig PCR is a useful method to analyse DNA damage qualitatively 
and quantitavely at a single nucleotide level (McGurk et al., 2001). For the Sslig PCRs 
performed in this investigation the previously well-characterised N-ras promoter exon 1 
region was selected (Thom et al., 1991).
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Fig. 3.13A: HT1080 Neo cells undergo apoptotic cell death after lhr 
exposure to BGIII21. In a representative experiment an ungated cell 
population was analysed according to the Annexin V-FITC apoptosis 
detection protocol. Annexin V-FITC (FLH1) and PI (FLH-2) are plotted 
against each other resulting in a quadrate with 4 sectors each representing 
a distinct cell population (section 3.3.9).
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Fig. 3.13B: HT1080 E2F 1-1 cells do not undergo apoptotic cell death 
afterlhr exposure to BGIII21. In a representative experiment an ungated 
cell population was analysed according to the Annexin V-FITC apoptosis 
detection protocol. Annexin V-FITC (FLH1) and PI (FLH-2) are plotted 
against each other resulting In a quadrate with 4 sectors each representing 
a distinct cell population (section 3.3.9).
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The N-ras promoter region produced a fragment of DNA of 274bp length when digested 
with MseI restriction enzyme and contained a single BGIII21 specific binding site 
(TTTTGA).
All four previously characterised cell lines were included in the first set of Sslig- 
PCR experiments. Cells were exposed to increasing doses of BGIII21 for 5 hours. In a 
study, Brooks et al., have previously shown that an exposure time of 5 hours was sufficient 
to produce DNA lesions in yeast cells (Brooks et al., 2000). As no published data was 
available on exposure times required to produce BGIII21 specific DNA lesions in 
mammalian cells a 5 hours exposure time was selected for initial experiments in HT1080 
cells. The representative result in Figure 3.14, showed that BGIII21 specific DNA lesions 
are produced at 5pM and 50pM BGIII21 in HT1080 Neo and HT1080 E2F 1-4 cells as 
determined by a lObp ladder run alongside the samples. No results were obtained for either 
HT1080 E2F 1-1 or E2F 1-6. This lack of results could not be explained by failure of the 
method or experimental error as results were obtained for both HT1080 Neo and E2F 1-4 
cell line. A number of repeats including adjustments of experimental variables such as 
MgCl2 concentration in PCR reactions and PCR cycle number consistently produced an 
identical result to the one above. The possibility of an impaired drug uptake BGIH21 by 
HT1080 E2F 1-1 and E2F 1-6 cells was rejected as even failure of BGIII21 to enter cells 
would have resulted in a full length (FL) PCR product band being detectable on the gel.
3.3.11 DNA amplification experiments reflect Sslig result
As experiments in section 3.3.10 gave no results for either HT1080 E2F 1-1 or E2F 1-6 
cells the investigation was extended to elucidate the possibility of any differences in DNA 
sequence and accessibility between the two sets of clones. Restriction digest experiments 
using a number of restriction enzymes covering the range of primarily purine to solely 
pyrimidine based restriction sites were set up. In addition, the DNA extraction method was 
modified by including an increased number of phenol-chloroform purification steps to 
ensure that extracted DNA was free of any DNA associated proteins, hence eliminating the 
possibility of DNA bound proteins blocking access of restriction enzymes or primers to the 
DNA sequence. All restriction enzyme experiments resulted in the DNA of all four cell 
lines being completely digested as observed in the characteristic DNA smear produced
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Fig. 3.14: BGIII21 specific DNA lesions (—► ) produced within 
HT1080 Neo (Neo) and HT1080 E2F 1-4 (1-4) as measured by Sslig-PCR. 
No result was obtained for HT1080 E2F 1-1 (1-1) or HT1080 E2F 1-6 (1-6). 
Cells were incubated with BGIII21 for 5hours with BGIII21.
Correct size of BGIII21 lesions was verified with radio-labelled lObp DNA 
ladder run alongside samples. FL (full length PCR product)
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when run on a 0.8% agarose mini-gel. Hence it was assumed that the DNA was accessible 
to restriction enzymes and henceforth should allow primer binding.
To investigate further why no Sslig result was obtained for two of the four clones, a 
number of PCR reactions were set up to examine primer binding in all four cell lines. A 
range of available primer sets was used to cover a variety of unrelated primer and DNA 
sequences. As shown in Figure 3.15 the PCR experiments using primer sets for the N-ras 
promoter region (Thom et al., 1991) and topoisomerase Ila  gene sequence (Accession no. 
J04088) produced a similar result. The sequence of the N-ras primers used for PCR 
reactions were different from the nested N-ras primer set used for Sslig-PCR experiments 
previously (Table 2.3). PCR products were obtained for HT1080 Neo and HT1080 E2F 1-4 
but neither for HT1080 E2F 1-1 and E2F 1-6. Results for an additional set of MDR1 
primers gave the same result as observed for the N-ras and topoisomerase I la  gene 
sequence.
3.3.12 Restriction patterns produced by Southern blot analysis reveal two sets of cells
Based on the above experimental outcome Southern blot analysis was performed to 
compare the restriction patterns of all four cell lines when the DNA was digested with the 
Dral restriction enzyme (Promega, Southanpton, UK) overnight (Fig. 3.16). The Dral 
restriction enzyme was chosen as it digested DNA at a relatively high frequency at the 5’- 
TTT-AAA-3’ recognition site and produced complete restriction digests in all four cell 
lines. The Southern blots were probed with N-ras and topoisomerase Ila  sequences that 
had been derived from the previous PCR experiments (section 2.2.9). The findings revealed 
a distinct difference in the restriction patterns between HT1080 Neo and E2F 1-4 on one 
hand and HT1080 E2F 1-1 and E2F 1-6 on the other hand. Nevertheless, within those two 
subsets of cell lines the restriction patterns were shown to be identical (Fig. 3.16). The 
differences in restriction patterns imply DNA sequence alterations as restriction patterns 
should be identical or similar in the case of DNA sequence alterations due to mutations 
occurring.
112
N-ras
M
o
Q) COI
3kb —  
2kb —
1 kb—
0.5kb—
Topoisom erase Ila
3kb —
2kb—
1 kb —
234bp
Fig. 3.15: Investigation into the binding of the N-ras promoter 
and topoisomerase I la  primer sets to DNA of E2F-1 transfectants.
PCR products were separated on 0.8% agarose mini-gels.
M (lkb DNA ladder); Neo (HT1080 Neo); 1-1 (HT1080 E2F 1-1);
1-4 (HT1080 E2F 1-4); 1-6 (HT1080 E2F 1-6)
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Fig. 3.16: Restriction digest pattern of E2F-1 transfectants as 
determined by Southern blot analysis. Genomic DNA was cut with 
Dral restriction enzyme overnight, resulting restriction fragments 
were separated on a 4% polyacrylamide gel and probed with N-ras 
promoter and topoisomerase Ila radioactively labelled probes. Neo 
(HT1080 Neo); 1-1 (HT1080 E2F 1-1); 1-4 (HT1080 E2F l-4);l-6 
(HT1080 E2F 1-6)
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3.3.13 Karyotypic analysis of E2F-1 overexpressing cell lines
The finding of DNA sequence alterations suggested that the four cell lines which had been 
proposed to be derived from the same HT1080 parent cell line were in fact two unrelated 
sets of cell lines. To confirm this, the cell lines were sent for karyotypic analysis (Royal 
Free Hospital, London, UK). Metaphase chromosome analysis verified the hypothesis that 
the two subsets of cell lines were unrelated. Initial investigations revealed unique 
differences between the HT1080 Neo/HT1080 E2F 1-4 and HT1080 E2F 1-1/HT1080E2F 
1-6 cell lines In F ig u re  3.17 HT1080 Neo and HT1080 E2F 1-1 are shown as 
representative cell lines for each sub-set. Both cell lines exhibited aneuploidy as well as 
chromosome amplification and deletion. For example, chromosome pair 13 is deleted in the 
HT1080 Neo cells while the pair is present in the HT1080 E2F 1-1. In contrast the 
chromosome pair 22 is present in the HT1080 Neo cells while being deleted in the HT1080 
E2F 1-1 cells. Of significance is the absence of the Y chromosome in the HT1080 E2F 1-1 
cells while it is present in the HT1080 Neo. The suggestion that HT1080 Neo and HT1080 
E2F 1-4 were of the same origin and completely different compared to the HT1080 E2F 1-1 
and HT1080 E2F 1-6 cell lines was proven. Further karyotypic analysis including a 
purchased CHO-AA8 cell line (Clontech, UK) verified the suggestion that the HT1080 E2F 
1-1 and HT1080 E2F 1-6 cell lines were in fact Chinese hamster ovary cell lines. Further 
discussion with the laboratory that had sent the cell lines confirmed that work had also been 
in progress with CHO cell lines. Therefore the source for this contamination was mixing of 
strains.
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Fig. 3.17: Karyotypes of HT1080 Neo and HT1080 E2F 1-1 examining 
differences in chromosome arrangement. Analysis revealed differences in 
chromosome pair deletion (chromosome 13 in HT1080 Neo and chromosome 
22 in HT1080 E2F 1-1) and highlighted absence of Y chromosome in HT1080 
E2F 1-1.
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3.3.14 E2F-1 inducible expression system
Following the discovery that two of the four HT1080 E2F-1 overexpressing clones were 
CHO rather than human fibrosarcoma cell lines, an E2F-1 inducible expression system was 
chosen to continue the investigation into the mechanism underlying the resistance to 
BGIII21 and to determine a possible correlation between overexpression of E2F-1 in 
HT1080 cells and resistance to BGIII21. To this end an E2F-1 inducible expression system 
in HT1080 Tet-Off cells was produced.
The E2F-1 cDNA insert in a pcDNA3-F2F-7 plasmid (gift from E. Lam) was 
excised and subsequently ligated into the modified multiple cloning site of the pTRE 
plasmid. HT1080 Tet-Off cells were stably transfected with the new pTRE-E2F-l plasmid 
construct (Fig. 3.18). The exogenous E2F-1 expression levels in the resultant clones were 
determined using Western blot analysis. Functionality of the overexpressed E2F-1 protein 
was examined by performing FACS analysis on serum starved and cell cycle arrested cells 
using nocodazole to determine the relative percentage of cells in S phase in non-induced 
and induced HT1080 Tet-Off cells. Finally, growth inhibition studies were carried out to 
analyse the effect of E2F-1 overexpression on BGIII21 chemosensitivity.
3.3.15 Construction of E2F-1 inducible expression system in HT1080 Tet-Off cells
The Tet-Off gene expression system (Clontech, Basingstoke, UK) and the pre-made 
HT1080 Tet-Off cell lines (Clontech, Basingstoke, UK) provide ready access to the 
regulated, high-level gene expression systems previously described by Gossen et al. 
(Gossen et al., 1992). In the Tet-Off system gene expression is turned on upon removal of 
doxocycline (Dox) from the culture medium. Gene expression is tightly regulated in 
response to varying concentrations of Dox. Expression levels in Tet systems are high and 
gene regulation is highly specific eliminating pleiotropic effects and non-specific induction 
(Clontech, Basingstoke, UK).
3.3.15.1 Release of E2F-1 cDNA insert from pcDNA3-E2F-l plasmid
A large-scale preparation of pcDNA3-E2F-l vector (Fig. 3.19) was prepared according to 
the E. coli transformation protocol (section 2.2.13) followed by the maxiprep procedure 
outlined within the protocol supplied with the Maxi-prep kit (Qiagen, UK) (section 2.2.13). 
The E2F-1 cDNA insert located in the multiple cloning site of the original pcDNA3 vector 
was released by restriction digest with BaniHl and FcoRI as shown in Figure 3.20. The
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A)
Sac!I EcoRI Kpn\ BamH\ Xba\ BamH\
amp P-tre
B)
----------------------------------- pTRE
Insert new linker:
AEcoRI BamHl Nhel Notl EcoRI ABamHl
Sac!I BamHl Nhe\ Not\ EcoRI
pTRE300
P-treamp
Insert E2F-1 as BamHl-EcoRl fragment
SacW BamHl EcoRI
pTRE-E2F-l
amp P-tre E2F-1
Fig. 3.18: Diagrammatic illustration of steps in the development of the 
pTRE-E2F-l inducible expression plasmid.
A) pTRE plasmid with the multiple cloning site downstream of P-tre 
promoter element, amp (ampicillin resistance gene)
B) Modified pTRE300 plasmid after insertion of linker. Former EcoRI 
and BamHl restriction sites in pTRE were deleted and new BamHl and 
EcoRI were created.
C) Insertion of E2F-1 cDNA as EomHI-EcoRI fragment into pTRE300. 
E2F-1 cDNA located downstream of P-tre promoter element.
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Fig. 3.19: Map of pcDNA3-E2F-l plasmid highlighting location of 
E2F-1 cDNA insert between BamHl and EcoRI restriction sites
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Fig. 3.20: Restriction digest with BamHl / EcoRI to release E2F-1 
cDNA insert from pcDNA3-E2F-l plasmid, lkb DNA ladder (M).
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digested pcDNA3 plasmid DNA and E2F-1 insert were separated on a 0.8% agarose mini­
gel containing ethidium bromide (Fig. 3.20). The released E2F-1 cDNA was 1.3kb in size 
as predicted from prior sequence analysis of the E2F-1 open-reading frame (ORF) 
(Accession number M96577).
3.3.15.2 Construction of linker required for restriction site modification
Part of the construction of the E2F-1 inducible expression system was the insertion of the 
released E2F-1 cDNA (1.3kb) into the pTRE plasmid (3.1kb). However, in order for the 
E2F-1 cDNA to be correctly transcribed, the EcoRI and BarriHl restriction sites within the 
multiple cloning site of the pTRE plasmid required modification. To achieve this, two 37bp 
oligomers were annealed and the linker inserted into the EcoRVBarriHL digested pTRE 
plasmid thereby abolishing the existing EcoRI and BamHl restriction sites and creating a 
new BamHl and EcoRI in the correct orientation (Fig. 3.18). The two oligomers pTRE-BE- 
FW and pTRE-BE-AS were annealed in such a way as to produce a 4 bp overhang on either 
side in order to abolish the EcoRI (AEcoRI) and BamHl (ABamHl) restriction sites and 
create the new 5’ BamHl and 3’ EcoRI restriction sites (Fig. 3.21).
AEcoRI BamHl Nhe I Noil
5’-AATl(&ATCCTATA<jCTAGCAAAGCGGCCGC(&ATTC-3’
3 ’ -CCTA^GAT ATCGATCGTTTCGCCGGCGC T TA ^J CTAG-5’
EcoRI ABamHL
Fig. 3.21: Annealing product of pTRE-BE-FW (5’-3’) and pTRE-BE-AS (3’-5’). The
introduced base-pair mutations necessary to abolish existing EcoRI and BamHl restriction 
sites are underlined. New BamHl and EcoRI restriction sites are marked y  and ^ .
New previously non-existing Nhel and Noil restriction sites introduced for verification 
purposes are marked with I .
3.3.15.3 Insertion of linker into pTRE
Next pTRE plasmid (Fig. 3.22) was digested with EcoRI and 20u BamHl. The digested 
plasmid was separated on a 0.8% agarose gel containing ethidium bromide and was 
subsequently extracted from the gel using the Gene-clean® II kit Bio 101 (Anachem, UK).
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The isolated DNA fragment was resuspended and a ligation reaction was set up containing 
digested pTRE plasmid.
Xho I
Sac II 
fcoRI
BamHI 
Xba I
BarrM\
Sea I TRE
minCMVIE
hCMV-1
A m p SV40 
poly ApTRE
3.1 kb
Him!
Col El 
ori
Fig. 3.22: Map of pTRE plasmid including multiple cloning site 
high-lighting EcoRI and BamHl restriction site selected for deletion 
to allow insertion of E2F-1 cDNA fragment.
Furthermore, the ligation reaction was digested with Xbal in order to linearise any 
remaining parental pTRE vector void of linker insert as the pTRE vector specific Xbal 
restriction site was eliminated upon insertion of the linker into the linearised pTRE plasmid.
To increase the amount of ligation product, E.coli were transfected with pTRE300 
as described previously (section 2.2.13) and plated out on ampicillin (100pg/ml) containing 
agar plates. The plates were left for 24 hours or until distinct visible colonies had grown. 
Twenty randomly selected single colonies were further processed and the plasmid DNA 
extracted from the bacterial cells according to instructions supplied with the Mini-prep kit 
(Qiagen, UK).
3.3.15.4 Verification of correct restriction sites in modified pTRE plasmid (pTRE300)
Restriction digests with Xbal, EcoRI, BamHl, NheI, Notl and Sacll were set up. These 
consisted of the pTRE300 plasmid DNA retrieved in the previous section. The restriction
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products were subsequently separated on 0.8% agarose gels containing ethidium bromide. 
Non-digested pTRE300 plasmid DNA was run next to the digested samples as a control 
(Fig. 3.23).
3.3.15.5 Ligation of E2F-1 cDNA insert into pTRE300
Before ligation both the pcDNA3-£2E-/ and pTRE300 were digested with the restriction 
enzymes BamHl and EcoRI in order to isolate the E2F-1 cDNA insert and open the 
recipient plasmid, respectively. Each sample was taken and separated on a 0.8% agarose 
mini-gel containing ethidium bromide to confirm completion of the enzyme reaction and 
separate the individual components needed for further processing (Fig. 3.24).
The E2F-1 cDNA insert and the digested pTRE300 plasmid were extracted from the 
gel using the Gene-clean® II Bio 101 kit (Anachem, UK). Following the instructions of the 
protocol provided with the kit only the last washing step was modified this time, as both 
samples were pooled together beforehand. The retrieved and pooled plasmid and insert 
DNA was resuspended and subsequently ligated.
To purify the ligation reaction of any undigested pTRE300, a restriction digest with 
NheI (NEB, UK) was performed. As before E.coli were transformed with the newly 
constructed pTRE-E2F-l plasmid and plated out on agar plates containing ampicillin. 
Bacterial colonies were harvested and the plasmid DNA was retrieved with a Mini-prep kit 
(Qiagen, UK).
3.3.15.6 Verification of pTRE-E2E-2 and transfection of HT1080 Tet-Off
All DNA minipreps were digested with BamHl and EcoRI to confirm the presence of the 
E2F-1 cDNA insert. Figure 3.25 shows 3 randomly selected restriction digested DNA 
mini-preps. All three DNA minipreps feature E2F cDNA of the correct size (1.3kb). A 
further verification step was carried out as both the original pcDNA3-E2F-l and newly 
made pTRE-E2F-l was digested with BamHl and EcoRI. A comparison of both digested 
plasmids is shown in Figure 3.26. Sizes of both E2F-1 inserts were equal hence providing 
proof of the correct insertion of E2F-1 cDNA into pTRE300 to obtain pTRE-E2F-l.
In addition to the above pTRE-E2E-i plasmid, an E2F-1 anti-sense plasmid had 
been developed simultaneously. For this design the E2F-1 cDNA insert was ligated directly 
into the pTRE plasmid therefore switching the E2F-1 ORF around resulting in transcription
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Fig. 3.23 Verification of pTRE300 plasmid with several restriction 
digests. Complete restriction digest of pTRE300 with EcoRI, 
BamHl, Notl and Nhel and SaclI. No restriction cut of pTRE300 
with Xbal.lkb DNA ladder (M)
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Fig. 3.24: Restriction digest with BamHl / EcoRI of modified 
pTRE300 and pcDNA3-E2F-l plasmids to release E2F-1 cDNA insert 
prior to ligation of E2F-1 cDNA insert into opened pTRE300 plasmid, 
lkb DNA ladder (M)
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M Uncut Cut Uncut Cut Uncut Cut
Fig. 3.25: Analysis of pTRE-E2F-l plasmid minipreps by
restriction digest with BamHl and EcoBl to release inserted E2F-1 cDNA 
(^—). Overall 9 correct plasmid minipreps were obtained and analysed for 
the presence of E2F-1 insert. lkb DNA ladder (M).
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Fig. 3.26 Restriction digest with BamHl/ EcoRI to confirm correct 
size of E2F-1 cDNA insert in pTRE-E2F-l plasmid by comparison to 
original pcDNA3-E2F-l plasmid, lkb DNA ladder (M).
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of anti-sense E2F-1 mRNA. The pTRE300 plasmid was used as an empty control plasmid 
for transfection into HT1080 Tet-Off cells. All plasmids were sent off to MWG, Ebersberg, 
Germany for sequencing to ensure correct sense and anti-sense orientation of E2F-1 cDNA 
insert.
Transfection of HT1080 Tet-Off cells was performed as described in section 2.2.15. The 
transfection efficiency had been determined prior to stable transfection using the pTRE-luc 
and pCHl 10 plasmids (section 2.2.14)
3.3.16 Increased expression of E2F-1 in HT1080 E2F-1 2 and E2F-113 clones
Of all transfected E2F-1 sense, E2F-1 anti-sense and pTRE300 clones, four were selected 
for further experiments. These included two E2F-1 sense clones HT1080 E2F-1 2 and E2F- 
1 13, one E2F-1 anti-sense clone HT1080 E2F-1 AS 44 and one pTRE300 11 clone. The 
selection was based on Western lot analysis performed to determine E2F-1 expression 
levels within each non-induced and induced clone. A time-course experiment was set up 
with protein samples taken every 24 hours for 12 days to determine the time-point of peak 
E2F-1 expression following doxocycline removal. The E2F-1 peak expression level within 
induced cells was established at 240 hours with expression levelling off at any further time- 
points. Upon 240 hours induction of the pTRE promoter following the removal of 
doxocycline, E2F-1 expression was increased in HT1080 E2F-1 2 and E2F-1 13 (Fig. 
3.27). In contrast, E2F-1 expression decreased in HT1080 E2F-1 AS 44 cells due to the 
transcribed anti-sense E2F-1 mRNA binding sense E2F-1 mRNAs (Fig. 3.27). No 
significant change in E2F-1 expression levels was observed in the pTRE300 control clone 
after induction (Fig. 3.27).
3.3.17 E2F-1 inducible system promotes S phase entry following serum-starvation
Previous studies by Shan et al. using a tetracycline controlled expression system to 
overexpress exogenous E2F-1 found induced expression of E2F-1 to promote premature S 
phase entry in Rat-2 fibroblasts (Shan et al., 1994). In a similar investigation Johnson et al. 
had shown that microinjection of E2F-1 cDNA was able to activate transcription in serum- 
starved REF-52 cells and induce S-phase entry in quiescent cells (Johnson et al., 1993).
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To analyse the potential of exogenous E2F-1 expression within the doxocycline repressible 
system to induce S phase in quiescent cells, HT1080 E2F-1 2, E2F-1 13, pTRE300 11 and 
E2F-1 AS 44 cells were grown in the absence of doxocycline for 240 hours. Following 
induction cells were grown in 0% FCS medium for 96 hours to arrest cells in G0/G1 phase. 
FACS samples of induced and non-induced cells of each clone were prepared following 
cell cycle arrest and DNA content of the cells measured to determine the percentage of cells 
in S phase. In Figure 3.28 a representative experiment shows induced and non-induced 
cells continued cell cycle progression suggesting serum starvation to have no marked effect 
on the E2F-1 inducible system under these conditions. However, a 5% increase of cells in S 
phase in induced compared to non-induced E2F-1 2 and E2F-1 13 clones suggested 
exogenously expressed E2F-1 to be functional and able to promote S phase entry in the 
absence of serum. In contrast the percentage of cells in S phase in non-induced and induced 
pTRE300 11 cells remained at 17%, while a decrease in the percentage of cells in S phase 
was observed comparing non-induced (14%) and induced (13%) AS 44 cells.
3.3.18 Increased percentage of E2F-1 overexpressing cells in S phase after G2 block
In a further attempt to analyse the potential of exogenous E2F-1 expression within the 
doxocycline repressible system to induce S phase entry in quiescent cells the above 
experiment was repeated using nocodazole rather than serum starvation to induce a cell 
cycle arrest. Nocodazole has been shown to arrest cells in G2 phase through inhibition of 
mitosis (Bowdon et al., 1987). In Figure 3.29 representative data for non-induced (A) and 
induced clones (B) E2F-1 2 clones is shown. A 5% increase in the percentage of cells in S 
phase was observed in induced compared to non-induced E2F-1 2 clones as a result of 
induction of E2F-1 expression for 240 hours (Ohrs). Following 18 hours of treatment with
0.5|Lig/ml nocodazole a distinct G2 block was observed in both non-induced and induced 
cells. Upon release of cells from the G2 block through the removal of nocodazole, induced 
clones showed a higher percentage of cells in S phase compared to non-induced E2F-1 2 
clones. At 4 hours post arrest 14% of induced compared to 8% non-induced E2F-1 2 cells 
were in S phase. The percentage of induced E2F-1 2 cells in S phase was observed for 19% 
for 8, 21% for 12 and 17% for 24 hours post G2 arrest. In comparison, the percentages for 
non-induced cells in S phase were 17% for 8, 21% for 12 and 13% for 24 hours following 
G2 arrest (Fig. 3.29).
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Fig. 3.28: Cell cycle analysis showing the percentage increase in S phase of E2F-1 overexpressing E2F-1 2 
and E2F-1 13 clones after 240hrs induction followed by 96 hours growth in 0% FCS. + (+Dox); - (-Dox)
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Fig. 3.29: Percentage of non-induced and induced (240hrs) E2F-1 2 cells 
after G2 arrest following 18hours treatment with nocodazole.
□ G1
□ S
□ G2
129
3.3.19 No increased resistance to BGIII21 in E2F-1 overexpressing HT1080 cells
After the construction of an inducible E2F-1 system and an analysis of inappropriate S 
phase entry after serum starvation and release from nocodazole induced G2 arrest, SRB 
growth inhibition assays were performed to investigate the effect of E2F-1 overexpression 
on BGIII21 chemosensitivity. Non-induced and induced (240hrs) E2F-1 2 cells were 
exposed to increasing concentrations of BGIII21 for 72 hours (Fig. 3.30). In a further assay 
E2F-1 2 cells were exposed to cisplatin as a means of control. No significant difference in 
chemosensitivity to BGIII21 or cisplatin was observed in non-induced and induced E2F-1 2 
cells (p < 0.0001). Increased expression of E2F-1 following induction did not lead to an 
increase in resistance to BGIII21. IC50 values for non-induced and induced E2F-1 2 cells 
following exposure to BGIII21 were identical (IC50 = ljxM ± 0.001). Equally, IC50 values 
were identical in both non-induced and induced E2F-1 2 cells after treatment with cisplatin 
(IC50 = 10.3pM ±0.003).
In conclusion E2F-1 overexpression in HT1080 human fibrosarcoma cells has no effect on 
chemosensitivity to BGIII21 and cisplatin. Resistance to BGIH21 does not occur as a result 
of E2F-1 overexpression.
3.4 Discussion
The results of the above investigation into the effects of E2F-1 overexpression on 
chemosensitivity in the HT1080 human fibrosarcoma cell line were overshadowed by the 
discovery of inter-species cross-contamination. Nevertheless a number of valid results were 
obtained. The connection between the elevated level of E2F-1 expression in the CHO cells 
as established by Western blot analysis and the decreased sensitivity to BGIII21 observed 
in the CHO cells requires further investigation. Further, the lack of significant differences 
in chemosensitivity in response to etoposide in CHO cells (‘HT1080 E2F 1-1') and 
HT1080 Neo contradicted data by Nip et al. and Banerjee et al. showing an increased level 
of E2F-1 expression resulting in an increase in chemosensitivity to etoposide. This result 
suggests that not only the expression level of a protein per se is important in determining 
the effects on chemosensitivity, but cell lineage appears to be also critical.
In addition, the production of BGIH21 specific DNA lesions in CHO cells and the 
type of repair pathways involved in their removal needs to be examined. As the N-ras
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promoter sequence has been shown, using Southern blot analysis, to contain sequence 
alterations preventing the nested N-ras primers from binding, a different DNA region in the 
CHO genome needs to be selected to detect BGIII21 lesions and analyse DNA repair.
To examine the possibility of E2F-1 overexpression directly influencing the 
chemosensitivity of HT080 to BGIII21, an E2F-1 inducible system was developed. E2F-1 
cDNA was inserted into the modified multiple cloning site of the pTRE plasmid and two 
E2F-1 overexpressing HT1080 clones were selected. Induction of E2F-1 expression was 
dependent on doxocycline removal from the growth medium. In addition, an E2F-1 anti­
sense and pTRE300 control plasmid were constructed.
An inducible E2F-1 expression system reduces the appearance of changes in protein 
expression levels related to a constitutive overexpression of E2F-1. Temporary induction of 
E2F-1 expression above normal level reveals more accurately the effect E2F-1 
overexpression has on E2F-1-regulated protein levels and the subsequent effects with 
respect to cell cycle progression. However, the use of an E2F-1 inducible system to 
examine the effect of E2F-1 overexpression on chemosensitivity provides several 
limitations. No natural amplification of the E2F-1 gene has been reported as yet, therefore 
artificially increasing the expression level of E2F-1 is prone to produce artefactual results. 
As an alternative it has been suggested to construct a cyclin D overexpressing system or 
selectively silence the cyclin-dependent kinase inhibitor p l6 INK4a to create a genetic 
environment more similar to situations observed in normal human tumours. These 
alternative approaches would also allow to investigate the effects of cyclin D 
overexpression or p l6 INK4a silencing on other members of the E2F transcription factor 
family thereby providing a more comprehensive insight into the individual processes that 
lead to the overexpression of individual E2F 's and the potential for exploiting these 
mechanisms using chemotherapy.
The use of a stable E2F-1 overexpression system as a tool to investigate the effects 
of E2F-1 overexpression on chemosensitivity is prone to the same limitations mentioned 
above in the context of the inducible system. However, in addition, the permanent 
expression of high levels of E2F-1 potentially leads to alterations in E2F-regulated genes 
downstream within the retinoblastoma pathway. It could be argued that this would create an 
artificial environment not observed in human tumours or instead it would provide a more
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realistic picture compared to the inducible system as overexpression of E2F-1 in human 
tumours may be assumed a permanent fixture.
Results showed an increase in E2F-1 expression level in two E2F-1 overexpressing 
clones after 240 hours of induction. In contrast, E2F-1 expression was reduced in the E2F-1 
anti-sense clone (AS 44) in the absence of doxocycline. Equal E2F-1 expression levels 
were observed in non-induced and induced pTRE300 11 control cells. In an attempt to 
investigate the functionality of the overexpressed E2F-1 protein FACS analysis of serum 
starved non-induced and induced E2F-1 2 were carried out. In contrast to prior 
investigations an increase of 5% of the percentage of cells in S phase was observed in 
induced E2F-1 2 and E2F-1 13 cells following release from serum starvation. All four 
clones examined did not undergo complete cell cycle arrest in G1 phase as would be 
expected following serum starvation.
A repeat experiment using nocodazole to induce a G2 arrest showed a distinct G2 
arrest in both non-induced and induced E2F-1 2 cells. A 2fold increase in percentage of 
cells in S phase following release from G2 arrest was observed in induced cells compared 
to non-induced cells at 4 hours post arrest.
The above data did demonstrate the potential for exogenously expressed E2F-1 to 
promote S phase entry in quiescent or cell cycle arrested cells. However, the observed 
percentage increase of cells in S phase was not as marked as had been published previously 
in Johnson et al. and Shan et al.. A suggested cause for the lack of a more significant 
inappropriate S phase entry in E2F-1 overexpressing HT1080 cells could be the HT1080 
Tet-Off cell line itself. As a transformed cell line it is presumed to contain a higher basal 
level of E2F-1 expression than for example the Rat-2 or REF52 cells used in previous 
studies (Johnson et al., 1993; Shan et al., 1994). An already elevated level of E2F-1 
expression would substantially obscure the effect of a further increase in E2F-1 expression 
as well as make it difficult for cells to be arrested in G0/G1 by serum starvation.
Finally, growth inhibition assays were performed to determine the effect of E2F-1 
overexpression on chemosensitivity in HT1080 Neo cells. No statistically significant 
increase or decrease in chemosensitivity in response to BGIII21 or cisplatin treatment was 
observed. Therefore it was concluded that E2F-1 overexpression was not the underlying 
factor causing an increased resistance to BGDI21.
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3.4.1 Aberrations of Kb pathway constituents and treatment prognosis
It has been proposed that aberration of a single constituent of the Rb pathway appears to be 
sufficient to alter cell cycle regulation. Furthermore, genetic alteration within any one gene 
within the Rb  pathway potentially eliminates the selective pressure for additional 
aberrations. Thus Rb or p l6 INK4a inactivation and cyclin D1 overexpression have been 
suggested to occur as mutually exclusive events.
Studies have revealed various malignancies to exhibit correlations between genetic 
alterations of individual members of the Rb pathway. Investigating the frequency of Rb 
deletions and cyclin D1 alterations, Rb deletions were found to be inversely correlated to 
cyclin D1 alterations in multiple myeloma (Kramer et al., 2002). However, no correlation 
was found between p l6 INK4a hypermethylation and cyclin D1 or Rb aberrations (Kramer et 
al., 2002). Further it was found that alterations within the cyclin D1 gene as well as Rb 
deletions resulted in a worse prognosis compared to p l6 INK4a hypermethylation which had 
no impact on survival (Kramer et al., 2002).
Further evidence of an existing inverse correlation between cyclin D1 
overexpression and Rb inactivation was reported by Schauer et al. looking at the expression 
levels of the respective proteins and their potential role in the etiology of lung cancer 
(Schauer et al., 1994). It has been suggested that different mechanisms account for the 
aberrations regarding cell cycle regulation within small and non-small cell lung cancer. 
Within non-small cell lung cancer cell lines cyclin D1 expression levels were found to be 
elevated compared to expression levels observed in small cell lung cancer and an 
immortalised human bronchoepithelial cell line. In contrast, non-small cell lung cancer cell 
lines expressed phosphorylation competent pRb at a constant level while expression of pRb 
in small cell lung cancer cell lines was non-detectable (Schauer et al., 1994). Therefore it 
was concluded that an inverse correlation between cyclin D1 overexpression and Rb 
deletion exists within two different types of lung cancer (Schauer et al., 1994).
The above examples of the relationship between cell cycle regulators such as Rb 
and cyclin D1 contribute to the understanding of aberrations of cell cycle constituents 
indicative of specific tumours. This knowledge aids the interpretation of data concerned 
with determining the potential prognostic effect these cell cycle elements have for the 
management of different types of cancer.
134
3.4.2 History of cell line and species cross-contamination
At present an estimated 20% of cell lines are assumed wrongly labelled as a direct 
consequence of intra- and inter-species contamination. The first extensively published case 
of cell cross-contamination involved HeLa. In 1968 Stan Gartler published the results of an 
investigation into the identity of 18 supposedly unique human cell lines. Analysing the 
expression of glucose-6-phosphate dehydrogenase and phosphoglucomutase he found HeLa 
and the 17 other cell lines to express the A form of glucose-6-dehydrogenase, almost 
exclusively found in black individuals, and to exhibit an identical phenotype for the 
polymorphic enzyme, phosphoglucomutase. Gartler concluded that all 18 cell lines might 
be HeLa cells (Masters, 2002). During the 1970s Walter Nelson-Rees continued to uncover 
HeLa cross-contaminations, nevertheless with little lasting success as a list of cell lines 
shows which have been proven to be HeLa but are still widely used under their original 
name in laboratories across the world (Table 3.3) (Masters, 2002; Nelson-Rees et al., 
1981).
A second significant case of cross-contamination of cell lines involves the human 
urinary bladder cancer cell line T24. Using isozyme analysis and human leukocyte antigen 
(HLA)-A-B-C typing O’Toole et al. found EJ(MGH-Ul) and some cultures of J82 to be in 
fact T24 cells (O’Toole et al., 1983). Further, applying cytogenetics and DNA profiling, the 
TSU-Prl and JCA-1 prostate carcinoma cell lines were identified to be derivatives of the 
bladder carcinoma cell line T24. Thus, TSU-Prl and JCA-1 are not of prostatic origin (van 
Bokhoven et al., 2001).
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Name Supposed origin Actual name and origin
KB Oral cancer HeLa (cervical cancer)
HEp-2 Larynx cancer HeLa (cervical cancer)
WISH, AV3 and FL Normal human amnion cells HeLa (cervical cancer)
L132 Normal human embryonic 
lung cells
HeLa (cervical cancer)
Intestine 407 Intestinal epithelium HeLa (cervical cancer)
Chang liver Normal liver cells HeLa (cervical cancer)
Table 3.3: Cross-contamination by HeLa cells. Illustration of cases in which identified 
HeLa cells are used under original names and functions of cell lines which have been 
eliminated by faster growing HeLa cells after cross-contamination of original cultures 
(Masters, 2002).
The above examples highlight the persisting problem of cross-contamination which in most 
cases result from poor cell culture technique when two cell lines accidentally enter the same 
culture and the faster dividing cell type outgrows the slower growing cells, or a clerical 
error -  mislabelling growing or frozen stocks.
It is difficult to determine which of the above mistakes led to the cross­
contamination of cells received from collaborators for the above investigation into the 
effects of E2F-1 overexpression on chemosensitivity. However, after examining original 
stocks of the supplied cell lines frozen down upon arrival and original stocks freshly 
supplied from the source it was possible to establish that any cross-contamination occurred 
at the source and not after cells had been supplied for the above investigation. In general 
cross-contamination of cell lines is an avoidable problem, if stringent controls of tissue 
culture technique are performed and karyotyping, isozyme analysis, human leukocyte 
antigen (HLA) typing or DNA fingerprinting (Stacey et al., 1992) are carried out upon any 
immediate possibility of cross-contamination having occurred (Masters, 2000). The latest 
technique suggested to provide an international reference standard for human cell lines is 
short tandem repeat (STR) profiling based on the amplification of polymorphic STR loci 
using commercially available sets of primers. PCR products are analysed with size 
standards using automated fluorescent detection techniques resulting in a unique numerical
136
code based on the lengths of the PCR products amplified at each locus. STR profiling has 
been shown to be inexpensive and work under routine conditions (Masters et al., 2001).
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4. BGIII21 CHEMOSENSITIVITY AND DNA REPAIR
4.1 Introduction
In the previous chapter analysis of the effects of E2F-1 overexpression on chemosensitivity 
to chemotherapeutic agents as well as a novel minor groove binding alkylating agent 
(BGIII21) was attempted. BGIII21, a distamycin A derivative was first described by Wyatt 
et a l , 1995. It is a tri-pyrrole compound that specifically binds to the minor groove of DNA 
in a sequence specific manner. The preferred binding site of BGIII21 is TTTTGPu. 
BGIII21 is a monofunctional alkylating agent, alkylating the N3-guanine or N3-adenine of 
the binding sequence, represented by Pu (Wyatt et al., 1995). Sulphorhodamine B (SRB) 
growth inhibition assays revealed a marked resistance to BGIII21 in two E2F-1 
overexpressing transfectants. However research into the presence of BGIII21 specific DNA 
lesions following treatment with BGIII21 was not successful, and further experiments 
revealed the two E2F-1 overexpressing cell lines to be of Chinese hamster ovary (CHO) 
origin.
Research into the decreased sensitivity within CHO compared with human cells, 
raised a number of questions. First, are BGIII21 specific DNA lesions produced within 
CHO cells? Does enhanced repair of BGIII21 lesions take place in CHO cells? What DNA 
repair pathways are involved and finally, what are the exact mechanisms of DNA damage 
recognition and repair?
A short introduction to the three principal DNA repair pathways examined in this 
chapter is given. Base excision repair (BER) was excluded from the investigation as BER is 
primarily concerned with the repair of endogenous DNA damage as a result of cellular 
metabolism (Hoeijmakers, 2001).
4.1.1 Nucleotide excision repair
Nucleotide excision repair (NER) is a versatile and highly conserved repair system capable 
of removing a wide range of helix-distorting DNA lesions, that interfere with base pairing 
and obstruct transcription and DNA replication. The majority of NER lesions are of 
exogenous origin and include the short-wave ultraviolet (UV) light-induced cyclobutane 
pyrimidine dimers, 6-4 photoproducts and bulky adducts. NER consists of two 
subpathways with overlapping substrate specificity. The general pathway termed global
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genome repair (GGR) removes lesions from the entire genome and the specialised pathway 
referred to as transcription-coupled repair (TCR) concentrates on damage blocking RNA 
polymerases. The study of syndromes associated with inborn defects in NER, namely 
Xeroderma pigmentosum (XP) and Cockayne syndrome (CS) revealed seven XP genetic 
complementation groups (XP-A to XP-G) representing different proteins in the NER 
pathway (Table 4.1). In addition, two CS genetic complementation groups (CS-A and CS-
B) exclusively associated with TCR were discovered (Hoeijmakers, 2001; Volker et al., 
2001) (Table 4.1).
NER repair proteins Function
XPA Binds damaged DNA; cooperates with 
replication protein A (RPA);
XPB 3’ to 5’ helicase
XPC Binds damaged DNA; cooperates with 
hHR23B; recruits other NER proteins
XPD 5’ to 3’ helicase
XPE ?
XPF Part of endonuclease (5’ incision)
XPG Endonuclease (3’ incision)
ERCC1 Part of endonuclease (5’ incision)
CS-A Transcription-coupled repair
CS-B Transcription-coupled repair
Table 4.1: Nucleotide excision repair (NER) proteins and their associated functions
during global genome repair (GGR) and transcription-coupled repair (TCR).
XPA to XPG (Xeroderma pigmentosum A-G); CS-A and B (Cockayne’s syndrome A and 
B)
NER is a multi-step process involving recognition of damaged DNA, opening up the 
surrounding DNA helix with helicases, followed by a dual incision and subsequent excision 
of the oligonucleotide containing the DNA lesion. A simplified view of the individual 
stages in mammalian global genome nucleotide excision repair is outlined in Figure 4.1.
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4.1.2 Homologous recombination repair
Homologous recombination repair and non-homologous end joining are the primary two 
mechanisms involved in the repair of double strand breaks (DSB) caused by ionising 
radiation or X-rays, free radicals, chemicals and during the replication of single strand 
breaks (SSB). Moreover DSBs arise naturally during meiosis and rearrangement of gene 
segments (VDJ joining) during immune cell development.
Homologous recombination repair predominantly occurs during S and G2 phase as 
this is a homology-driven mechanism requiring regions of identical DNA sequence. Non- 
homologous end joining having no requirement for regions of identical DNA sequence is 
active almost exclusively during G1 phase of the cell cycle. However, it has been suggested 
that a certain amount of overlap exist between the two mechanisms. A simplified view of 
the classic model of homologous recombination repair is depicted in Figure 4.2 
(Hoeijmakers, 2001).
4.1.3 Mismatch repair
Mismatch repair (MMR) removes nucleotides mispaired by DNA polymerases and 
insertion/deletion loops (>1-10 base pairs) that result from slippage during replication of 
repetitive sequences or during recombination.
The principal steps involved in MMR include mismatch recognition primarily 
carried out by the MSH2/MSH6 (detects base mismatches and single-base loops) and 
MSH2/MSH3 (recognises insertion/deletion loops) heterodimers and interaction of the 
hMLHl/hPMS2 and hMLHl/hPMSl heterodimeric complexes with the MSH complexes 
and replication factors as strand discrimination may be dependent on contact with the 
nearby replication machinery. A number of proteins are implicated in the excision of the 
new strand past the mismatch and re-synthesis steps including pol5/e, RPA, PCNA, 
reduced folate carrier (RFC), exonuclease 1, and endonuclease FEN1 (Hoeijmakers, 2001).
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Fig. 4.1: Simplified diagram of mammalian nucleotide excision 
repair (McHugh et al., 2001).
Fig 4.1: A simplified diagram of mammalian nucleotide excision 
repair (McHugh et al., 2001). DNA damage recognition (II) is the first 
step, and the exact identity of the damage recognition factor has been a 
matter of debate. The proposed candidates involved, are the XPC- 
hHR23B and XPA-RPA complexes and evidence for their involvement 
in mammalian NER is contradictory. Assembly of the NER complex 
requires the recruitment of the basal transcription factor EH (TFIIH) 
complex containing the helicases XPB and XPD necessary for 
unwinding ~30 base pairs of the DNA helix around the site of damage. 
The resulting open intermediate complex is stabilised by the single- 
stranded-binding protein RPA (IE). The endonucleases ERCC1-XPF 
and XPG make an incision at the 5’ and ‘3 end at either side of the 
DNA damage site (IV). Whereas ERCC1-XPF is dependent on XPA for 
its recruitment to the DNA damage and XPA has been implicated in 
assisting the anchoring of ERCC1-XPF in the incision complex, XPG 
recruitment is independent of XPA. However, incision by XPG appears 
to be dependent on activation by the XPA-RPA complex. Finally, the 
damage-containing oligonucleotide is released (V) and the DNA helix 
is restored by gap closure via DNA synthesis and ligation (VI) 
(Hoeijmakers, 2001; McHugh et al., 2001; Volker et al., 2001).
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Fig. 4.2: A simplified diagram of mammalian homologous 
recombination repair (Hoeijmakers, 2001; McHugh et al., 2001)
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Fig. 4.2: A simplified diagram of mammalian homologous 
recombination repair (Hoeijmakers, 2001; McHugh et al., 2001).
An initial DSB instigates strand exchanges between sister chromatids 
or homologues (A). First, the 5’-3’ exonuclease activity of the 
RAD50 complex exposes both 3’ ends in order to promote strand 
invasion into the homologous sequences (B). Meanwhile, RPA 
facilitates the assembly of a RAD51 nucleoprotein filament that 
possibly includes RAD51-related proteins XRCC2, XRCC3, 
RAD51B, C and D (C). Next, the exchange of the single strand with 
the same sequence from a double-stranded DNA molecule occurs 
whereby correct positioning of the sister chromatids by cohesions 
facilitates the identification of the homologous sequence (D). Finally, 
the open ends are closed by DNA synthesis (E) and the existing 
Holliday junction is resolved by resolvases (F) (Hoeijmakers, 2001; 
McHugh et al., 2001).
During the process of non-homologous end-joining, the ends of the 
existing DSB are simply joined together without any template, using 
the end-binding heterodimeric KU70/KU80 complex. Recruitment of 
DNA-PK stabilises the ends and facilitates ligation by the 
XRCC4/DNA ligase 4 complex. Non-homologous end-joining occurs 
primarily during G1 phase as cells are only provided with the 
homologous chromosome for recombination repair. However, this 
chromosome might be difficult to find in the complex genome and in 
addition there is a potential danger using it as a template for repair as 
it could lead to homozygosity of recessive mutations (Hoeijmakers, 
2001; McHugh et al., 2001).
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4.1.4 Chapter aims
The aims of the following experiments were:
• to investigate BGIII21 specific DNA lesions in CHO cells
• to analyse differential repair of BGIII21 specific DNA lesions in CHO cells if 
present
• to determine the repair pathway involved in the removal of BGIII21 specific lesions 
in CHO cells
• to elucidate the mechanism of BGIII21 specific DNA damage recognition and 
repair in CHO cells
4.2 Materials and Methods
4.2.1 Experimental cell lines
4.2.1.1 Chinese hamster ovary (CHO)
The Chinese hamster ovary cell line (CHO-AA8 ) purchased from Clontech, Basingstoke, 
UK was maintained in F-12 HAM medium supplemented with 10% FCS and 2mM 
glutamine. Confluent cultures were seeded at l-3xl0 4  cells/cm2  unless otherwise stated 
(ECACC).
4.2.1.2 NER deficient CHO cell lines
AA8  is the parental strain for all NER deficient cell lines. Both, parental and repair 
deficient cell lines were grown in F-12 HAM medium supplemented with 10% FCS and 
2mM glutamine. The parental plus all NER deficient cell lines are listed in Table 4.2.
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Name Defective gene
AA8 None (wild-type)
UV23 XPB
UV47 XPF
UV61 CSB
UV96 ERCC1
UV135 XPG
Table 4.2: NER deficient CHO cell lines used
4.2.1.3 Homologous recombination repair deficient CHO cell lines
V79, AA8  and CHO-K1 are the parental strains for the homologous recombination 
deficient cell lines irsl (XRCC2 deficient), irslSF (XRCC3 deficient) and xrs5 (XRCC5 
deficient) respectively. The parental and repair deficient cell lines were maintained in F I2- 
HAM medium supplemented with 10% FCS and 2mM glutamine.
4.2.1.4 Mismatch repair deficient CHO cell lines
The mismatch repair deficient CHO clone B cell line was supplied by Gabriele Aquilina, 
Istituto Superiore di Sanita, Section of Chemical Carcinogenesis, Rome, Italy. The clone B 
cells were isolated from CHO cells in 1988 by selection for tolerance to methylating agents 
(Aquilina et al., 1988). Clone B is defective in mismatch binding and exhibits a mutator 
phenotype and microsatellite instability (Aquilina et al., 1994; Aquilina et al., 2001). The 
mismatch defect is not characterised. The CHO clone B and parent cell line were 
maintained in FI 2-HAM supplemented with 10% FCS and 2mM glutamine.
4.2.1.5 Mismatch repair deficient human colon cancer cell lines
All colon cancer cell lines were maintained in FI 2-HAM supplemented with 10% FCS and 
2mM glutamine. They were obtained from the departmental cell culture stock. Cell lines 
include LoVo (Drewinko et al., 1976), HT29 (von Kleist et al., 1975), LS174T (Rutzky et 
a l, 1979) and HCT15 (Tibbetts et a l, 1977).
146
4.2.1.6 Mismatch repair deficient human prostate cancer cell lines
All prostate cancer cell lines were kindly provided by John Masters, Dept. Urology, UCL, 
UK. Cells were maintained in DMEM supplemented with 10% FCS and 2mM glutamine. 
Cell lines include LNCaP (Gibas et al., 1984), DU145 (Starring et al., 1982) and PC3 
(Kaighn et al., 1979).
4.3 Results
4.3.1 Resistance to BGIII21 in CHO -AA 8  cells
Following the results obtained in the previous chapter it was considered of importance to 
obtain a fully characterised CHO cell line to determine the basis of BGIII21 resistance in 
CHO cells as compared with human cells. Sulphorhodamine B (SRB) growth inhibition 
assays were performed to verify results previously obtained with respect to the novel minor 
groove binding alkylating agent BGIII21. As shown in Figure 4.3, the graph for CHO-AA8  
confirmed the previously observed statistically significant decrease in sensitivity to 
BGIII21 (IC5 0  > 50pM) compared to HT1080 Neo (p < 0.0001). HT1080 Neo (IC5 0  = 
0.68|liM) and ‘HT1080 E2F 1-1’ (CHO) (IC5 0  > 50pM) were used as reference cell lines in 
these experiments. The IC50s were determined from each graph representing 3 or more 
individual experiments.
4.3.2 BGIII21 DNA lesions produced in CHO-AA8  cells
DNA sequence alterations detected within the N-ras promoter region of CHO cells led to 
the selection of the sequenced hypoxanthine guanine phosphoribosyltransferase (HPRT) 
exon 9 region as a DNA region suitable to perform Sslig-PCRs on (Rossiter et al., 1991). 
The 336bp long HPRT exon 9 DNA sequence obtained after restriction cutting with Seal 
(NEB, Hitchin, UK) contains a single BGIII21 specific binding site (TTTTGA).
The experimental parameters were identical to the Sslig protocol used for the 
analysis of the N-ras promoter region. Cells were incubated with increasing concentrations 
of BGIII21 for 5 hours, harvested and processed as described in section (2.2.10).
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Fig. 4.3: Inhibition of proliferation by BGIII21 on CHO-AA8 , 
HT1080 Neo and ‘E2F 1-1’ cells as measured by Sulphorhodamine 
B growth inhibition assay. Drug exposure was continuous (72 hrs) 
and graphs represent combined data of 3 or more experiments. 
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In the CH0-AA8 cells BGIII21 specific DNA lesions were produced in two sites within the 
chosen HPRT DNA sequence at 50pM BGIII21 (Fig. 4.4). The lower band marked the 
TTTTGA BGIII21 specific binding site present within the HPRT sequence. The upper 
BGIII21 specific DNA lesion represented a binding site within an A-T rich region of DNA 
previously not recognised as a BGIII21 specific binding site. Both bands representing 
BGIII21 lesions were reproduced throughout a number of experimental repeats.
For comparison, a representative Sslig experiment showing BGIII21 specific DNA 
lesions within HT1080 Neo cells was included in Figure 4.4. An increase in intensity of the 
BGIII21 specific lesions with increasing drug concentrations in HT1080 Neo cells was 
observed. In contrast, no BGIII21 specific lesions were produced at IOjxM BGIII21 in 
CHO-AA8  cells. Bands representing BGIII21 lesions were present at 50pM BGIII21. 
BGIII21 uptake was suggested to be inhibited in CHO-AA8  cells up to a threshold 
concentration placed between 10 and 50pM BGIII21. Once the threshold concentration was 
reached BGIII21 entered the CHO-AA8  cells resulting in two bands representing the 
BGIII21 specific DNA lesions.
4.3.3 No repair of BGIII21 specific DNA lesions in HT1080 Neo or CHO-AA8
Previously two observations regarding the HT1080 Neo and CHO-AA8  cell lines were 
made. First, CHO-AA8  alone exhibited resistance to BGIII21 and second, BGIII21 specific 
DNA lesions were produced in both, the HT1080 Neo and CHO-AA8  cell lines. In order to 
determine the underlying causes for the differences in cell growth inhibition of BGIII21 in 
both cell lines, Sslig-PCRs were performed to examine the repair of BGIII21 induced DNA 
damage. HT1080 Neo and CHO-AA8  cells were incubated with 50pM BGIII21 for 5 hours 
and samples were taken immediately before and after drug exposure. Following drug 
removal, samples were collected at 24 hrs, 48 hrs and 72hrs post drug exposure. The post 
drug exposure time-points provided a scale on which to observe either the lack of DNA 
repair i.e. lesions persist at 72hrs, or to observe DNA repair i.e. lesions are expected to have 
decreased in intensity or disappeared within 72 hours. The drug concentration of 50|liM 
BGHI21 was selected to provide a comparison between the two cell lines. 50pM BGIII21 
were expected to generate a clearly detectable amount of DNA damage in HT1080 Neo and
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Fig. 4.4: BGIII21 specific DNA lesions (— ► ) produced within 
HT1080 Neo and CHO-AA8  cells as measured by Sslig-PCR.
Cells were incubated with BGIII21 for 5 hours. Correct size of BGIII21 
lesions was verified with radio-labelled lObp DNA ladder run alongside 
samples. FL (full length PCR product)
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CH0-AA8 cells and the 72 hours duration for DNA repair was considered sufficient for 
any DNA repair to become visible as a reduction in band intensity.
As shown in Figure 4.5 and 4.6, no DNA repair of BGIII21 lesions was observed 
throughout the post exposure time-span in both HT1080 Neo and CHO-AA8  cells. The 
BGIII21 specific DNA lesions remained clearly visible at 72 hours post drug exposure. The 
intensity of the bands representing the BGIII21 specific DNA lesions did not alter 
throughout the post drug exposure time-course.
Although no DNA repair was observed in either of the two cell lines, a complete 
lack of DNA repair in CHO-AA8  cells seemed unlikely. As established previously CHO 
(‘HT1080 E2F 1-1’) cells continued to proliferate even after exposure to 50pM BGIII21 
albeit with an altered cell cycle profile (section 3.3.8). Also, as proven by Sslig-PCR, 50|liM 
BGIII21 caused BGIII21 specific DNA lesions in CHO-AA8  cells. It appears that CHO- 
AA8  cells continue proliferating after having sustained a significant amount of DNA 
damage. A more detailed analysis of DNA repair occurring was proposed, as DNA repair is 
considered essential to maintain genomic integrity for cell survival. The failure to detect 
any amount of DNA repair using the Sslig method might be attributed to the initial high 
concentration of BGIII21 required to giving rise to detectable DNA damage.
4.3.4 NER and repair of BGIII21 specific DNA damage
To analyse any repair of BGIII21 specific lesions in CHO-AA8  cells, it was necessary to 
investigate the involvement of a variety of specific DNA repair mechanisms in the repair of 
the BGIII21 specific lesions. To explore the involvement of nucleotide excision repair 
(NER) in the removal of BGIII21 specific DNA damage, a parental and 5 NER deficient 
CHO cell lines (section 4.2.1.2) were exposed to increasing concentrations of BGIII21 in a 
continuous SRB growth inhibition assay.
None of the NER deficient cell lines were significantly more sensitive to BGIII21 in 
comparison to each other and the parental cell line (p = 0.1510) (Fig 4.7). Although values 
for the percentage of cell proliferation for respective BGIII21 concentrations in five cell 
lines were similar up to lOpM BG13I21, the CSB deficient cell line appeared more resistant 
(IC7 5  = lOpM) than the parental AA8  cell line (IC7 5  = 5.9pM) suggesting loss of 
transcription coupled repair to increase resistance to BGIII21. However, any divergence of 
graphs was not reflected in the result of the subsequent statistical analyses (Fig. 4.7).
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Fig. 4.5: No repair of BGIII21 specific DNA lesions ( ---- ► ) in
HT 1080 Neo cells as measured by Sslig-PCR. Cells were treated 
with 50 piM BGIII21 for 5 hours prior to repair time-course. Correct 
size of DNA lesion was verified with radio-labelled lObp size marker 
run alongside samples. FL (full length PCR product)
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Fig. 4.6: No repair of BGIII21 specific DNA lesions ( <4----  ) in
CHO-AA8  cells as measured by Sslig-PCR. Cells were treated with 
50/*M BGIII21 for 5 hours prior to repair time-course. Correct size 
of BGIII21 lesion was verified with radio-labelled lObp size marker. 
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Fig. 4.7: Inhibition of proliferation by BGIII21 on NER deficient 
CHO cell lines after continuous exposure (72 hours) to BGIII21 as measured 
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In conclusion, no significant difference in sensitivity was observed with respect to BGIII21 
when comparing various NER deficient cell lines to the parental AA8  cell line using 
multiple regression analysis. Therefore BGIII21 specific DNA lesions do not appear to be 
repaired by NER.
4.3.5 Homologous recombination repair and BGIII21 specific DNA damage
The investigation was extended to include homologous recombination repair deficient CHO 
cell lines. Homologous recombination repair deficient cell lines were selected including 
irsl and irslSF, deficient in the RAD51-like XRCC2 and XRCC3 protein respectively. In 
addition, xrs5 deficient in XRCC5, a protein involved in non-homologous end-joining, was 
chosen. SRB growth inhibition assays were performed as before and the mean IC5 0  values 
determined from three or more separate experiments. Results for all three homologous 
recombination repair deficient cell lines in comparison to each respective parental cell line 
exhibited no significant difference in sensitivity in response to BGIII21 (Fig. 4.8). The 
XRCC2 deficient cells were no more sensitive (IC50 = 13pM) than the V79 parental cell 
line (IC50= 13.8pM). Similarly, the IC5 0  for the XRCC3 deficient cell line (IC50 = 65pM) 
was insignificantly lower than the IC5 0  (= 70pM) for the parental cell line AA8 . Finally, the 
XRCC5 deficient cell line (IC5 0  = 35pM) appeared to be marginally more sensitive to 
BGIII21 than the CHO-K1 parental cell line (IC5 0  = 49jxM). The above results were further 
substantiated by statistical analysis using multiple regression analysis (section 2.2.3.3). No 
significant difference in chemosensitivity to BGIII21 was found between V79 vs. irsl (p = 
0.1723), AA8  vs. irslSF (p = 0.9180 and CHO-K1 vs. xrs5 (p = 0.0052) respectively. In 
conclusion, neither NER nor homologous recombination repair was involved in the repair 
of BGIII21 specific lesions in CHO cells as illustrated by the above results.
Following the above results sets of human mismatch repair deficient colon and prostate 
cancer cells were selected to investigate the involvement of MMR in the removal of 
BGIII21 lesions. The selection of the colon and prostate cancer cell lines, in part, resulted 
from the temporary lack of availability of MMR-deficient CHO cell lines. Although 
differences in protein expression due to species- and tissue-specificity were taken into 
account, investigation into the involvement of MMR in the repair of BGIII21 lesions using 
these cell lines was considered a valuable indicator of the mechanisms underlying repair.
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Fig. 4.8: Inhibition of proliferation by BGIII21 on homologous 
recombination deficient CHO cells following continuous exposure 
(72hours) to BGIII21 as measured by SRB growth inhibition assay. 
Mean IC^ values were determined from the combined data of 3 or 
more separate experiments.
156
4.3.6 Mismatch repair implicated in resistance to BGIII21 in human colon cancer
A number of genetic alterations have been described in colorectal cancers including allelic 
losses on specific chromosomal arms, mutations of oncogenes, tumour suppressor genes 
and mismatch repair genes, microsatellite instability in coding repeat sequences of target 
genes and methylation defects in gene promoters. Hence, a great genetic heterogeneity 
occurs within hereditary non-polyposis (HNPCC) and sporadic colorectal carcinomas that 
is reflected in a comprehensive study performed by Gayet et al., characterising a series of 
human colorectal cancer cell lines for genetic alterations (Gayet et al., 2001). On the basis 
of the above study, colon cancer cell lines were selected for further experiments in order to 
analyse the involvement of mismatch repair (MMR) as a mechanism responsible for the 
repair of BGIII21 specific damage. These included LoVo, LS174T, HCT15 and HT29 
containing a range of differences in mismatch repair protein deficiency or complete 
mismatch repair proficiency. The mismatch repair deficiency characteristics of each cell 
line are illustrated in Table 4.3.
hMSH2 hMSH3 hMSH6 hMLHl hPMSl hPMS2
LoVo - + + + N/A +
LS174T + - - - + +
HCT15 + + - + + +
HT29 + + + + + +
Table 4.3: Mismatch repair protein deficiencies in a variety of human colon cancer 
cell lines according to Gayet et al., 2001. + (proficient); - (deficient); N/A (not analysed)
Continuous SRB growth inhibition assays including all four human colon cancer cell lines 
were performed as described previously (section 2.2.3.1). These provided a drug response 
profile showing LoVo (IC5 0  = 79pM) and HCT15 (IC5 0  = 42pM) cell lines to be more 
resistant to BGIII21 than the LS174T (IC5 0  = 7pM) and HT29 (IC5 0  = 8.2pM) cell lines 
(Fig. 4.9). As before, mean IC5 0  values were determined from 3 or more separate 
experiments. Statistical analysis including a global multivariate model revealed significant 
differences in chemosensitivity to BGIII21 between HCT15 and LoVo on one hand 
compared to LS174T and HT29 on the other hand. Differences in chemosensitivity between
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Fig. 4.9: Inhibition of proliferation by BGIII21 on MMR deficient 
human colon cancer cell lines as measured by SRB growth inhibition 
assay. Cell were incubated with increasing concentrations of BGIII21 for 
72 hours. Mean IC^ values were determined from the combined data of 
3 or more separate experiments.
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HCT15 and LoVo as well as LS174T and HT29 were non-significant. The difference in 
sensitivity between the two sets of cell lines appeared to be independent of deficiency in 
any specific mismatch repair protein. However, O’Regan et al. stated in a study 
investigating the DNA mismatch recognition by human proteins that LoVo and 
DLD1/HCT15 cells are defective in G»T mismatch binding while LS174T cells are G«T 
mismatch binding proficient. All three human colon cancer cell lines appeared proficient in 
A#C mismatch binding (O’Regan et al., 1996). Hence it might be possible to explain 
differences in BGIII21 chemosensitivity in human colon cancer cell lines with the loss of 
G#T mismatch binding proficiency.
4.3.7. Mismatch repair implicated in resistance to BGIII21 in human prostate cancer
In addition to the analysis of MMR deficient human colon cancer cell lines to establish a 
relationship between mismatch repair protein deficiency and resistance to the novel minor 
groove binding alkylating agent BGIII21, MMR deficient human prostate cancer cell lines 
were selected for further SRB growth inhibition assays. The range of prostate cancer cell 
lines chosen included LNCaP, PC3 and DU145. Cell line specific mismatch repair protein 
deficiencies are described in Table 4.4 and are based on studies by Chen et al. and Leach 
et al. The prostate cancer cell lines were characterised in view of the presence or absence of 
specific MMR proteins as determined by Western blot analysis. All three characterised cell 
lines exhibited microsatellite instability as determined by the pCAR-IF/OF P-galactosidase 
assay (Chen et al., 2001).
hMSH2 hMSH3 hMSH6 hMLHl hPMSl hPMS2
LNCaP - + + + + +
PC3 + - + + + +
DU145 + + + - - -
Table 4.4: Presence (+) or absence (-) of mismatch repair proteins in human prostate 
cancer cell lines as determined by Western blot analysis (Chen et al., 2001; Leach et al., 
2000).
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In Figure 4.10 continuous SRB growth inhibition assays performed as described (section
2.2.3.1) showed LNCaP (IC5 0  = 7.4pM) and PC3 (IC5 0  = 7.4pM) cells to exhibit a higher 
resistance to BGIII21 compared to observed sensitivity to BGIII21 in DU145 cells (IC5 0  = 
1.3pM). The mean IC5 0  values were calculated from 3 or more separate experiments. The 
statement above was further validated by statistical analysis using a global multivariate 
model that showed significant differences between DU145 and LNCaP as well as DU145 
and PC3 but no significant differences in chemosensitivity between LNCaP and PC3 
(section 2.2.3.3).
Following the above completion of the experimental series shown above, an MMR- 
deficient CHO cell line became available and was subsequently included in the 
investigation. Analysis of the involvement of MMR in the removal of BGIII21 lesions 
within the CHO genetic background was suggested to provide a more accurate insight into 
the potential involvement repair mechanisms that result in the resistance effect observed in 
response to BGHI21 in CHO cells.
4.3.8 No increased resistance to BGIII21 in MMR deficient CHO Clone B cells
In addition to the investigations into the relationship between resistance to BGIII21 and 
MMR deficiency in colon and prostate cancer cell lines, experiments were performed using 
an MMR deficient CHO cell line. The MMR deficiency in the CHO Clone B cell line has 
not been characterised. Studies with BGIII21 were carried out as the resistance effect to 
BGIII21 had been previously observed in a CHO-AA8  cell line. SRB growth inhibition 
assays were performed and the mean IC5 0  calculated from 3 repeat experiments. In addition 
to BGIII21, cisplatin was included in the study as a second investigative drug as MMR 
deficient cells have been reported to display resistance to cisplatin (Fink et al., 1998). An 
increase in sensitivity to BGIII21 was observed in the MMR deficient CHO Clone B cells 
(IC5 0  = 9pM) compared to the parental CHO cells (IC5 0  = 17pM). A minimal decrease in 
sensitivity to cisplatin was observed in the MMR CHO Clone B cells (IC5 0  = 2.3pM) 
compared to the CHO parent strain (IC5 0  = 1.9pM) (Fig. 4.11). However, statistical analysis 
revealed neither differences in chemosensitivity between Clone B and parental cells to be 
significant at p <0.0001 (p = 0.3111 for BGIII21; p = 0.8480).
160
120
c
■2 100
CL 60 -
40 -
20 -
1 10 1000.001 0.01 0.10
BGIII21 (|jM)
LNCaP ic507.4|jM
PC3 ic507.4(jM
DU145 IC50 1.3|jM
Fig. 4.10: Inhibition of proliferation by BGIII21 on MMR deficient 
human prostate cancer cell lines as measured by SRB growth inhibition 
assay. Cells were incubated with increasing concentrations of BGIII21 for 
72 hours. Mean IC^ values were determined from the combined data of 3 or 
more separate experiments.
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Fig. 4.11: Inhibition of proliferation in MMR deficient CHO clone B cells 
following continuous exposure (72hours) to BGIII21 and Cisplatin as
measured by SRB growth inhibition assay. Mean IC50 values were 
determined from the combined data of 3 or more separate experiments.
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4.5 Discussion
4.5.1 Resistance to BGIII21 and drug uptake
In this chapter resistance to BGIII21 previously observed in CHO cells as compared with 
human cells was confirmed. In an SRB growth inhibition assay the newly obtained CHO- 
AA8  cell line proved to be more than 70fold more resistant to the novel minor groove 
binding alkylating agent BGIII21 than the HT1080 Neo cell line.
To investigate the underlying mechanism of BGIII21 resistance in CHO-AA8  cells 
a number of Sslig-PCR analyses were performed on the HPRT exon 9 region. Results 
showed two BGIII21 specific DNA binding sites at 50pM BGIII21. The DNA sequence of 
one binding site (TTTTGA) had been described previously by Wyatt et al. The second 
binding site was found in an A-T rich region within the 336bp DNA fragment obtained 
after restriction digest with Seal. No BGIII21 specific lesions were produced at lOpM 
BGIII21. In contrast, in HT1080 Neo cells BGIII21 specific lesions of increasing intensity 
occurred at 5pM and 50pM BGIII21, respectively. The discrepancy in the production of 
DNA damage between both cell lines suggested an underlying difference in drug uptake. 
While BGIII21 readily entered HT1080 Neo cells within the concentration range, a drug 
concentration threshold appeared to prevent BGIII21 from entering CHO-AA8  cells at 
lOpM BGIII21. Therefore, the suggested concentration threshold lay between 10pM and 
50pM as BGIII21 specific lesion formation showed BGIII21 drug uptake in CHO-AA8  
unaffected at 50pM. To confirm the above observation of a differential drug uptake in 
HT1080 Neo and CHO-AA8  cells, experiments using radioactively labelled BGIII21 would 
need to be performed. Unfortunately at this point such as radioactively labelled substrate is 
not available.
4.5.2 NER and homologous recombination repair of BGIII21 specific DNA lesions
The investigation into the underlying mechanism involved in resistance to BGIII21 in CHO 
cells showed in a number of Sslig-PCRs, that BGIII21 lesions were not repaired in either 
HT1080 Neo or CHO-AA8  cells. This result challenged the hypothesis that CHO-AA8  
cells were resistant to BGIII21 due to a more efficient repair of BGIII21 induced DNA 
damage compared to HT1080 Neo cells. BGIII21 induced DNA damage was not repaired 
in HT1080 Neo cells that subsequently underwent apoptosis as observed before (section
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3.3.9). In contrast, persistence of BGIII21 induced DNA damage was tolerated in CHO- 
AA8  cells and cellular viability was maintained. This would lead to continual acquisition of 
irreparable DNA damage leading to mutagenesis and long-term loss of genomic integrity. 
Therefore, considering the high dose of BGIII21 required the production of DNA lesions it 
was suggested that low levels of DNA repair activity might not have been detectable.
Nucleotide excision and homologous recombination repair deficient CHO cell lines 
were selected to examine the potential involvement of these repair pathways in the removal 
of BGIII21 specific DNA damage. NER deficient cell lines plus the parental strain were 
exposed to increasing concentrations of BGIII21. Analysis of the cell growth inhibition 
profiles revealed none of the NER deficient cell lines to be more resistant to BGIII21 than 
the parental cell line. To conclude NER repair was not involved in the repair of BGIII21 
specific DNA lesions.
Further, three homologous recombination repair deficient CHO cell lines and 
respective parental strains were treated with increasing concentrations of BGIII21. Neither 
XRCC2, XRCC3 nor XRCC5 deficient cell lines were more sensitive to BGIII21 when 
compared to the respective parental strain. Therefore it was concluded that homologous 
recombination repair did not participate in the removal BGIII21 specific DNA damage.
4.5.3 Mismatch repair of BGIII21 specific DNA lesions
Defective mismatch repair is associated with hereditary non-polyposis colon cancer 
(HNPCC) and many sporadic cancers including endometrial, small and non-small cell lung 
cancer, pancreatic, gastric, ovarian, cervix and breast cancer (Fink et al., 1998). In addition, 
loss of mismatch repair has been observed in prostate cancer (Chen et al., 2001). Loss of 
MMR results in drug resistance directly by impairing the ability of the cell to detect DNA 
damage and activate apoptosis and indirectly by increasing the mutation rate throughout the 
genome (Fink et al., 1998).
Within eukaryotes post-replicative MMR in connection with DNA polymerase 
proof-reading maintains the fidelity of the genome. Any remaining errors following proof­
reading and editing are also corrected by MMR (Aquilina et al., 2001). MMR function is 
carried out by MutSa (hMSH2:hMSH6), MutSP (hMSH2:hMSH3) and MutLcx (hMLHl: 
hPMS2) complexes. The MutSa and MutSp complexes partake in the recognition of 
replication errors, whereby MutSa preferentially recognises single mismatches and loops of
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1 base and MutSP binds insertion and deletion loops (IDL) of 2 to 8  bases. Some functional 
overlap between the complexes exists with respect to the recognition of 1 base IDLs 
(Aquilina et al., 2001). Upon initial recognition of the mismatch or IDL by MutSa and 
MutSP, MutLa associates with either recognition complex. This association is suggested to 
increase the efficiency of MutS binding to mismatched DNA (Aquilina et al., 2001).
As MMR deficient CHO cell lines were not available to investigate the effects of 
MMR deficiency on growth inhibition in response to BGIII21 treatment initially, a variety 
of MMR deficient human colon and prostate cancer cell lines were selected for a 
preliminary investigative screening. Characterisation of MMR deficiency in each cell line, 
based on published data, is supplied in Table 4.3 and 4,4. Collectively, the chosen cell lines 
cover the range of MMR deficiencies characterised.
SRB growth inhibition assays revealed the two colon cancer cell lines LoVo and 
HCT15 to be more resistant to BGIII21 in comparison to LS174T and the MMR proficient 
HT29 colon cancer cell lines. A lOfold increase in resistance was observed in LoVo, and 
HCT15 cells were 5-6 times more resistant compared to LS174T and HT29. Analysis of 
three MMR deficient prostate cancer cell lines showed LNCaP and PC3 to be 7 times more 
resistant to BGIII21 than DU145. A comparison of BGIII21 resistance and MMR protein 
deficiency was carried out, taking account of tissue related drug sensitivity and a pattern 
with respect to BGIII21 resistance emerged (Table 4.5). Both hMSH2 deficient as well as 
hMSH6 or hMSH3 deficient cell lines were more resistant to BGIII21 than either hMLHl 
deficient cell lines. Note was taken that LS174T cells were also deficient in hMSH6  and 
hMSH3. Finally, the MMR proficient HT29 colon cancer cell line was sensitive to BGIII21. 
In conclusion, MMR deficiency plays a critical role in the resistance to BGIII21 observed 
in human colon and prostate cancer cells. It appears that hMSH2 and hMSH6 or hMSH3 
deficiency predisposes to BGIII21 resistance while hMLHl deficiency promotes cellular 
sensitivity to BG13I21.
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Name MMR status IC5 0  value Resistant/Sensitive
LoVo (CC) hMSH2 79|xM R
LNCaP (PC) deficient 7.4|iM R
HCT15 (CC) hMSH6  or hMSH3 42pM R
PC3 (PC) deficient 7.4pM R
LS174T (CC) hMLHl 7pM S
DU145 (PC) deficient 1.3pM S
HT29 (CC) proficient 8.2pM S
Table 4.5: Comparison of MMR status with resistance (R) or sensitivity (S) observed 
in colon cancer (CC) and prostate cancer (PC) cell lines.
In previous studies MMR-deficient cells have been shown to be more resistant to the 
cytotoxic effect of alkylating agents such as the monofunctional methylating agents N- 
methyl-N’-nitro-N-nitrosoguanidine (MNNG) and N-methyl-N-nitrosourea (MNU), bulky 
chemicals such as cisplatin and ionising radiation (Jiricny, 1998; Karran, 2001). In, addition 
Colella et al. reported a 2-3fold increase in resistance of MMR deficient HCT-116 colon 
cancer cells to a number of minor groove binding alkylating agents including tallimustine, 
carzelesin and CC-1065 (Colella et al., 1999).
In view of the results obtained for colon and prostate cancer cell lines in this study, it was 
suggested that lack of hMSH2 and hMSH6 or hMSH3 deficiency cause cells not to 
recognise BGIII21 induced damage hence lead to alkylation tolerance. It appears that 
hMSH2 alone is not able to convey an apoptotic signal to initiate programmed cell death 
but is dependent on the presence of hMSH6 or hMSH3. However, this theory appears 
incorrect with respect to LS174T cells, as these are hMSH6 and hMSH3 deficient and 
would therefore be expected to exhibit alkylation tolerance. Nevertheless, the additional 
absence of hMLHl may reverse any potential for alkylation tolerance and instead sensitises 
LS174T cells to BGIII21 treatment. This reversal theory is supported by the BGIII21 
sensitivity observed in hMLHl deficient DU145 prostate cancer cells. Further research into 
the relationships between individual mismatch repair complexes and their recognition and
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apoptosis function to initiate programmed cell death following BGIII21 specific DNA 
damage in human colon and prostate cancer cell lines is required.
Following the preliminary screening of human colon and prostate cancer cell lines to 
investigate the effects of DNA repair deficiencies on altering the chemosensitive response, 
MMR-deficient CHO Clone B cells were obtained. Although experiments performed using 
the human colon and prostate cancer cell lines resulted in a number of observations that 
could be potentially useful in unravelling the mechanism underlying the decreased 
sensitivity seen in CHO cells following treatment with BGIII21, any further investigation 
required an MMR-deficient CHO cell line to eliminate species and tissue-related 
differential gene expression.
A series of growth inhibition experiments showed the Clone B cells to be twice as 
sensitive to BGIII21 than the parental CHO cell line. In addition, the parental CHO cell line 
exhibited a more than 2fold increase in sensitivity to BGIII21 compared to the CHO-AA8  
cell line used in previous experiments. This result highlights the fact that even when using 
cell lines of the same identity, differences in response to drug treatment may occur. 
Possible explanation for any observed variations in sensitivity to treatment with the same 
drug, may be prior differences in growth media and supplements used as well as differences 
in passage number. Further, depending on the longevity of growth of the cell line, 
additional genotypic alterations may have occurred within resulting subclones of the same 
cell line that result in an altered chemosensitivity within those subclones in response to 
drug exposure. However, in contrast to results obtained for BGIII21, the parental and MMR 
deficient cell line in response to cisplatin showed a similar degree of sensitivity.
As mentioned previously the MMR protein deficiency in CHO Clone B cells has 
not been characterised. However, attempts by Aquilina et al. to complement hMSH2 
deficient LoVo cell extracts with CHO Clone B extracts in order to restore MMR failed, 
indicating that these cell lines share a common defect -  hMSH2 deficiency. Further, CHO 
Clone B cells were shown to be resistant to DNA methylation damage as a consequence of 
containing a defective GvT mismatch binding protein (Aquilina et al., 1994).
To conclude, indications exist for CHO Clone B cells to be hMSH2 deficient and 
CHO Clone B cells have been proven to be defective in G#T mismatch binding. Therefore 
CHO Clone B cells, in view of previous observations made in human colon and prostate
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cancer cells would be expected to be more resistant to BGIII21 than the parental CHO cells. 
Instead, CHO Clone B cells display an increased sensitivity to BGIH21.
Studies by Mello et al. have shown that hMSH2 recognises and specifically binds 
DNA, containing cisplatin adducts in vitro (Mello et al., 1996). Two mechanisms for the 
involvement of MMR in the modulation of chemosensitivity to cisplatin exist. First, 
recognition and binding of ciplatin-modified bases by KMSH2, followed by the recruitment 
of additional MMR proteins would result in misdirected repair attempts at the sites of 
cisplatin damage. Futile rounds of MMR lead to an accumulation of double strand breaks 
resulting in signal for apoptosis (Mello et al., 1996).
Secondly it has been proposed that the elevated levels of hMSH2 found particular in 
ovarian and testicular tissue aid to shield cisplatin adducts from nucleotide excision repair 
(Mello et al., 1996). Therefore an hMSH2 deficiency in CHO Clone B cell would either be 
expected to result in tolerance of cisplatin adducts due to lack of recognition and repair or 
an increased sensitivity to cisplatin following the loss of the protective mechanism.
To draw any comparisons between results seen within the human colon and prostate 
cancer cell lines and MMR-deficient CHO cells, MMR proficiency would need to be 
restored within the MMR-deficient human colon and prostate cells in order to investigate 
any alterations in chemosensitivity in response to BGIII21. In addition, the relative levels 
of MMR protein expression would need to be analysed to eliminate the possibility of 
differential protein expression having an effect on chemosensitivity in response to BGIII21. 
However, species- and tissue-related differences in gene expression continue to persist and 
need to be taken into account. Hence, results obtained from the preliminary screening of the 
human colon and prostate cancer cells should rather be taken as an suggestion into potential 
repair mechanisms involved and provide an indication for further research required to be 
carried out in CHO cell lines. Further investigations into the involvement of MMR in the 
removal of BGIII21 lesions require the full characterisation of MMR-deficiencies in the 
CHO Clone B cell line as well as establishing CHO cell lines covering a range of MMR 
protein deficiencies.
In conclusion, it was found that BGIII21 specific DNA damage was produced within 
HT1080 Neo and CHO-AA8  cell lines and was not repaired by NER or homologous 
recombination repair pathways. Results indicate that MMR, in particular the MutSa and
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MutSP complexes, is involved in the removal of BGIII21 specific DNA damage in human 
prostate and colon cancer cell lines. However, the above results could not be verified within 
the CHO cell line.
Finally, a proposed model for the mechanism involved in the repair of DNA damage 
produced by alkylating agents suggests the persisting DNA lesions to initiate futile rounds 
of mismatch repair where the DNA polymerase attempts to match the alkylation site with a 
complementary nucleotide resulting in an imperfect base pair. The MutSa complex of the 
mismatch repair machinery detects the mismatch followed by the DNA polymerase failing 
to complement the alkylation site once more. Repair is re-initiated resulting in futile rounds 
of replication and repair. It has been suggested that these rounds of ‘futile repair’ result in a 
signal to the apoptotic machinery to initiate programmed cell death in a p53-independent 
manner (Hickman et al., 1999; Jiricny, 1998).
In contrast, a second model proposes the alkylation site in the template strand to 
bring about chain termination and dissociation of the DNA polymerase followed by 
continuation of DNA synthesis behind the damage. The resulting single strand gap opposite 
the alkylation site causes a double strand break during the following cycle of DNA 
replication (Jiricny, 1998). In MMR deficient cells absence of DNA damage recognition 
and repair results in the persistence of alkylated base damage causing alkylation tolerance.
The mismatch repair complex involved in mismatch recognition and apoptotic 
signalling pathway, with respect to the methylating agent MNNG appear to be the MutSa 
(Hickman et al., 1999). However, cisplatin-induced growth inhibition in HCT-116 cells was 
found to be dependent on MutSa or MutSp in combination with functional MutLa (Aebi et 
a l , 1997).
In addition, exogenous damage is usually removed more rapidly from the 
transcribed strands than from non-transcribed strands of active genes. MMR proteins in 
connection with NER proteins have been found to participate in the removal of DNA 
damage from the transcribed strand (Peltomaeki, 2001). This combination repair system 
might explain the suggested involvement of transcription-coupled repair in the removal of 
BGIII21 adducts from transcribed strands.
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5. E2F-1 INHIBITION AND CHEMOSENSITIVITY
5.1 Introduction
5.1.1 Peptides as therapeutic agents
There has been sustained interest in the development and application of synthetic or organic 
peptides able to interfere with protein components of important biological pathways. These 
peptides have the potential to inhibit the biochemical activities of a target protein, are able 
to delineate the target protein interactions within a biological pathway and present a novel 
approach for the discovery of potential therapeutic targets. New therapeutic approaches 
include the application of peptides as a treatment for infectious diseases, immune system 
disorders, cardiovascular disease, neurological disorders and cancer (Lauta, 2000).
The majority of synthetic peptides are produced via solid phase synthesis (up to 50 
residues) or recombinant DNA technology (more than 50 residues). In order to achieve 
optimum levels of peptide activity for therapeutic applications structural modifications are 
carried out including formulation, glycosylation and disulphide bond formation. The post­
synthetic assessment of the chemical and physical properties of the peptide includes the 
structural analysis, solubility, dimensions, antigenicity and immunogenic properties to 
ensure effective biological activity. Size and structure of a peptide influences stability and 
degradation of the peptide. For example, small linear peptides with no structural 
modifications are rapidly degraded having a half-life of 2-5 minutes. In contrast, larger 
modified peptides are more stable with a half-life of 1-2 hours (Lauta, 2000).
Initial selection of peptides with specific inhibitory functions may be accomplished 
with the use of a counter-selectable yeast two-hybrid system called ‘reverse two-hybrid 
system’. This system is based upon the interaction of two known binding partners whereby 
binding results in the activation of a negative selectable marker. Negative selection is 
avoided through the inhibitory action of a third component. This system provides 
information about the interaction between two known binding partners and helps to identify 
molecules able to disrupt a given protein-protein interaction (Hoppe-Seyler et al, 2001).
In contrast, the peptide aptamer system allows selection of peptides on the basis of 
their ability to bind to a given target protein. The selected peptides are further evaluated for
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their inhibitory effect on the activity and binding of the target protein to its interaction 
partner. For the selection of inhibitory aptamers neither the structure of the target protein 
nor the identity of the binding partner are required (Hoppe-Seyler et al., 2001). The peptide 
aptamer system has been proven successful in the elucidation of novel components within 
regulatory pathways and functional studies of known regulatory proteins in vitro and in 
vivo.
As an example, Cohen et al. isolated a peptide that bound CDK2 and inhibited its 
associated kinase. Inhibition of CDK2 was competitive and prevented progression through 
G1 phase of the cell cycle by interrupting the activity of CDK2 on substrates required for 
Gl-S phase progression (Cohen et al., 1998).
Another study showed the expression of two peptides to cause substrate specific 
inhibition of essential cyclin-dependent kinases DmCDKl and DmCDK2 in Drosophila 
melanogaster. Simultaneous inhibition of DmCDKl and DmCDK2 during eye 
morphogenesis resulted in a ‘rough’ eye phenotype due to disruption of normal eye 
development as a result of cell cycle inhibition. Subsequent overexpression of both cyclin- 
dependent kinases alleviated the inhibitory function of the peptides as observed by the 
development of wild-type eyes (Kolonin et al., 1998).
5.1.2 E2F inhibition by peptides
Peptides were generated to inhibit E2F, a transcription factor controlling the transition from 
G1 to S phase of the cell cycle. The inhibitory peptides were isolated using a yeast two- 
hybrid assay. Two selected peptides (Apt4 and Apt5) were shown to inhibit E2F/DP1 
heterodimerisation in vitro and blocked cell cycle progression of synchronised primary 
human fibroblasts from G1 to S phase in vivo. A third modified peptide (Pept5) inhibited 
E2F/DP1 heterodimerisation with an increased efficiency. Further, Pept5 abolished the 
formation E2F-pocket protein complexes as detected by EMSA analysis, reduced 
transactivation of an E2F-responsive promoter and prevented human fibroblasts 
microinjected with Pept5 from re-entering S phase. Mutation analysis suggested that E2F 
inhibitory peptides compete with DPI by binding to E2F within the region of the DPI 
heterodimersation domain therefore preventing the formation of transcriptionally active 
E2F/DP heterodimers (Fabbrizio et al., 1999).
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In an earlier study, Bandara et al. isolated E2F-1 inhibitory peptides H and H2 which 
inhibited the DNA binding activity of E2F-1 in F9 embryonal carcinoma cell extracts. DNA 
binding analysis of an H2 peptide containing two mutated residues within the DEF box 
domain suggested the DEF domain to be necessary for effective heterodimerisation of E2F- 
1 and DP-1. Cells treated with penetratin tagged H2 exhibited a change in cellular 
morphology indicative of programmed cell death while treatment with tagged peptides 
mutated within the DEF domain or containing a scrambled sequence of residues resulted in 
a lack of apoptosis. Finally, to assess the transcriptional activity of the cyclin A promoter 
regulated through a repressing E2F site, U20S cells were treated with H2 resulting in a 
significant increase in promoter activity and cyclin A expression (Bandara et al., 1997).
5.1.3 Chapter aims
A concise strategy for the development of E2F-1 antagonists as part of a potential therapy 
for the treatment of diseases such as cancer is shown in Figure 5.1. In a first step, novel 
E2F/DP1 antagonists are obtained in high throughput E2F/DP-1 activity assays, followed 
by analysis of peptide activity in mammalian cell-based activity assays. Peptides exhibiting 
potential anti-proliferative effects are selected and further evaluated using mouse-based 
progression assays. Peptides resulting in a significant reduction of tumour or interference 
with the tumour growth are further selected to partake in clinical evaluations.
Following the results obtained by Bandara et al., this project was intended to evaluate 
the use of peptides for the treatment of uncontrolled cell proliferation as a result of 
deregulated expression of E2F-1. Experiments focused on the analysis of peptide activity in 
mammalian cell-based assays. As the results by Bandara et al. suggested the activity of the 
E2F-1 inhibiting peptide (H2) promoted apoptotic cell death as part of the cellular response 
to E2F-1 inhibition by the H2 peptide, the aim was
• to investigate the application of the E2F-1 inhibitory peptides in a variety of 
established cancer cell lines in order to examine the relationship between tissue 
specific E2F-1 expression and inhibitory activity of the peptide.
• to investigate the potential treatment advantages of combining the inhibitory peptide 
with a variety of cell cycle specific and non-specific anti-cancer agents. This
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included an examination of the effect the inhibitory peptide has on the cell cycle 
distribution of various cancer cell lines.
High throughput 
E2F-DP1 activity assays
IE2F/DP1 antagonists
Mouse-based (E2F-dependent) 
progression assay
Mammalian cell-based activity assays 1
Clinical evaluation
Fig. 5.1: Strategy for the developm ent o f novel sm all peptide therapeutics 
for the treatm ent of proliferative diseases. For details refer to text.
5.2 Materials and Methods
5.2.1 E2F inhibitory peptides AH2 and D611
E2F-1 inhibiting peptides were supplied by Prolifix, 91, Milton Park, Abingdon, Oxon, UK 
and G. Bloomberg, Dept. Biochemistry, Medical School, University of Bristol, UK (table
5.1).
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Name (structure) Amino acid sequence Function
AH2 (linear) ROIKIWFONRRMKWKK-
RRRVYDALNVLMAMNIISK
Prevents heterodimer formation 
between E2F and DP subunit
AHS2 ROIKIWFONRRMKWKK-
DRVKAVRNLMIASYRNMLI
Control to AH2
D611 (branched) not available Prevents heterodimer formation 
between E2F and DP subunit
Mut not available Control to D611
Table 5.1: E2F inhibiting peptides
Underlined sequence represents the penetratin subunit of the peptide required for cell entry.
Peptides were dissolved in double distilled water (ddH2 0) to give a ImM stock solution 
and were stored at -80°C until further use. Subsequent serial dilutions were made in 
complete growth medium.
Lack of solubility of the peptides was encountered, particularly with respect to the 
peptides supplied by G. Bloomberg, Bristol. In order to increase the solubility of the 
peptides, DMSO (up to 10%) were added. Control experiments showed the percentage of 
DMSO to have no effect on cell viability when used.
5.2.2 Experimental cell lines
5.2.2.1 HT1080 and derivatives HT1080 Neo, ‘E2F1-1’ (CHO) and ‘E2F 1-6’ (CHO)
As experimental investigations for projects described in chapter 3 and 5 were performed 
simultaneously, the results concerning the CHO identity of ‘HT1080 E2F1-1’ and ‘HT1080 
E2F 1-6 ‘ cells influenced results within the following investigation. However, certain data 
obtained from preliminary experiments was included in the results section of this chapter. 
HT1080 Neo and ‘HT1080 E2F1-1’ cell lines were propagated as previously described in 
section 3.2.1.1.
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5.2.2.2 MCF-7
Confluent cultures of the human breast cancer cell line (Soule et al., 1973) were seeded 2- 
4xl0 4  cells/cm2  according to EC ACC
5.2.2.3 Human suspension cell lines
All suspension cell lines were maintained in RPMI 1640 medium supplemented with 10% 
FCS and 2mM glutamine. Suspension cell lines included HL60 (Fontana et al., 1980), 
Jurkat (Weiss et al., 1984), K562 (Andersson et al., 1979) and U937 (Sundstrom et al., 
1976). HL60 and K562 cultures were maintained at a concentration between l-5xl0 5  
cell/ml (ECACC). Jurkat and U937 were maintained at concentrations of 3-9xl06  cells/ml 
and 2-9x106 cells/ml, respectively (ECACC).
5.3 Results
5.3.1 Correlation between inhibitory peptide activity and endogenous level of E2F-1
In an investigation to establish a potential relationship between the level of endogenous 
E2F-1 expression and the inhibitory effect of the inhibitory peptides, the HT1080 Neo and 
identified CHO cell lines ‘HT1080 E2F1-1* and ‘HT1080 E2F1-6’ were treated with 
increasing doses of AH2 and D611 peptide. The data regarding both CHO cell lines is 
included in this chapter as a higher E2F-1 expression level was observed in the CHO cells 
compared to HT1080 Neo and these experiments were performed prior to full 
characterisation of the E2F-1 overexpressing cell lines (section 3.3.2).
Figure 5.2 shows representative experiments for HT1080 Neo, ‘E2F 1-1’ (CHO) 
and ‘E2F 1-6’ (CHO) cell lines treated with either inhibitory peptide AH2 or D611 for 72 
hours. Each experiment included the respective control peptides. HT1080 Neo cells 
exhibited an increased sensitivity to AH2 compared to either ‘E2F1-1’ (CHO) or ‘E2F1-6’ 
(CHO). At 15|iM AH2, cell proliferation was inhibited by 30% in HT1080 Neo while 90% 
of ‘E2F1-1’ (CHO) and ‘E2F1-6’ (CHO) cells continued to proliferate in response to 
treatment with AH2. A unreduced level of cell proliferation was observed with respect to 
the AHS2 control peptide in all three cell lines.
175
HT1080 Neo
1 10
peptide (pM) 
E2F1-1 (CHO)
100
0  120
1  100
p 80
100
peptide (pM)
§ 1 0 0
2
£
2Cl
0 1 10 1 0 0
peptide (pM) 
E2F1-6 (CHO)
o 100
0  80
o.
o 40
100
peptide (pM)
£ 100
2  60
100 100
peptide (pM) peptide (pM)
Fig. 5.2: Inhibition of proliferation by E2F-1 inhibitory peptides on 
HT1080 Neo, ‘E2F1-1’ (CHO) and ‘E2F1-6’ (CHO) cells as measured by 
representative SRB growth inhibition assays. Exposure to peptides was 
continuous (72 hours).—■ -AH2; AHS2; D611; Mut
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Following 72 hours exposure to D611, a 45% inhibition of cell proliferation was observed 
for HT1080 Neo at 15pM D611 whilst inhibition of cell proliferation for ‘E2F1-1’ (CHO) 
and ‘E2F1-6’ (CHO) was highest at 5pM D611 with 48% and 40%, respectively. The 
values for inhibition of cell proliferation at 10 and 15pM D611 in ‘E2F1-1’ (CHO) and 
E2F1-6’ (CHO) suggested the D611 activity to have reached its peak and no further 
increase in activity at higher peptide concentrations occurs.
The data indicated that an increased level of E2F-1 expression results in a decrease 
in inhibition of cell proliferation following AH2 treatment, as a consequence of E2F-1 
being in excess compared to the AH2 inhibitory peptide. In contrast, treatment with D611 
caused a reduction in cell proliferation across the spectrum of cell lines. HT1080 Neo cells 
showed a more progressive reduction in cell proliferation whilst a 1 0 0 % cell proliferation 
of ‘E2F1-1’ (CHO) and ‘E2F1-6’ (CHO) cells was maintained up to lpM D611 followed 
by a decrease in cell proliferation with increasing concentration of peptide to a level seen in 
HT1080 Neo cells. In conclusion, inhibitory activity of AH2 and D611 was suggested to be 
dependent on the endogenous level of E2F-1 expression within cells. D611 inhibitory 
activity in cells with an elevated level of endogenous E2F-1 appears most effective between 
1 and 5pM concentration.
5.3.2 Effect on cell proliferation in response to combined peptide/drug treatment
To evaluate the potential use of the inhibitory peptides in combination with 
chemotherapeutic agents, HT1080 Neo and ‘E2F1-1’ (CHO) cells were treated with 1 or 
10pM AH2 individually and in combination with 1 or lOpM BGIII21. BGIII21 is a novel 
minor groove binding alkylating agent that had been shown to produce sequence specific 
DNA damage in HT1080 as well as CHO cells (section 3.3.10 and 4.3.2). ‘E2F1-1’ (CHO) 
cells had previously exhibited a marked resistance to BGIII21 which was shown to occur 
independently of E2F-1 overexpression and was suggested to be a consequence of an 
underlying mismatch repair deficiency. For all drug/peptide combination experiments 
results were analysed according to the following criteria.
• Additive - an additive effect was defined as the observed combined decrease in cell 
proliferation of individual treatments following combination treatment.
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• More than additive - a more than additive effect was considered a decrease in cell 
proliferation in excess of the expected additive effect.
As the majority of experiments presented in this chapter are representative data, a more 
than additive decrease in cell proliferation following combined treatment was defined as a 
> 1 0 % decrease in cell proliferation in addition to the additive effect to account for variation 
seen in repeat experiments. The variations seen within experiments and experimental series 
were considered to be results of differences in activity encountered and were suggested to 
be a consequence of using different peptide batches, differences in length of storage of 
peptides with the result of loss of inhibitory activity of peptide and marked variations with 
respect to the solubility of the peptides from separate suppliers.
Representative results of combination experiments showed in response to the 
combined treatment of HT1080 Neo cells with 10pM AH2 and lpM BGIII21 a more than 
additive increase in growth inhibition (26.5%) compared to AH2 (85.5%) and BGIII21 
(46.5%) alone (Fig. 5.3 A). No such decrease in cell proliferation was found with respect to 
any of the other peptide/ drug treatment combinations. A more than additive decrease in 
cell proliferation was observed in response to the combined treatment of HT1080 Neo cells 
with lOpM AHS2 and lpM BGIII21 (33.7%) relative to AHS2 (108%) and BGIII21 
(41.8%) alone (Fig. 5.3 B). Again none of the other peptide/drug combination treatments 
exhibited a pronounced decrease in cell proliferation in comparison to the inhibitory effect 
observed for individual peptide or drug treatments.
In contrast, ‘E2F1-1’ (CHO) cells exhibited a more than additive decrease in cell 
proliferation in response to all combination treatments with AH2 and BGIII21 (Fig. 5.4 A). 
The percentage of cell proliferation was found to be 96% and 100% for 10pM and lpM 
AH2 respectively. Equally, values of 91.6% and 105.7% cell proliferation were determined 
for lOpM BGIII21 and lpM respectively. A range of values between 66.7% to 82.9% was 
obtained for all four peptide/drug combination treatments.
Evaluation of the data obtained after combined treatment of ‘E2F1-1’ (CHO) cells 
with AHS2 and BGIII21, showed a more than additive decrease in cell proliferation across 
all combinations as observed with AH2 before (Fig. 5.4 B). Therefore, inhibitory or control
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Fig. 5.3: Representative drug/ peptide combination assay to show individual 
and combined effects of BGIII21 and E2F-1 inhibiting peptide on 
HT1080 Neo cells. Cells were incubated with peptide and BGIII21 separately 
or in combination for 72 hrs.
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Fig. S.4: Representative drug/ peptide combination assay to show individual 
and combined effects of BGIII21 and E2F-1 inhibiting peptide on 
‘E2F 1-1’ (CHO) cells. Cells were incubated with peptide and BGIII21 
separately or in combination for 72 hrs.
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peptide plus drug in combination were suggested to work together to achieve a decrease in 
percentage of cell proliferation not seen with peptide or drug individually.
5.3.3 Increased sensitivity of MCF-7 cells to inhibitory peptides
An aim of this study was to evaluate the effect of the inhibitory peptides on a variety of 
cancer cell lines. To this end, MCF-7 cells were exposed to increasing doses of AH2 and 
D611 for 72 hours. Figure 5.5 shows an observed increase in sensitivity in response to both 
peptides. At 15 pM AH2 a 38% decrease in the percentage of cell proliferation with regard 
to MCF-7 cells was detected. In contrast, a 20% decrease in the percentage of cell 
proliferation was observed in response to 15pM D611. To conclude, MCF-7 cells were 
found to be more sensitive to AH2 than D611 following continuous exposure. This stands 
in contrast to results previously obtained for HT1080 Neo and ‘E2F1-1’ (CHO) cells.
5.3.4 Effect on cell proliferation in response to combined peptide/drug treatment
Following the finding of increased sensitivity of MCF-7 cells to AH2, a number of 
peptide/drug treatment combinations were investigated. The drugs selected were the novel 
minor groove binding alkylating agent BGIII21 and melphalan, a representative alkylating 
agent.
An additive decrease in cell proliferation was observed with regard to all 
AH2/BGIII21 combination treatments compared to individual peptide or drug treatments 
(Fig. 5.6 A). Combining lpM AH2 (97.6%) andlpM BGIII21 (96.8%) gave a more than 
additive decrease (83.3%) in cell proliferation. In contrast, the combination of lpM AH2 
(97.6%) and lOpM BGIII21 (34.3%) resulted in an additive decrease in the percentage of 
cell proliferation (29.2%). Finally, the combination of lOpM AH2 (91.1%) and lpM 
BGIII21 (96.8%) as well as lOpM AH2 (91.1%) and lOpM BGIII21 (34.3%) had a more 
than additive effect (80.8% and 16.1% respectively) on the percentage of cell proliferation.
A more than additive decrease (17.2%) in the percentage of cell proliferation 
occurred in response to the combination of lOpM AH2 (54.9%) and lpM melphalan (74%) 
(Fig. 5.6 B). However, the combination of lpM AH2 (93.8%) and lOpM melphalan (35%) 
as well as lOpM AH2 (54.9%) and lOpM melphalan (35%) resulted in a protective effect 
upon combination (55.8% and 26.2% respectively). Finally, the remaining combination
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Fig. 5.5: Inhibition of proliferation by E2F-1 inhibiting peptides on 
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Fig. 5.6: Representative drug/ peptide combination assay to show individual 
and combined effects of BGIII21 or Melphalan and E2F-1 inhibiting 
peptide on MCF-7 cells. Cells were incubated with peptide and BGIII21 
separately or in combination for 72 hrs.
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treatment consisting of lpM AH2 (93.8%) and lpM melphalan (74%) produced no further 
decrease in cell proliferation (72.4%). To conclude, a more than additive reduction in the 
percentage of cell proliferation in MCF-7 cells resulted from the combination of lpM AH2 
and lpM  BGIEI21 as well as lOpM AH2 and lpM melphalan. However, no reproducible 
pattern emerged with respect to the effectiveness of each of the individual peptide/drug 
combinations.
5.3.5 Relative levels of endogenous E2F-1 expression in leukemic cell lines
Prior to investigating the effect of the inhibitory peptides on a number of leukemic cell 
lines, it was of importance to examine the relative level of endogenous E2F-1 expression in 
each of the cell lines. To this end, Western blot analysis (Method 2) was performed. Figure
5.7 shows U937 to express the highest level of endogenous E2F-1. By comparison U937 
was found to contain more E2F-1 than Jurkat. Both HL60 and K562 exhibited an almost 
lOfold lower level of endogenous E2F-1 expression.
To complement the above result, the doubling times for the leukemic cell lines were 
measured as described in section 2.1.3.3 (table 5.2). The results show that none of the 
doubling times for HL60, K562 and U937 were differed markedly from each other. 
Therefore, there was no direct correlation between the amount of E2F-1 expressed and the 
time required for cells to traverse the cell cycle.
Cell line Doubling time (hours)
HL60 36
Jurkat N/A
K562 45
U937 41
Table 5.2: Doubling times for established leukemic cell lines
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Fig. 5.7: Relative level of endogenous E2F-1 expression in leukemic cell 
lines as determined by Western blot analysis. Correct size of E2F-1 protein 
band was confirmed with Kaleidoscope pre-stained standard size marker. 
Equal loading was verified by staining blot with Coomassie blue. Levels 
of protein loading are not shown as staining of pre-selected reference bands 
was too weak.
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5.3.6 Correlation between inhibitory peptide activity and endogenous E2F-1 
expression in leukemic cell lines
Leukemic cancer cell lines were selected in order to examine the effect of the AH2 and 
D611 inhibitory peptides on cell proliferation and cell cycle distribution. The choice of a 
leukemic cell system was based on an anticipated clinical application of the peptide and 
reports suggesting a 1 0 0 % bioavailability of peptide to target cells following intravenous 
injection (Lauta, 2000). The high percentage of bioavailability within the bloodstream 
could lead to a high degree of peptide activity at individual target sites throughout the body. 
In addition, the intravenous route offers a relatively easy way of introducing the peptides to 
the body.
Following continuous incubation, the HL60 cell line was found to be equally 
sensitive to both, the AH2 (IC5 0  = 3.9pM) and D611 (IC5 0  = 4.3pM) inhibitory peptide in a 
representative experiment (Fig. 5.8). However, an increased sensitivity in response to the 
control peptide AHS2 (IC5 0  = 16.5pM) was also noted. In contrast, a 10% decrease in cell 
proliferation was detected following exposure to 15pM Mut control peptide.
K562 cells were less sensitive to AH2 (IC5 0  = 16pM) compared to HL60 but were 
found to be equally as sensitive to AHS2 (IC5 0  = 19pM) as HL60 cells. Finally, Jurkat cells 
were more resistant to D611 (IC5 0  = >15pM) compared to HL60. All mean IC50s were 
calculated from 3 or more experiments.
5.3.7 Apoptotic cell death in response to inhibitory peptides
Following the observation that an increased amount of endogenous E2F-1 in cells appears 
to lead to a more than additive decrease in cell viability in response to combined treatment 
an investigation into the effect of each individual treatment on the cell cycle profile was 
necessary. This would provide information to establish the most effective treatment routine 
with respect to timing of application and dose of peptide or drug.
In a representative experiment U937 and HL60 cells were treated continuously for 
72 hours with 15pM of AH2 and D611 including the relevant control peptides. Samples 
were taken at 24, 48 and 72 hours and cell cycle analysis performed to determine the 
relative DNA content of the peptide treated cells. In Figure 5.9 a continual increase in the 
percentage of apoptotic cells as depicted by the sub-Gl phase was observed following
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exposure of U937 cells to D611. After 72 hours around 90% of D611 treated U937 cells 
had undergone apoptosis. By contrast, only 16% of U937 cells underwent apoptosis after 
treatment with 15pM AH2 for 72 hours. Neither AHS2 nor Mut appeared to affect the cell 
cycle distribution of U937 cells.
HL60 cells exhibited a G1 arrest after treatment with 15pM D611 for 48 hours (Fig. 
5.10). The G1 arrest persisted throughout the remaining time-course. No effect of AH2 was 
observed on HL60 cells for the duration of the experiment. Treatment with the Mut control 
peptide for 24 hours provoked a decline in G1 phase with a concomitant increase in the 
percentage of cells in S phase. A similar pattern had been observed with respect to AH2, 
AHS2 and Mut treated U937 cells after 24 hours.
5.3.8 Effect of inhibitory peptides on cell proliferation of HL60 and K562
A new supply of peptide was obtained from G. Bloomberg, Dept. Biochemistry, University 
of Bristol, UK. The new AH2 and AHS2 peptides ordered were synthesised having the 
sequence of residues as listed in section 5.1.1. It was not possible to obtain any D611 or 
Mut peptides as information on the amino acid sequence was not available. Cell 
proliferation assays were performed to determine the inhibitory effect of the new batch of 
peptides on a selection of leukemic cell lines used during previous experiments. Figure 
5.11 shows all cell lines were sensitive to AH2 and AHS2. HL60 cells were found to be the 
most sensitive to AH2 and AHS2 with IC5 0  values of 4.1pM and 9,9pM respectively. A 
similar range of IC5 0  values was determined for Jurkat cells in response to AH2 (IC5 0  = 
7.1pM) and AHS2 (IC5 0  = 13pM). By comparison K562 cells turned out to be least 
sensitive to AH2 (IC5 0  = 18pM) and AHS2 (IC5 0  = 23pM). All IC5 0  values are based on 3 or 
more experiments. As previously observed in section 5.3.6,
HL60 were found to be the most sensitive to AH2 and AHS2. However, HL60 
appeared more sensitive to AHS2 compared to earlier results. K562 cells retained the level 
of sensitivity in response to AH2 and AHS2. No comparison was possible for Jurkat cells 
as these had been exposed to D611 and Mut rather than AH2 and AHS2 in previous 
experiments.
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5.3.9 G1 arrest in response to inhibitory peptide
To continue the ongoing investigation into the evaluation of the effects of peptide treatment 
on leukemic cell lines, HL60 and K562 were dosed with lOpM and 25pM AH2 or AHS2 
for 24, 48 and 72 hours as described before (section 5.3.7). A G1 arrest was observed in 
HL60 cells after treatment with 25pM AH2 for 24 hours with a concomitant decrease in the 
percentage cells in G2 phase (Fig 5.12 A). The lack of G1 arrest after 24 hour long 
exposure to 10|xM AH2 indicated the cell cycle alterations to be dose-dependent. The G1 
arrest was maintained throughout the 48 and 72 hours samples suggesting that no peptide 
activity had been lost throughout the time-course or cells were unable to re-enter the cell 
cycle. No G1 arrest was detected in K562 cells following FACS analysis of the all time- 
course samples (Fig. 5.12 B).
5.4 Discussion
The development of peptides that interfere with specific proteins offers a number of novel 
opportunities to study specific protein functions in vivo, investigate interactions between 
protein components within biological pathways and aid the discovery of unknown binding 
partners of target proteins. In addition, novel peptides designed to inhibit the activity of 
proteins involved in cell proliferation such as CDK2 and E2F-1, provide a means to 
elucidate the molecular basis of diseases such as cancer as well as present a potential new 
type of therapy.
The aim of the above study was to evaluate the potential benefits associated with the 
treatment of cancer cells with E2F-1 inhibiting peptides. The active peptides chosen were 
AH2 and D611 for which only the amino acid sequence of the former is available. The 
AH2 peptide is linear in structure not containing any known post-synthetic modifications. 
AH2 is linked to a penetratin subunit derived from the third helix of the Drosophila 
melanogaster antennapedia homeodomain protein in order to ensure translocation across 
the cell membrane (Bandara et al., 1997).
The respective control peptides for AH2 and D611 were AHS2 and Mut. Again, 
only the amino acid sequence of the former is available. AHS2 consists of the scrambled 
amino acid sequence of AH2 linked to a penetratin subunit.
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5.4.1 Variations observed with respect to peptide activity
The majority of data presented in the results section were representative experiments of an 
experimental series as it proved difficult to obtain homogenous sets of data due to 
significant inter-experimental variation. However, despite inter-experimental variation, 
observed trends were preserved between individual experiments. As an example, in figure 
5.8, HL60 dosed with AH2 and AHS2 showed an 80% decrease in cell proliferation at 
10p,M AH2 and a 17% decrease in response to AHS2. The experiment shown is 
representative as a result of marked variation in peptide activity observed (cell proliferation 
values ranged from 30% decrease to 100% decrease) when repeats were performed. Further 
experiments using a new peptide supply (G. Bloomberg, Bristol) showed persistent 
variations in peptide activity although to a lesser extent which allowed standard deviations 
to be included in the graphs (Fig. 5.11 A). A possible explanation for the increased inter- 
experimental variation might be an inconsistent level of activity within peptide samples due 
to a number of factors such as:
5.4.1.1 Variation in peptide activity between batches
Peptides were supplied in 2-5 vials of lmg or 2mg each by the manufacturer. In general, 
one or two vials were required for each experiment. Invariably a new peptide batch had to 
be ordered in order to complete an experimental series. As a result, variations observed 
within experimental series may be explained by differences in activity between different 
batches supplied by the manufacturer.
5.4.1.2 Progressive loss of activity following different length of storage periods
As experiments were not performed simultaneously but rather in sequence, variations in 
length of storage periods did occur and might have contributed to the differences in activity 
of peptide seen within experimental series. It may be speculated that peptide activity 
decreased with increasing length of storage in powder form and/or that peptide activity 
decreased with increasing length of storage once the peptide had been solubilised.
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5.4.1.3 Variations in solubility of peptides
Further, marked differences in solubility were seen with respect to peptides supplied by the 
original manufacturer compared to peptides supplied by the second supplier (G. 
Bloomberg, Bristol). While peptide batches supplied by the manufacturer were on average 
soluble in distilled water with the occasional addition of DMSO, peptides supplied by G. 
Bloomberg always required additional DMSO in order to completely solubilise the 
peptides. The difference in solubility may have been a result of secondary structural 
modifications of the peptides by the manufacturer that were not indicated to the new 
supplier.
5.4.1.4 Structural modifications of peptides
Observed differences in activity and solubility of peptides supplied by the manufacturer and 
G. Bloomberg, Bristol were suggested to be a result of structural modifications of the 
peptides following initial amino acid chain synthesis. For example, the addition of 
disulphide bonds would increase the stability of the peptides and prolong their period of 
activity compared to unmodified peptides. As information on any potential modifications to 
the peptide structure was not available, any peptide supply from a secondary source 
contained unmodified peptides only.
5.4.1.5 Effect of growth state and cell cycle distribution of cells on peptide activity
Differences in passage number and growth states of individual cell lines could also provide 
an explanation for the differences in peptide activity seen within an experimental series. 
Possible improvements to the previous experimental set-ups might include the use of cells 
with the exact same passage number as well as FACS analysis to examine the cell cycle 
distribution of the cells used for the peptide experiment to ensure that the cell cycle 
distribution remains constant for each experimental repeat.
5.4.1.6 Interaction of peptides with components of cell culture medium
Although the peptides were dissolved in ddH2 0 , preparation of further dilutions in serum 
containing medium and potential interaction of peptides with serum components could 
account for the variability in peptide activity observed.
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5.4.2 Studies to investigate peptide activity
In addition to the studies into the activity of the E2F-1 inhibitory peptides carried out by 
Bandara et al., further investigations should include experiments that observe any changes 
of mRNA and protein levels of selected E2F-1 target genes in response to peptide. 
Additional assays to investigate the levels of peptide activity are reporter assays that show 
the effect of peptide activity on gene expression (Bandara et al., 1997).
Multi-protein complexes involved in regulatory processes and transcription 
including transcriptional activation and inactivation are associated with chromatin structure. 
Hence, protein-protein and DNA-protein interactions may be examined using the chromatin 
immunoprecipitation (CHIP) assay. Therefore the CHIP assay potentially provides a means 
of analysing the effect of inhibitory peptide action on E2F-l-protein (e.g. DP-1) 
interactions as well as E2F-1 DNA-binding. Finally, microarrays may be used to examine 
the gene expression levels of a wide range E2F-1 regulated genes in response to inhibitory 
peptide.
5.4.3 Discussion of representative experimental data and conclusion
The majority of experiments for the above investigation yielded representative data as a 
result of inter-experimental variations in peptide activity. Possible explanations for the 
differences in peptide activity seen are given in section 5.4.1.
The investigation to examine the relationship between inhibitory peptide activity and the 
level of endogenous E2F-1 expression, a direct correlation between E2F-1 protein 
expression and AH2 activity was observed. In contrast, the level of endogenous E2F-1 
expression had no direct effect on the activity of D611. Instead, D611 inhibitory activity 
displayed the same trend with respect to all experimental cell lines. A levelling off in D611 
activity was observed with increasing peptide concentrations in cells expressing high levels 
of E2F-1. The plateau in activity was suggested to be the result of D611 reaching its 
maximum level of protein-protein interaction and activity. Consequently, no further 
increase in E2F-1 inhibition is possible. No such plateau phase was detected in cells 
containing an overall lower level of E2F-1.
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In HT1080 Neo cells, combination treatment with inhibitory peptide AH2 and BGIII21, 
resulted in an additive or more than additive inhibitory effect in three of the four 
peptide/drug combinations used. It was noted that IOjiM AH2 appeared to protect a small 
fraction of HT1080 Neo cells from cell death after treatment with 10p,M BGIII21 for 72 
hours. Combining AHS2 and BGIII21 produced an additive decrease in cell proliferation 
for all four possible combinations.
By contrast, a consistent more than additive decrease in cell proliferation was 
observed for all four combination treatments in E2F1-1 (CHO) cells, presented as a further 
decrease in the percentage of cell proliferation in addition to the expected additive 
inhibitory effect. As Figure 5.5 shows, neither AH2 nor BGHI21 alone caused a significant 
loss of cell proliferation. However, upon combination a marked loss in cell proliferation 
was observed. Simultaneous incubation of cells with peptide appeared to increase 
sensitivity of E2F-1 (CHO) cells towards BGIII21. Nevertheless no explanation for the 
underlying mechanism for this peptide “ priming” of ‘E2F1-1’ (CHO) cells is given at this 
point in time.
A more than additive decrease in the percentage of cell proliferation of ‘E2F 1-1’ 
(CHO) was detected following two combinations of AHS2 and BGIII21. As AHS2 alone 
was shown to have no marked effect on cell proliferation in ‘E2F1-1’ (CHO) cells in the 
SRB growth inhibition studies (Fig. 5.5 B), the more than additive loss in cell proliferation 
was suggested to be a result of introducing exogenous peptide into cells. This hypothesis 
however does not hold true for the lack of combined effect observed in HT1080 Neo cells 
unless the differential response to the introduced peptide is based on tissue specificity.
A third cell system in the form of MCF-7 breast cancer cells was selected and initial 
SRB growth inhibition assays showed MCF-7 cells to be more sensitive to the same 
concentration of AH2 than D611. Continuous exposure to either control peptides did not 
result in a marked decrease in the percentage of cell proliferation. Following combination 
treatment with lpM AH2 and BGIII21 an additional decrease in cell proliferation was 
observed to the expected additive inhibitory effect, indicating combined activity between 
AH2 and BGIII21. The remaining three peptide/drug combinations resulted in an additive 
or more than additive decrease in percentage cell proliferation. In comparison to ‘E2F1-1’ 
(CHO), MCF-7 cells were more sensitive to BGIII21 but not as sensitive as HT1080 Neo
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cells. Levels of sensitivity towards both concentrations of AH2 were found to be within a 
close range of each other.
A suggested pattern emerged whereby sensitivity towards BGIII21 potentially led to 
loss of more than additive cell proliferation with respect to combination treatments. 
HT1080 Neo was most sensitive to BGIII21 but showed no more than additive sensitivity 
regarding peptide/drug combinations. In contrast, ‘E2F1-1’ (CHO) cells were least sensitive 
to BGIII21 but exhibited more than additive loss of cell proliferation with respect to each 
peptide/drug combination. MCF-7 cells showed an intermediate level of sensitivity with 
respect to BGIII21 and subsequent loss of cell proliferation was more than additive in the 
context of some but not all combination treatments. To conclude, a more than additive 
effect of peptide and drug treatment in combination appeared to be dependent on the level 
of sensitivity observed towards the drug alone within a particular cell system.
To investigate whether the above hypothesis was specific for BGIII21 alone or 
whether it applies to other drugs, MCF-7 cells were exposed to peptide/drug combinations 
including melphalan. MCF-7 cells were more sensitive to lpM melphalan than lpM 
BGIII21. Sensitivities to IOjxM melphalan and lOpM BGIII21 were equal. A more than 
additive effect was observed as a result of combining IOjxM AH2 and lpM  melphalan. 
However in contrast to previous data, exposure to 10pM AH2 resulted in a 50% decrease in 
cell proliferation therefore suggesting an enhancement of peptide inhibitory effect through 
additional drug rather than an increased sensitivity towards the drug through the presence 
of the peptide.
In addition, for the treatment combination of lpM AH2 and lOpM melphalan, the 
combined result showed an increase in the percentage of cell proliferation compared to 
melphalan alone suggesting a protective effect. Overall, the above data for MCF-7 cells and 
combination treatment including melphalan remain inconclusive.
As part of the investigation to expose a range of different cancer cell lines to the 
inhibitory peptides alone or in combination with drugs, a number of leukemic cell lines 
were selected. Leukemic cell lines have the advantage of being suspension cell lines so that 
any promising discoveries within this study had the potential of being translated into the 
next phase of the therapeutic peptide development. Part of the development of any new 
anti-cancer agent is the consideration of how to best target the specific agent to the cancer
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cells. In contrast to most localised solid tumours leukemic cells may be easily targeted via 
the intravenous route. In addition, 100% bioavailability of the peptide is accomplished as 
the peptide is just required to translocate across the cell membrane and does not need to 
cross any further endothelial or epithelial barriers to reach its target. The disadvantage of 
this system is that healthy as well as cancer cells will be targeted unless there is a way of 
discriminating the two and a substantially higher dose of peptide would be required as the 
peptide will be diluted upon application.
In a first step, the relative level of endogenous E2F-1 expression was examined and 
U937 cells were found to contain 3-5 fold more E2F-1 than Jurkat. Jurkat however 
expressed around 10 fold more E2F-1 than either HL60 or K562. Analysis of each 
individual cell lines doubling time revealed HL60 to be the fastest growing cell line (36 
hours) and K562 the slowest (45 hours). The doubling time for Jurkat cells was not 
obtained. The doubling times of the leukemic cell lines did not correlate to the endogenous 
level of E2F-1 expression
Cell proliferation assays found HL60 cells to be equally as sensitive to AH2 and 
D611. However, whereby HL60 exhibited a low degree of sensitivity towards Mut, the 
precentage of cell proliferation was markedly decreased in response to AHS2. K562 cells 
were less sensitive to AH2 than HL60 but exhibited the same degree of loss of cell viability 
following treatment with AH2 or AHS2. No data for K562 cells treated with D611 was 
obtained. Further, no significant decrease in the precentage of cell proliferation was 
observed for Jurkat in response to D611. No data was obtained for Jurkat treated with AI12. 
In conclusion HL60 cells appeared to be most sensitive to either inhibitory peptide. It is 
possible to speculate that a faster cell doubling time might result in an increased sensitivity 
to the E2F-1 inhibiting peptides. However, a more comprehensive investigation is required 
to substantiate the above speculation.
Following the cell proliferation studies, an investigation into the effect of peptide 
treatment on the cell cycle profile of each cell line was carried out. U937 and HL60 cells 
were treated with 15jliM of each peptide for 24, 48 and 72 hours. Cell cycle analysis 
showed that U937 cells underwent apoptotic cell death in response to exposure to D611. 
This result supported previous results by Bandara et al. who reported the occurrence of 
apoptosis as a result of treatment with E2F-1 inhibiting peptide in E2F-4/Ha-ras
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transformed cells. It was proposed that the observed apoptotic cell death correlated directly 
with the E2F-regulating activity of the peptide as E2F-1 was implicated in the initiation of 
apoptosis via the pl6Arf-MDM2-p53 pathway (Bandara et al., 1997). Hence, apoptosis 
observed in response to D611 was suggested to be a direct result of the more effective E2F- 
regulating activity of D611 compared to the less effective AH2 peptide. By contrast, a lack 
of apoptosis was observed with respect to AH2.
Further, the level of endogenous E2F-1 expressed was suggested to raise 
susceptibility to the apoptosis-inducing activity of the peptide (Bandara et al., 1997). A lack 
of apoptosis observed in HL60 cells suggests a correlation between endogenous E2F-1 
levels and initiation of apoptosis following E2F-1 inhibiting peptide treatment especially as 
U937 cells were shown to contain a higher level of E2F-1 than HL60 cells. G1 arrest 
induced by D611 in HL60 cells might be regarded as the precursor to programmed cell 
death.
The investigation was continued with new stocks of AH2 and AHS2. To ensure a similar 
level of activity of the new peptides compared to previous batches, cell proliferation assays 
were carried out using HL60, K562 and Jurkat cell lines. As previously observed, HL60 
cells were most sensitive to AH2 compared to K562 or Jurkat. The level of sensitivity was 
equal to the previous level observed with the old stock of AH2 peptide. The Jurkat cell line 
was less sensitive to AH2 than HL60 but nevertheless more sensitive than K562 cells. It 
was noted that Jurkat cells appeared to be significantly more susceptible to AH2 than D611 
activity. A similar result had been previously observed in MCF-7. In contrast, HT1080 
Neo, ‘E2F1-1’ (CHO) and HL60 cells were substantially more sensitive to D611 than AH2. 
This suggests that a differential sensitivity to both peptides maybe based on cell line 
specificity.
HL60, K562 and Jurkat showed a decrease in the percentage of cell proliferation 
following exposure to AHS2. Whether this decrease in cell proliferation was due to an 
underlying E2F-1 inhibitory activity of the control peptide (AHS2) or whether it was a 
result of peptide introduction to the cells, remains to be elucidated. However, the former 
seemed unlikely, as the amino acid sequence of AHS2 was scrambled and retention of E2F- 
1  inhibiting activity seemed unlikely.
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In a repeat of earlier experiments using the new stock of peptides, cell cycle analysis was 
performed to assess the effect of inhibitory peptide treatment on HL60 and K562 cells. The 
two cell lines were chosen as they represented the most and the least sensitive cell line to 
AH2 and AHS2, respectively. A pronounced G1 arrest was observed in HL60 cells in 
response to 25pM AH2 after 24 hours while an increase in the percentage of cells in G1 
phase was detected in K562 for the same concentration after 72 hours. Based on the 
suggestion that inhibitory activity of the peptide is correlated to the level of endogenous 
E2F-1, a marked G1 arrest would have been expected in K562 cells at an earlier time-point 
as the level of E2F-1 expression is equal in both cell lines. It has been proposed for G1 
arrest to act as the precursor to apoptosis in peptide treated cells (Bandara et al., 1997). 
However, increasing concentrations of AH2 maintained G1 arrest rather than initiate 
apoptosis in HL60. Hence it was suggested that D611 and AH2 activity manifests itself in 
different ways within cells, the former resulting in apoptotic cell death and the latter merely 
initiating G 1  arrest.
In conclusion, E2F-1 inhibiting peptide activity appears to employ its inhibitory 
activity through a number of pathways within different cell lines resulting in a range of 
varied physiological responses of the one or possibly several independent origins. 
Therefore, until these response pathways are elucidated, peptide treatment does not 
constitute a potential therapy for the treatment of diseases as a result of disturbed cell cycle 
regulation.
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6. DISCUSSION AND CONCLUSION
Perturbation of the balance between the mechanisms of cell proliferation, differentiation 
and apoptosis is a hallmark of cancer. The constitutive activation of oncogenes such as ras 
and functional inactivation of tumour suppressor genes such as Rb and p53 leads to aberrant 
gene expression of genes that regulate the cell cycle, cellular differentiation and apoptosis 
leading to cellular transformation (Gottlieb et al., 1996; Liu et al, 1995). The family of 
E2F transcription factors plays an important role in cell cycle regulation, differentiation, 
apoptosis and oncogenic transformation. The E2F transcriptional activators have been 
found to be part of the G1 restriction point mechanism deciding on cell cycle progression or 
apoptosis (Johnson et al., 1998; Slansky et al., 1996). E2F-1 as part of the Rb- tumour 
suppressor pathway has been found to be deregulated in a number of cancer as a result of 
cyclin D1 overexpression (Bartkova et al., 1995) and mutation or deletion of Rb or the 
pl6INK4a cyclin-dependent kinase inhibitor gene (Kaelin, 1999; Schauer et al., 1994; 
Weinberg et al., 1995). Understanding of the regulatory pathways of gene expression 
provides a starting point for the design of molecular tools that reverse or utilise deregulated 
transcription levels and inhibit tumour-cell growth and progression. The aim is to develop 
new measures that have a direct or indirect effect on components of the transcription 
regulatory pathway such as E2F resulting in the counteraction of deregulated transcription 
activity. The investigations within this PhD thesis were set out to elucidate the effects of 
deregulated E2F-1 expression on chemosensitivity to a variety of chemotherapeutic agents. 
Further, the use of a novel E2F-1 antagonising peptide was examined for its potential to 
inhibit E2F-1, in order to restrain or alter aberrant cell cycle progression within E2F-1 
overexpressing cells and to provide a rational approach for the development of a peptide 
and drug combination treatment for receptive cancer types.
Aside from providing a number of valuable results the data presented also highlighted the 
pitfalls of scientific research in the form of inter-species cross-contamination. Measures for 
the prevention of inter- as well as intra-species cross-contamination are discussed within 
the relevant chapter (chapter 3) and hence have been exempt from the following discussion.
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Results in the first chapter concerned with the deregulation of E2F-1 expression and 
chemosensitivity, indicated the basal level of E2F-1 expression to be significantly higher in 
CHO cells relative to the HT1080 cells. No alteration in chemosensitivity was found in 
response to etoposide in CHO cells. Hence, results did not confirm previous reports of an 
increased level of E2F-1 expression to result in an increase in chemosensitivity to etoposide 
in E2F-1 overexpressing HT1080 as well as 32D.3 myeloid progenitor cells (Banerjee et 
al., 1998; Nip et al., 1997). In conclusion, results suggest cell lineage to be an important 
factor in determining degrees of chemosensitivity to various agents.
An inducible E2F-1 expression system using HT1080 cells was developed in order 
to examine the possibility of E2F-1 overexpression directly influencing the 
chemosensitivity of HT1080 to the novel minor groove binding alkylating agent BGIII21. 
The hypothesis was that an increase in E2F-1 expression leads to a decrease in 
chemosensitivity in response to treatment with BGIII21. However no decrease in 
chemosensitivity in E2F-1 overexpressing HT1080 cells was observed in response to 
BGIII21 treatment.
Furthermore, although induction through doxocycline removal resulted in a lOfold 
increase in E2F-1 expression, the percentage of cells entering premature S phase remained 
low. A possible explanation for the lack of a pronounced increase in the fraction of cells 
entering S phase could lie in the choice of cell line. As HT1080 cells are an immortalised 
cancer cell line, it has been suggested that mutations, deletions or amplifications of genes 
within the Rb pathway have occurred previously thereby resulting in an increased basal 
level of E2F-1 expression. Hence, it would be of importance to create a second inducible 
system using a primary cell line and repeat the above investigation to excluding the 
possibility of an increased basal level of E2F-1 expression.
The marked resistance of CHO cells to the novel minor groove binding agent 
BGIII21 was confirmed in experiments using a characterised CHO-AA8 cell line. 
Following exposure to drug, BGIII21 specific DNA lesions were observed and mapped to a 
previously reported target sequence as well as an A-T rich region of DNA within the 
selected Hprt exon 9 DNA fragment. A comparison of BGIII21 specific DNA damage 
produced in HT1080 and CHO-AA8 cells found a differential amount of DNA lesions to be 
produced. The difference in amount of DNA damage produced was suggested to depend on 
a differential drug uptake between HT1080 and CHO-AA8 cells. However, any
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investigation into a potential difference in affecting BGIII21 uptake could not be carried 
out as neither fluorescent nor radioactively labelled drug was available. Repair analysis 
using single strand-ligation PCR found no repair to take place within HT1080 or CHO 
cells. Further investigations showed that neither NER nor homologous recombination repair 
pathways partake in the removal of BGIII21 specific DNA lesions. Analysis of BGIII21 
resistance in MMR deficient human colon and prostate cancer cell lines suggested 
decreased chemosensitivity to BGIII21 to be a consequence of mismatch repair protein 
deficiencies affecting the MutSa and MutS(3 mismatch recognition complexes.
In contrast, the mismatch repair deficient CHO Clone B cell line was found to be 
twice as sensitive to BGIII21 than the parental CHO line. This result contradicted the 
hypothesis that MMR deficient cells exhibited resistance to minor groove binding 
alkylating agents. Previous reports suggested the CHO Clone B cell line to lack the 
mismatch repair protein hMSH2 that forms an essential part of the MutSa and MutSP 
mismatch recognition complexes (Aquilina et al., 1994). Following these reports, CHO 
Clone B cells would be expected to be more resistant to BGIII21 than the parental CHO 
cell line. No explanation for the above discrepancy can be provided at this point.
In contrast to the investigations described above which exclusively focused on exploiting 
an increased level of E2F-1 expression as a means to increase chemosensitivity to various 
chemotherapeutic agents, the third part of this thesis was designed to counteract E2F-1 
overexpression by means of an antagonistic peptide therefore sensitising cells to a 
subsequent treatment with a variety of drugs.
Attempts were made to utilise the knowledge available about E2F transcription 
factors for a rational approach for the development of an E2F-1 inhibitory peptide. Two 
inhibitory peptides were obtained through collaborators both of which inhibited the 
formation of active E2F-DP heterodimers with the result of inhibiting transcriptional 
activation but not DNA binding. Success within this part of the PhD project was limited in 
that the data obtained revealed inconsistencies in the form of inter-experimental as well as 
tissue specific variation. However, a direct correlation between endogenous E2F-1 levels 
and peptide activity was observed with respect to the linear peptide AH2 but not the 
branched peptide D611. Results of the investigations into the benefits of combining peptide 
and drug treatments ranged from additive to more than additive effects suggesting the effect
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to be dependent on the initial level of chemosensitivity of the cells analysed to the drug 
used. Data for CHO cells showed the linear peptide to “prime” cells causing an increased 
sensitivity to drug when peptide and drug combined.
However, an observed sensitivity to control peptide suggested that instead of the 
above hypothesis, any effects observed using peptide/drug combinations might be a result 
of peptide introduction into cells alone causing an unspecific sensitisation of cells to the 
drug. In addition, it is necessary to take into account the difference of origin and molecular 
background of the cell lines used in the investigation. The level of E2F-1 present in the 
HT1080, CHO and MCF-7 cell lines might not be increased compared to the level of E2F-1 
expression in non-cancerous cells with the same origin.
Therefore it was suggested that the observed peptide activity might be due to the 
general presence of peptide rather than a result of the specific antagonistic action of the 
peptide. In addition, any effect observed following peptide and drug combinations was 
again suggested to be due to the introduction of exogenous peptide to the cells than due to 
the specific E2F-1 antagonising action of the peptide. Therefore this particular peptide 
approach was deemed unreliable unless significantly more research is carried out.
Investigations using an alternative cell system of leukemic cells revealed the E2F-1 
expression level not to correlate with the doubling times of the cells. This data contradicts 
previous statements whereby an increased expression of E2F-1 results in a faster traversal 
of cells through G1 to S phase leading to an increased fraction of cells in S phase. 
Nevertheless an observed increase in sensitivity to the AH2 and D611 antagonistic peptides 
was suggested to be a result of a faster doubling time of HL60 cells compared to the other 
leukemic cell lines. Further a correlation between the endogenous level of E2F-1 and the 
occurrence of apoptotic cell death were suggested as apoptosis was observed in U937 cells 
expressing a high level of E2F-1 compared to HL60 and K562 cells both expressing a 
lower level of E2F-1. Instead, HL60 and K562 cells exhibited a persistent G1 arrest.
Regarding the relationship between E2F-1 deregulation and chemosensitivity several 
conclusions can be drawn:
• No increase in chemosensitivity was observed in E2F-1 overexpressing cell in 
response to any chemotherapeutic agents used.
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• A decreased chemosensitivity to the minor groove binding alkylating agent BGIII21 
was found to be the result of an underlying MMR deficiency in human colon and 
prostate cancer cell lines but not CHO Clone B cells.
• Investigations into the effects of E2F antagonising peptides alone or in combination 
with chemotherapeutic agents require more research regarding the origin and 
molecular background of cell lines and the pathways through which the inhibitory 
peptides initiate either apoptosis or cell cycle arrest
6.1 Alternative approaches and future directions
A promising success for an alternative approach to counteract E2F activity has been 
reported by two independent groups using an oligonucleotide decoy for the E2F 
transcription factor that successfully abolished the in vitro DNA binding activity of E2F. 
Cell growth following serum stimulation was inhibited in human and rat mesangial cells 
upon cationic liposome transfection with the E2F oligonucleotide decoy and severe 
reductions in CDK2 kinase and PCNA mRNA as well as protein levels were detected in 
E2F decoy transfected human and rat mesangial cells. (Maeshima et al., 1998; Tomita et 
al., 1998). These studies show that an efficient and specific inhibition of E2F activity is 
possible using an E2F oligonucleotide decoy rather than a peptide strategy. Several studies 
report that transcription factor-decoy technology has been successfully implemented to 
inhibit the expression of several genes using synthetic double-stranded oligonucleotide 
decoys containing the consensus binding sequence of a transcription factor (Bielinska et al., 
1990; Sullenger et a l , 1990). However, decoy therapy depends on the efficient delivery of 
the decoy oligonucleotide to its target cells.
A number of other direct or indirect approaches to controlling the aberrant cell cycle 
progression as a result of E2F deregulation have been put forward. These include analysis 
of tissue specific expression of E2Fs, more specific targeting of chemotherapeutic agents to 
DNA sequences such as the E2F recognition site within the promoter regions of E2F 
regulated genes as well as the use of chemotherapeutic agents that target other components 
of the G1 restriction point resulting in an indirect regulation of transcription activity. 
Further, the use of histone deacetylase inhibitors has been proposed as a new measure to 
control deregulated transcription activity.
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Analysis of E2F-1 expression patterns within normal and cancerous cells within certain 
tissue types by Northern blot analysis and microarrays provide a useful decision-making 
tool for the selection of an appropriate treatment regimen for a specific cancer type. For 
example, any direct approach to counteract the transactivation activity of E2F-1 using an 
antagonistic peptide or decoy oligonucleotide is only of use in cancer cells whose E2F-1 
expression level is significantly higher relative to normal cells. In addition, knowledge 
about the relative E2F-1 expression levels within cancer types provides a good indication 
about the potential success of chemotherapy with an E2F-regulated gene product as the 
drug target. It has been reported that lung metastasis originating from a colorectal cancer 
contain a higher level of TS than liver metastasis of the same origin and are therefore less 
responsive to treatment with 5-fluorouracil. Analysis of a number of tumour samples found 
the resistance to 5-fluorouracil a direct consequence of the lung metastasis having a 
significantly higher E2F-1 expression level compared to the hepatic metastasis leading to 
an equally high increase in TS, a target enzyme for 5-fluorouracil (Banerjee et al., 2000).
A classic example of specific targeting of chemotherapeutic agents to DNA 
sequences such as the E2F recognition site within the promoter regions of E2F regulated 
genes are the microgonotropen (MGT) DNA binding drugs based on the chemical structure 
of distamycin. MGTs have been found to be potent inhibitors of transcription factor binding 
to promoter sequences with the result of disrupting gene expression. The MGTs mimic the 
transcription factor by sharing a common DNA sequence recognition and groove 
preference with the transcription factor. Most DNA binding drugs were limited in the 
sequence preference to either A-T or G-C rich regions and were only able to bind to one 
DNA groove. However, Chiang et al. found MGTs that more specifically recognise the 
binding site of the E2F-1 transcription factor are substantially more effective as inhibitors 
than substances that compete only for a portion of the transcription factor binding site on 
the DHFR promoter (Chiang et al., 1997).
Chemotherapeutic agents to target other components of the G1 restriction point 
resulting in an indirect regulation of transcription activity fall into several categories. The 
class of cyclin-dependent kinase inhibitors include flavopiridol and UCN-01. Both are 
potent inhibitors of CDKs 1,2 and 4 while the former also inhibits CDK7 and the latter has 
been shown to be a specific inhibitor of protein kinase C (PKC). Flavopiridol and UCN-01 
induce cell cycle arrest at Gl/S transition as a direct result of a decrease in cyclin D
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expression and dephosphorylation of pRb and CDK2s respectively. UCN-01 also induces 
p21and p27. Both drugs are currently undergoing Phase I clinical trials (Owa et al., 2001). 
In a study, flavopiridol was shown to potentitate gemcitabine-induced apoptosis in human 
pancreatic, colorectal and gastric cancer cells treated with gemcitabine and flavopiridol in a 
sequence-dependent manner. The potentiation was dependent on the downregulation of 
RR-M2 expression and RR-M2 downregulation was a direct result of flavopiridol induced 
proteasome-mediated degradation of E2F-1 and hypophosphorylation of pRB (Jung et a l, 
2001). This shows how treatment with flavopiridol, a cyclin-dependent kinase inhibitor 
indirectly the transactivation potential of E2F-1 leading to a reduction in E2F-regulated 
gene expression levels and subsequent cell death.
Finally, histone-deacetylase inhibitors induce hyperacetylation to reactivate gene 
expression of tumour suppressor genes as part of a multitude of cellular effects that inhibit 
the growth and survival of tumour cells. Histone-deacetylase inhibitors include sodium 
butylate, trichostatin A, FR901228 and MS-27-275 which all have been found to induce G1 
cell cycle arrest, apoptosis and differentiation in vitro and exhibited potent anti-tumour 
activities in vivo suggesting potential therapeutic utility (Johnstone, 2002; Owa et al., 
2001). Specifically, HD AC inhibitors were found to activate transcription of the cyclin- 
dependent kinase inhibitor p21 therefore inhibiting cyclin E-CDK2 and cyclin A-CDK2, 
resulting in the hypophosphorylation of pRb followed by the inhibition of S phase 
progression as transcription of E2F regulated genes required for S phase entry is stalled. 
Therefore elucidation of the substrate and functional specificities of HDACs coupled with 
the production of specific HDAC inhibitors will lead to a more targeted and efficient 
approach to regulating the expression of specific genes or gene subsets using HDAC 
inhibitors (Johnstone, 2002).
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